Dartmouth College
Report on Federal Awards in Accordance with OMB Circular A-133
June 30, 2015
EIN #020222111
Dartmouth College
Report on Federal Awards in Accordance with OMB Circular A-133
Index
June 30, 2015

Page(s)

Independent Auditor’s Report........................................................................................................... 1–2

Financial Statements ......................................................................................................................... 3–6

Notes to the Financial Statements .................................................................................................. 7–28

Schedule of Expenditures of Federal Awards .................................................................................. 29–51

Notes to the Schedule of Expenditures of Federal Awards................................................................. 52–53

Independent Auditor’s Report on Internal Control over Financial Reporting and on
Compliance and Other Matters Based on an Audit of Financial Statements
Performed in Accordance with Government Auditing Standards ................................................... 54–55

Independent Auditor’s Report on Compliance with Requirements That Could Have a
Direct and Material Effect on Each Major Program and on Internal Control Over
Compliance in Accordance with OMB Circular A-133.................................................................. 56–57

Schedule of Findings and Questioned Costs ..................................................................................... 58–59

Summary Schedule of Prior Audit Findings....................................................................................... 60–61

Management’s Views and Corrective Action Plan.............................................................................. 62
Independent Auditor's Report

To the Board of Trustees of Dartmouth College:

We have audited the accompanying consolidated financial statements of Dartmouth College (“Dartmouth”), which comprise the consolidated statement of financial position as of June 30, 2015 and the related consolidated statement of activities and changes in net assets, statement of operating expenses and cash flows for the year then ended, and the related notes to the financial statements.

Management’s Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditor’s Responsibility

Our responsibility is to express an opinion on the consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to Dartmouth’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Dartmouth’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Dartmouth College as of June 30, 2015, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.
Other Matter

We have previously audited Dartmouth College’s 2014 financial statements, and we expressed an unmodified audit opinion on those audited financial statements in our report dated October 20, 2014. In our opinion, the summarized comparative information presented herein as of and for the year ended June 30, 2014 is consistent, in all material respects, with the audited financial statements from which it has been derived.

Other Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by Office of Management and Budget Circular A-133, Audits of States, Local Governments, and Non-Profit Organizations and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with Government Auditing Standards, we have also issued our report dated October 19, 2015 on our consideration of Dartmouth’s internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing and not to provide an opinion on internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with Government Auditing Standards in considering Dartmouth’s internal control over financial reporting and compliance.

PricewaterhouseCoopers LLP

October 19, 2015
Consolidated Statement of Financial Position
As of June 30, 2015, with comparative information as of June 30, 2014
(in thousands)

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$289,137</td>
<td>$200,750</td>
</tr>
<tr>
<td>Receivables and other assets, net</td>
<td>143,339</td>
<td>151,986</td>
</tr>
<tr>
<td>Investment related receivables</td>
<td>9,157</td>
<td>14,681</td>
</tr>
<tr>
<td>Pledges receivable, net</td>
<td>164,368</td>
<td>97,258</td>
</tr>
<tr>
<td>Investments</td>
<td>5,704,691</td>
<td>5,547,788</td>
</tr>
<tr>
<td>Land, buildings, equipment, and construction in progress, net</td>
<td>968,902</td>
<td>955,531</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>$7,279,594</td>
<td>$6,967,994</td>
</tr>
<tr>
<td><strong>Liabilities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and other liabilities</td>
<td>$66,090</td>
<td>$72,532</td>
</tr>
<tr>
<td>Investment related payables</td>
<td>30,627</td>
<td>22,366</td>
</tr>
<tr>
<td>Deferred revenues and deposits</td>
<td>43,298</td>
<td>40,741</td>
</tr>
<tr>
<td>Liability for split-interest agreements</td>
<td>49,894</td>
<td>51,876</td>
</tr>
<tr>
<td>Pension and other employment related obligations</td>
<td>451,354</td>
<td>390,390</td>
</tr>
<tr>
<td>Bonds, mortgages, and notes payable, net</td>
<td>1,098,157</td>
<td>1,113,333</td>
</tr>
<tr>
<td>Interest rate swap liabilities, at fair value</td>
<td>167,417</td>
<td>141,219</td>
</tr>
<tr>
<td>Conditional asset retirement obligations</td>
<td>23,804</td>
<td>23,144</td>
</tr>
<tr>
<td>Government advances for student loans</td>
<td>20,492</td>
<td>20,443</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td>1,951,133</td>
<td>1,876,044</td>
</tr>
<tr>
<td><strong>Net Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted</td>
<td>1,312,188</td>
<td>1,349,963</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>2,772,958</td>
<td>2,561,992</td>
</tr>
<tr>
<td>Permanently restricted</td>
<td>1,243,315</td>
<td>1,179,995</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td>5,328,461</td>
<td>5,091,950</td>
</tr>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td>$7,279,594</td>
<td>$6,967,994</td>
</tr>
</tbody>
</table>

See accompanying notes to the financial statements.
### Dartmouth College

**Consolidated Statement of Activities**

For the year ended June 30, 2015, with summarized financial information for the year ended June 30, 2014

(in thousands)

<table>
<thead>
<tr>
<th>Endowment Activities</th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gifts</td>
<td>$141</td>
<td>$1,929</td>
<td>$43,959</td>
<td>$46,029</td>
</tr>
<tr>
<td>Net investment return</td>
<td>80,044</td>
<td>269,172</td>
<td>701</td>
<td>349,917</td>
</tr>
<tr>
<td>Distributed for spending</td>
<td>(48,942)</td>
<td>(165,235)</td>
<td>(48)</td>
<td>(214,225)</td>
</tr>
<tr>
<td>Other changes</td>
<td>3,045</td>
<td>(5,325)</td>
<td>3,094</td>
<td>814</td>
</tr>
<tr>
<td>Amounts transferred (to) from other funds, net</td>
<td>4,946</td>
<td>140</td>
<td>7,651</td>
<td>12,737</td>
</tr>
<tr>
<td><strong>Change in net assets from endowment activities</strong></td>
<td>39,234</td>
<td>100,681</td>
<td>55,357</td>
<td>195,272</td>
</tr>
</tbody>
</table>

| Operating Activities | | | | |
|----------------------| | | | |
| Revenues             | | | | |
| Tuition and fees     | 326,580       | -                      | -                      | 326,580 | 320,224 |
| Student scholarships | (129,186)     | -                      | -                      | (129,186) | (128,398) |
| Net tuition and fees | 197,394       | -                      | -                      | 197,394 | 191,826 |
| Sponsored research grants and contracts | 182,118 | -                      | -                      | 182,118 | 177,539 |
| Dartmouth College Fund and other gifts | 80,474 | 4,359                  | -                      | 84,833  | 85,584 |
| Distributed endowment investment return | 206,999 | 5,494                  | -                      | 212,493 | 187,043 |
| Other operating income | 124,860 | 204                    | -                      | 125,064 | 152,556 |
| Auxiliaries          | 74,345        | -                      | -                      | 74,345  | 72,195 |
| Net assets released from restrictions | 12,953 | -                      | -                      | -       | - |
| **Total revenues**   | 879,143       | (2,896)                | -                      | 876,247 | 866,743 |

| Expenses             | | | | |
|----------------------| | | | |
| Academic and student programs | 568,685 | -                      | -                      | 568,685 | 544,984 |
| Sponsored programs   | 126,105      | -                      | -                      | 126,105 | 127,308 |
| General institutional services | 105,125      | -                      | -                      | 105,125 | 97,159 |
| Auxiliaries          | 85,468        | -                      | -                      | 85,468  | 83,659 |
| **Total expenses**   | 891,128       | (2,896)                | -                      | 891,128 | 853,110 |

| Change in net assets from operating activities | (12,285) | (2,896) | - | (15,181) | 13,633 |

| Non-operating Activities | | | | |
|--------------------------| | | | |
| Gifts                    | -                      | 86,091                 | 94                     | 86,185  | 27,733 |
| Other non-operating changes, net | (3,078) | 535                   | -                      | (2,543) | 30,524 |
| Distributed endowment investment return | 362 | 1,369                  | -                      | 1,731   | 1,503 |
| Increase/decrease in outstanding pledges | - | 56,142                 | 10,968                 | 67,110  | 2,547 |
| Pension and postretirement benefit related changes | (40,739) | -                     | -                      | (40,739) | (103,413) |
| Disposals and non-capitalized expenditures | (5,245) | (565)                 | -                      | (5,810) | (11,929) |
| Change in unrealized gain (loss) related to interest rate swap agreements | (26,198) | -                     | -                      | (26,198) | (7,997) |
| Net assets released from restrictions | 13,850 | (13,850) | - | - | - |
| Amounts transferred (to) from endowment, net | (3,676) | (9,061) | - | (12,737) | 102 |
| Net change in split-interest agreements | - | (7,480) | (3,099) | (10,579) | (7,066) |
| **Change in net assets from non-operating activities** | (64,724) | 113,181 | 7,963 | 56,420 | (67,996) |

| Change in net assets | (37,775) | 210,966 | 63,320 | 236,511 | 680,260 |

| Net Assets, beginning of year | 1,349,963 | 2,561,992 | 1,179,995 | 5,091,950 | 4,411,690 |

| Net Assets, end of year | $1,312,188 | $2,772,958 | $1,243,315 | $5,328,461 | $5,091,950 |

---

See accompanying notes to the financial statements.
### Consolidated Statement of Operating Expenses

For the year ended June 30, 2015, with summarized financial information for the year ended June 30, 2014 (in thousands)

<table>
<thead>
<tr>
<th></th>
<th>Academic &amp; Student Programs</th>
<th>Sponsored Programs</th>
<th>General Institutional Services</th>
<th>Total Expenses</th>
<th>Auxiliaries</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salaries and wages</td>
<td>$242,440</td>
<td>$58,012</td>
<td>$28,100</td>
<td>$18,583</td>
<td>$20,524</td>
<td>$67,207</td>
<td>$14,784</td>
</tr>
<tr>
<td>Employee benefits</td>
<td>90,295</td>
<td>16,251</td>
<td>9,695</td>
<td>6,590</td>
<td>7,278</td>
<td>23,833</td>
<td>5,243</td>
</tr>
<tr>
<td>Fellowships and student support</td>
<td>11,049</td>
<td>4,267</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>536</td>
</tr>
<tr>
<td>Materials, equipment, and supplies</td>
<td>36,728</td>
<td>9,276</td>
<td>8,187</td>
<td>2,040</td>
<td>2,031</td>
<td>12,258</td>
<td>16,630</td>
</tr>
<tr>
<td>Purchased services</td>
<td>45,825</td>
<td>44,830</td>
<td>4,969</td>
<td>3,449</td>
<td>7,148</td>
<td>15,566</td>
<td>10,137</td>
</tr>
<tr>
<td>Utilities, taxes, and occupancy</td>
<td></td>
<td></td>
<td>-</td>
<td>40,586</td>
<td>40,586</td>
<td>7,505</td>
<td>48,091</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>41,690</td>
<td></td>
<td>4,019</td>
<td>4,428</td>
<td>253</td>
<td>8,700</td>
<td>10,156</td>
</tr>
<tr>
<td>Lodging, travel, and similar costs</td>
<td>21,467</td>
<td>3,042</td>
<td>1,057</td>
<td>71</td>
<td>1,800</td>
<td>2,928</td>
<td>237</td>
</tr>
<tr>
<td>Interest</td>
<td>21,467</td>
<td>3,042</td>
<td>1,057</td>
<td>23,969</td>
<td>23,969</td>
<td>3,416</td>
<td>24,512</td>
</tr>
<tr>
<td>Other expenses</td>
<td>3,107</td>
<td>472</td>
<td>953</td>
<td>240</td>
<td>441</td>
<td>1,634</td>
<td>225</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>492,601</td>
<td>136,150</td>
<td>37,250</td>
<td>99,083</td>
<td>39,475</td>
</tr>
<tr>
<td>Facilities operation &amp; maintenance</td>
<td>76,084</td>
<td></td>
<td>4,315</td>
<td>(99,083)</td>
<td>85</td>
<td>(94,653)</td>
<td>18,599</td>
</tr>
<tr>
<td>Total expenses for FY15</td>
<td>$568,685</td>
<td>$136,150</td>
<td>$61,565</td>
<td>$39,560</td>
<td>$101,125</td>
<td>$85,468</td>
<td>$891,428</td>
</tr>
<tr>
<td>Total expenses for FY14</td>
<td>$544,984</td>
<td>$127,308</td>
<td>$61,826</td>
<td>$35,333</td>
<td>$97,159</td>
<td>$83,659</td>
<td>$853,110</td>
</tr>
</tbody>
</table>

See accompanying notes to the financial statements.
## Consolidated Statement of Cash Flows

For the year ended June 30, 2015, with comparative information for the year ended June 30, 2014  
(in thousands)

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash flows from operating activities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total change in net assets</td>
<td>$ 236,511</td>
<td>$ 680,260</td>
</tr>
<tr>
<td>Adjustments to reconcile total change in net assets to net cash used by operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>60,989</td>
<td>58,557</td>
</tr>
<tr>
<td>Change in estimated value of interest rate swap agreements</td>
<td>26,198</td>
<td>7,997</td>
</tr>
<tr>
<td>Change in estimated pension and post-retirement benefit obligation</td>
<td>56,743</td>
<td>110,337</td>
</tr>
<tr>
<td>Net change in split-interest liability</td>
<td>(1,982)</td>
<td>10,372</td>
</tr>
<tr>
<td>Change in pledges receivable, net</td>
<td>(67,110)</td>
<td>(2,547)</td>
</tr>
<tr>
<td>Other non-cash transactions</td>
<td>(532)</td>
<td>12,141</td>
</tr>
<tr>
<td>Contributions, investment income, and other changes restricted for long-term investment</td>
<td>(80,390)</td>
<td>(152,481)</td>
</tr>
<tr>
<td>Net realized and unrealized gains</td>
<td>(330,960)</td>
<td>(849,311)</td>
</tr>
<tr>
<td>Changes in operating assets and liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Receivables and other assets, net</td>
<td>4,415</td>
<td>(5,861)</td>
</tr>
<tr>
<td>Accounts payable and other liabilities</td>
<td>(5,516)</td>
<td>3,347</td>
</tr>
<tr>
<td>Deferred revenues and deposits</td>
<td>2,557</td>
<td>(406)</td>
</tr>
<tr>
<td>Employment related obligations</td>
<td>4,221</td>
<td>7,603</td>
</tr>
<tr>
<td>Net cash used in operating activities</td>
<td>(94,856)</td>
<td>(119,992)</td>
</tr>
</tbody>
</table>

| Cash flows from investing activities |         |          |
| Student loans granted               | (8,242)  | (8,150)  |
| Student loans repaid                | 12,902   | 14,389   |
| Purchases of land, buildings, and equipment | (74,518) | (78,687)|
| Proceeds from the sale of land, buildings, and equipment | -       | 77       |
| Net change in unsettled trades      | 13,785   | (11,984) |
| Purchases of investments            | (5,607,635) | (4,270,901)|
| Sales and maturities of investments | 5,781,692| 4,296,669|
| Net cash provided by (used in) investing activities | 117,984  | (58,587) |

| Cash flows from financing activities |         |          |
| Repayment of debt                   | (15,181) | (13,458) |
| Contributions, investment income, and other changes restricted for long-term investment in: |         |          |
| Facilities                          | 27,473   | 7,942    |
| Endowment, life income, and similar funds | 52,918   | 144,539  |
| Changes in government advances for student loans | 49      | 111      |
| Net cash provided by financing activities | 65,259  | 139,134  |

<table>
<thead>
<tr>
<th>Net change in cash and cash equivalents</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>88,387</td>
<td>(39,445)</td>
</tr>
<tr>
<td>Cash and cash equivalents, beginning of year</td>
<td>200,750</td>
<td>240,195</td>
</tr>
<tr>
<td>Cash and cash equivalents, end of year</td>
<td>$ 289,137</td>
<td>$ 200,750</td>
</tr>
</tbody>
</table>

| Supplemental disclosure of cash flow information |         |          |
| Cash paid for interest                       | $ 53,273| $ 52,357 |
| Accounts payable related building and equipment additions | $ 266   | $ 1,888  |
| Contributed securities received              | $ 52,092| $ 29,633 |

See accompanying notes to the financial statements.
A. Summary of Significant Accounting Policies

Description of Organization
Dartmouth College (Dartmouth) is a private, nonprofit, co-educational, nonsectarian institution of higher education with approximately 4,300 undergraduate and 2,000 graduate students. Established in 1769, Dartmouth includes the four-year undergraduate college, with graduate schools of business, engineering, and medicine, and several graduate programs in the arts and sciences.

Basis of Presentation
The accompanying consolidated financial statements have been prepared on the accrual basis. Dartmouth's consolidated financial statements include the accounts of its wholly owned subsidiaries and certain affiliated organizations over which it has financial control. The wholly owned subsidiaries and financially controlled entities include real estate corporations, which own real estate in the Hanover, NH area; the Dartmouth Education Loan Corporation (DELC), which provides scholarships and loans to Dartmouth students who are unable to finance their education through other sources; and various separately incorporated entities which support experiential learning and other activities that enrich the experience of students and the community.

In accordance with U.S. generally accepted accounting principles (GAAP), net assets, revenues, gains, and losses are classified into three categories: unrestricted, temporarily restricted, or permanently restricted. Unrestricted net assets include all resources that are not subject to donor-imposed restrictions and therefore may be used for any purpose in furtherance of Dartmouth's mission. Under the authority of Dartmouth's management and Board of Trustees, in order to support Dartmouth's strategic initiatives, all or a portion of unrestricted net assets may be set aside in segregated Dartmouth-designated reserve accounts and earmarked for use in future years by specific departments, cost centers, or the professional schools, to cover program costs or contingencies. These Dartmouth-designated net assets include funds designated for operating initiatives, facilities, and long-term quasi-endowment. The purposes for which Dartmouth-designated net assets are earmarked may be changed under the authority of Dartmouth's management or Board of Trustees. The use of designated net assets is at the discretion of the responsible department. All expenses are recorded as a reduction of unrestricted net assets.

Temporarily restricted net assets carry donor-imposed restrictions on the expenditure or other use of contributed funds. Temporary restrictions may expire either because of the passage of time or because actions are taken to fulfill the restrictions. Temporarily restricted net assets include unexpended endowment return, unexpended restricted use gifts, term endowment funds, loan funds, certain uncollected pledges, and life income and similar funds. Donor-restricted resources intended for capital projects are released from their temporary restrictions and presented as unrestricted support when the related asset is placed in service. Temporarily restricted endowment distribution and donor-restricted gifts which are received, and either spent or deemed spent within the same fiscal year, are reported as unrestricted.

Permanently restricted net assets are those that are subject to donor-imposed restrictions which will never lapse, thus requiring that the net assets be retained permanently. Based upon a legal interpretation of New Hampshire State Law, Dartmouth has determined that appreciation on restricted endowment funds should be classified as temporarily restricted net assets until such time as the appreciation is appropriated by the Board of Trustees. Investment return from endowment activities that has been appropriated by Dartmouth’s Board of Trustees is presented as an increase in operating or non-operating activities according to the unrestricted or temporarily restricted nature of the donor’s intended use of the funds. In the case of quasi-endowment funds designated for long-term investment by Dartmouth, investment return that has been appropriated by Dartmouth’s Board of Trustees is presented as an increase in unrestricted operating or non-operating activities, depending upon Dartmouth’s intended use of the funds. Permanently restricted net assets consist of the original principal of endowment gifts, life income and similar funds, and certain pledges.

Comparative Financial Information
The 2015 consolidated financial statements are presented with certain prior-year comparative information summarized in total but not by net asset class. Such information does not include sufficient detail to constitute a presentation in conformity with GAAP. Accordingly, such information should be read in conjunction with Dartmouth's consolidated financial statements for the year ended June 30, 2014, from which the summarized information was derived. Certain prior year amounts have been reclassified to conform to the fiscal year 2015 presentation.
Use of Estimates
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates in these consolidated financial statements are the fair value of investments, interest rate swap agreements and bonds payable (for disclosure only), pension and postretirement benefit obligations, conditional asset retirement obligations, liabilities for self-insured programs and split-interest agreements, and allowances for uncollectible accounts and pledges receivable. Actual results could differ materially from these estimates, particularly during periods of investment and/or interest rate volatility.

Recent Accounting Pronouncements
Dartmouth adopted Accounting Standards Update (ASU) 2012-05, Not-for-Profit Entities: Classification of the Sale of Proceeds of Donated Financial Assets in the consolidated Statement of Cash Flows, which addresses the classification of the sale of donated securities in the consolidated Statement of Cash Flows. This pronouncement requires that the sale of donated securities that are received and immediately sold, are reported within the consolidated Statement of Cash Flows as an operating activity. If there are restrictions on the use of the contributed securities for long-term purposes, they are reported within the consolidated Statement of Cash Flows as a financing activity.

Dartmouth adopted ASU 2015-07, Disclosures for Certain Entities That Calculate Net Asset Value per Share (or its Equivalent), which removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using net asset value per share as the practical expedient.

The adoption of ASU 2012-05 and ASU 2015-07 did not have a material effect on Dartmouth’s consolidated financial statements.

Consolidated Statement of Activities
Operating activities presented in the consolidated Statement of Activities consist of revenues earned, endowment net investment return appropriated by Dartmouth’s Board of Trustees, and expenses incurred in conducting Dartmouth’s programs and services. Auxiliary enterprises, primarily the operation of residence halls, dining services, and recreational facilities, are included in operating activities. Expenses such as development, public affairs, and central services and administration are reported as general institutional services. Depreciation and facilities operations and maintenance expenses are allocated to functional classifications of expenses based on the square footage of each building. Interest expense is allocated to functional classifications of expenses based on the use of each building that has been debt financed.

Non-operating activities presented in the consolidated Statement of Activities consist of gifts for facilities projects and gifts whose purpose has not yet been finalized, grants, investment income, other earnings, and endowment investment return appropriated by Dartmouth’s Board of Trustees for loan programs and the construction, purchase or sale of capital assets, non-capitalizable construction in progress, net change in life income and similar split-interest agreements, the net change in pledges receivable, the net change in the estimated value of interest rate swap agreements, and postretirement benefit changes other than net periodic benefits costs.

Endowment activities presented in the consolidated Statement of Activities consist of gifts that are restricted by donors to invest in perpetuity, amounts designated by Dartmouth’s management and Board of Trustees for long-term investment, the net investment return on these invested funds, and the annual distribution of an amount appropriated by Dartmouth’s Board of Trustees to support operating and non-operating activities. Other endowment activities include increases in endowment net assets from certain matured split-interest agreements.

Endowment and non-operating activities also include transfers of net assets that occur when donors change the restrictions on certain gifts or when Dartmouth changes the designation of unrestricted funds.
Cash and Cash Equivalents
Cash and cash equivalents consist principally of U.S. treasury funds, money market accounts, certificates of deposit, commercial paper, and liquid short-term investments with maturities of 90 days or less at the date of acquisition. Cash and cash equivalents are carried at cost, which approximates fair value.

Tuition and Fees and Student Scholarships
Tuition and fees revenue is recognized in the fiscal year in which substantially all of the academic program occurs. Tuition and fees revenue from undergraduate enrollment represents approximately 66 percent of tuition and fees revenue for the years ended June 30, 2015 and 2014. Student scholarships provided by Dartmouth are presented in the consolidated Statement of Activities as a reduction in tuition and fees revenue. In addition, Dartmouth acts as an agent for recipients of scholarships from other sponsors in the amounts of $5,921,000 and $5,375,000 for the years ended June 30, 2015 and 2014, respectively, which are not presented in the consolidated Statement of Activities.

In fiscal 2015, Dartmouth admitted students to its undergraduate program without regard to financial need. Beginning with the undergraduate class that will matriculate in fiscal 2017, Dartmouth plans to consider the financial need of international students during the admissions process. The financial aid program assists all students with demonstrated need, defined in accordance with a uniform formula, by providing a mix of scholarships, loans and/or employment designed to cover costs of attendance when combined with student and family contributions, based on ability to pay.

Sponsored Research Grants and Contracts
Revenues from government and private sponsored research grants and contracts are recognized when the direct costs associated with the sponsored program are incurred. Revenue from the reimbursement of facilities and administrative costs incurred by Dartmouth on U.S. government grants and contracts is based upon negotiated predetermined cost rates through June 30, 2015. Dartmouth recovered facilities and administrative costs of approximately $42,121,000 and $42,754,000 during the years ended June 30, 2015 and 2014, respectively.

Taxes
Dartmouth is exempt from federal income taxes under Section 501(c)(3) of the U.S. Internal Revenue Code (the Code), except with regard to unrelated business income, which is taxed at corporate income tax rates. Dartmouth is also subject to state and local property tax on the value of dormitories and dining and kitchen facilities in excess of $150,000, as well as on the value of its off-campus rental properties, commercial properties, and other real estate holdings to the extent they are not used or occupied for Dartmouth’s tax exempt purposes. Certain Dartmouth real estate entities are exempt from federal income tax under Sections 501(c)(2) and 501(c)(25) of the Code. As of June 30, 2015, tax years ended June 30, 2012 through June 30, 2014 remain open and are subject to federal and state taxing authority examination. Dartmouth believes it has taken no significant uncertain tax positions.

Affiliation with Dartmouth-Hitchcock Medical Center
Dartmouth, through the Geisel School of Medicine (Geisel), is a member of the Dartmouth-Hitchcock Medical Center (DHMC), a confederation of health care organizations intended to coordinate medical education and health care delivery for the residents of New Hampshire and Vermont. DHMC is a nonprofit, tax-exempt corporation organized under New Hampshire State Law. The other members of DHMC are: (i) Mary Hitchcock Memorial Hospital (Hitchcock Hospital), (ii) Dartmouth-Hitchcock Clinic (Clinic), and (iii) Veterans Administration Medical Center of White River Junction, Vermont (VAMC). The staff of the Clinic serves as the primary resource for Geisel clinical faculty, with the Hitchcock Hospital and the VAMC acting as principal sites of clinical instruction for Geisel students. Each member of DHMC is a separately organized, governed, and operated institution, with Dartmouth having no ownership interest in any other member.

Certain costs, including salaries, facilities use (including construction planning and management, and facilities operation and maintenance), and direct and indirect research, incurred by Geisel and the other members of DHMC are shared among the members based on negotiated allocations of the costs on an annual or project specific basis. The members of DHMC, excluding the VAMC, are also parties to a Condominium Ownership Agreement that governs the ownership and operation of the DHMC facilities. During the years ended June 30, 2015 and 2014, Dartmouth paid approximately $25.3 million and $26.4 million, respectively, and received approximately $26.5 million and $30.0 million, respectively, in connection with these arrangements.
Dartmouth College  
Notes to Consolidated Financial Statements
For the years ended June 30, 2015 and 2014

Insurance
Dartmouth maintains several insurance arrangements with the objective of providing the most cost effective and comprehensive coverage for most insurable risks. Both conventional and alternative insurance coverage approaches, including utilization of appropriate deductible or self-insured retention amounts, are in place to cover trustee errors and omissions and employment practices, crime bond, commercial general and automobile liability, pension trust fiduciary errors and omissions liability, and property losses. Workers’ compensation losses are covered by a self-insured retention and excess insurance program. Dartmouth currently participates in three risk retention groups that provide general liability and professional and medical malpractice liability insurance.

Dartmouth’s annual premium payments for conventional insurance coverage are included in operating expenses. Estimated liabilities for losses under Dartmouth’s deductible and/or self-insurance retention limits are reflected in the consolidated Statement of Financial Position, which includes estimates for known losses and for losses incurred but not yet reported. Insurance reserves are based on actuarial analysis and/or estimates of historical loss experience, and while management believes that the reserves are adequate, the ultimate liabilities may be different than the amounts provided.

Gifts and Pledges Receivable
Total contributions to Dartmouth include gifts that are received and the net change in pledges receivable during a period. Gifts, pledges and pledge payments are recognized as increases in the appropriate category of net assets in the period the gift or pledge is received. The net change in total pledges is recorded as a net increase (decrease) in non-operating activities in the consolidated Statement of Activities. Contributions of capitalizable assets other than cash are recorded at their estimated fair value at the date of gift. Pledges are stated at the estimated present value of future cash flows, net of an allowance for uncollectible amounts. Conditional promises to give are not recognized until the conditions on which they depend are substantially met.

Investments
Investments are reported at fair value in accordance with GAAP. Purchases and sales of securities are recorded on the trade date, and realized gains and losses are determined on the basis of the average cost of securities sold. Cash and cash equivalents designated for investment purposes is included in investments and may include money market funds, foreign currency held for investment purposes, and U.S. treasury securities with an original or remaining maturity of three months or less when purchased. These investments are valued based on market price or cost which approximates fair value. Advance contributions to commingled fund investments and redemptions receivables from commingled fund investments at June 30, 2015 and June 30, 2014 are included within Investments as presented on the consolidated Statement of Financial Position.

For investments held directly by Dartmouth for which an active market with quoted prices exists, the market price of an identical security is used as fair value. Fair values for shares in listed commingled funds are based on the quoted market value or share prices reported as of the last business day of the fiscal year. Dartmouth’s interest in certain other private commingled funds and private partnership interests are reported at the net asset value (NAV) as determined by the external fund manager. As permitted by GAAP, Dartmouth uses NAV as a practical expedient to estimate the fair value of Dartmouth’s ownership interest, unless it is probable that all or a portion of the investment will be sold for an amount different from NAV. Dartmouth performs due diligence procedures related to these investments to support recognition at fair value at fiscal year-end. Because many of these investments are not readily marketable, the estimates of fair value involve assumptions and estimation methods which are uncertain, and therefore the estimates could differ from actual results.

Commencing in fiscal year 2014, Dartmouth extended its accounting closing process related to receiving valuations from private investment managers. This extension allows Dartmouth to improve the accuracy of reporting private investment values at fiscal year-end. As a result of implementing this extension, a previously unreported unrealized gain from June 30, 2013 of $59,432,000 was recorded within the $777,453,000 net investment return for the year ended June 30, 2014 on the consolidated Statement of Activities. Dartmouth assessed the impact of the $59,432,000 out-of-period unrealized gain adjustment on both the 2013 and 2014 fiscal years and concluded that it is immaterial.
Directly held real estate is reflected at fair value in accordance with Dartmouth’s valuation policy. The valuation policy includes: the estimated price that would be received from the sale of the asset in an orderly transaction between market participants, prices determined by independent external appraisals for at least one third of the properties in a given year, or at cost which approximates fair value for properties held for less than a year or which are being actively developed.

Total investment return (interest, dividends, rents, royalties, and net realized and changes in unrealized gains and losses) earned by Dartmouth’s endowment investments is included in endowment activities on the consolidated Statement of Activities, while the net income earned by the non-endowment investments is included in other operating or non-operating income on the consolidated Statement of Activities. Dividend income is recognized, net of applicable withholding taxes, on the ex-dividend date. Non-cash dividends are recorded at the fair value of the securities received on the date of distribution. Interest income and expenses are recorded net of applicable withholding taxes on the accrual basis of accounting. Dartmouth amortizes bond premiums and accretes bond discounts using the effective yield method and when cash collection is expected. Fees charged by external investment managers are generally based on contractual percentages of the fair market value of assets under management or on annual total investment return and are, in most cases, netted against investment return. However, certain expenses paid directly by Dartmouth for investment management and custody services, including certain internal costs, amounted to approximately $13,136,000 and $11,947,000 for the years ended June 30, 2015 and 2014, respectively, and have been netted against total investment return and other operating and non-operating income in the accompanying consolidated Statement of Activities.

The asset allocation of Dartmouth’s investment portfolio involves exposure to a diverse set of markets. The investments within these markets involve various risks such as price, interest rate, market, sovereign, currency, liquidity, and credit risks. Additionally, the investments in real assets through commingled funds and direct real estate expose Dartmouth to a unique set of risks such as operational, environmental, and political risks. Dartmouth anticipates that the value and composition of its investments may, from time to time, fluctuate substantially in response to any or all of the risks described herein.

Endowment

Dartmouth’s endowment and similar funds consist of gifts restricted by donors and unrestricted net assets designated by management and the Board of Trustees for long-term support of Dartmouth’s activities, and the accumulated investment return on these gifts and designated net assets. Accumulated investment return consists of endowment net investment return that has not been appropriated by the Board of Trustees for expenditure to support Dartmouth’s operating and non-operating activities. Generally, only a portion of accumulated net investment return is made available for spending each year in accordance with a Board of Trustees-approved endowment utilization policy and New Hampshire State Law. However, certain donor restricted endowment funds do allow for the expenditure of principal, and Dartmouth-designated endowment funds are unrestricted net assets that may be re-designated for authorized expenditures.

Giving consideration to the New Hampshire Uniform Prudent Management of Institutional Funds Act (UPMIFA), Dartmouth classifies as permanently restricted net assets all endowment funds that must be retained permanently in accordance with stipulations imposed by a donor at the time of a gift, plus the original value of assets donated to permanent endowment, along with any investment earnings that are directed by the donor to be reinvested in perpetuity (i.e., historic book value). The remaining portion of the donor-restricted endowment fund that is not classified in permanently restricted net assets is classified as temporarily restricted net assets until those amounts are appropriated for expenditure in a manner consistent with the standard of prudence prescribed by UPMIFA.

Unrestricted endowment net assets include Dartmouth funds and certain unrestricted gifts from donors, and any accumulated investment return thereon, which may be expended; however, by trustee or management designation, these net assets may remain invested in the endowment for the long-term support of Dartmouth activities. Investment return on unrestricted endowment net assets and the annual distribution of a portion of accumulated investment return to operating and non-operating activities are presented as changes in unrestricted net assets in the consolidated Statement of Activities. Temporarily restricted endowment net assets include certain expendable endowment gifts, and any retained income and appreciation thereon, which are restricted by the donor to a specific purpose or by law. When the temporary restrictions on these funds have been met, the gifts ordinarily remain in the endowment by trustee designation to continue supporting the same activities as those specified by the donors, but the net assets are reclassified to unrestricted endowment net assets.
Investment return on temporarily and permanently restricted net assets are generally presented as changes in temporarily restricted net assets in the consolidated Statement of Activities.

**Split-Interest Agreements**

Certain donors have established irrevocable split-interest agreements with Dartmouth, primarily charitable gift annuities, pooled life income funds, and irrevocable charitable remainder trusts, whereby the donated assets are invested and distributions are made to the donor and/or other beneficiaries in accordance with the agreement for a specified period of time, after which time the remaining assets and future investment return are retained by Dartmouth. At the discretion of the donor, Dartmouth may or may not serve as trustee for the split-interest agreement.

Dartmouth has recorded the estimated fair value of the investments associated with irrevocable split-interest agreements and an estimated liability, using a discount rate of 2.0% and 2.2% for June 30, 2015 and 2014, respectively, for the net present value of the future cash outflows to beneficiaries of the agreements for which Dartmouth serves as trustee. When Dartmouth is not the trustee of the assets associated with a split-interest agreement, a receivable for Dartmouth’s beneficial interest is established when Dartmouth is notified of the trust’s existence and when the third-party trustee has provided Dartmouth with sufficient reliable information to estimate the value of the receivable, which Dartmouth considers a Level 3 measurement. Dartmouth requests information regularly from third-party trustees for financial reporting purposes; however, these trustees are not obligated to provide Dartmouth with the information necessary to estimate fair value and record the asset. Dartmouth respects the privacy of donors and trustees in these limited instances. Dartmouth reports the net change in split-interest agreements as a non-operating change in net assets in the consolidated Statement of Activities.

**Land, Buildings, Equipment, and Construction in Progress**

Land, buildings, equipment, and construction in progress are recorded at cost at the date of acquisition or, if acquired by gift, at the estimated fair value as of the date of the gift. Purchases, construction, and renovations of assets which exceed Dartmouth’s specified dollar threshold and have a useful life greater than one year are capitalized, while scheduled maintenance and minor renovations of less than that amount are charged to operations.

Land, buildings, and equipment are reflected net of accumulated depreciation calculated on a straight-line basis over the following estimated economic lives.

<table>
<thead>
<tr>
<th>Asset</th>
<th>Economic Life</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buildings and building components</td>
<td>13 - 50 years</td>
</tr>
<tr>
<td>Depreciable land improvements</td>
<td>15 - 20 years</td>
</tr>
<tr>
<td>Equipment</td>
<td>5 - 20 years</td>
</tr>
</tbody>
</table>

Depreciation expense for facilities that are primarily used for sponsored research is based on the estimated economic lives of each component.

**Collections**

Dartmouth’s collections include works of art, literary works, historical treasures, and artifacts that are maintained in its museum and libraries. These collections are protected and preserved for public exhibition, education, research, and the furtherance of public service. Each of the items is cataloged, preserved, and cared for, and activities verifying their existence and assessing their condition are performed continuously. The collections are subject to a policy that requires proceeds from their sale to be used to acquire other items for collections.

The collections, which were acquired through purchases and contributions since Dartmouth’s inception, are not recognized as assets in the consolidated Statement of Financial Position. Purchases of collection items are recorded in the consolidated Statement of Activities as non-operating decreases in unrestricted net assets in the year in which the items are acquired or in temporarily restricted net assets if the assets used to purchase the items are restricted by donors. Contributed collection items are not recorded in the consolidated financial statements.
B. Receivables and Other Assets

Receivables and other assets consisted of the following at June 30 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Student accounts</td>
<td>$2,277</td>
<td>$3,039</td>
</tr>
<tr>
<td>Sponsored research grants and contracts</td>
<td>22,003</td>
<td>19,667</td>
</tr>
<tr>
<td>Other accounts</td>
<td>38,277</td>
<td>46,396</td>
</tr>
<tr>
<td>Notes and student loans</td>
<td>64,140</td>
<td>68,800</td>
</tr>
<tr>
<td>Less: allowance for uncollectible accounts</td>
<td>(3,287)</td>
<td>(4,047)</td>
</tr>
<tr>
<td>Receivables, net</td>
<td>$123,410</td>
<td>$133,855</td>
</tr>
<tr>
<td>Prepaid costs, inventories, and other assets</td>
<td>19,929</td>
<td>18,131</td>
</tr>
<tr>
<td>Total receivables and other assets, net</td>
<td>$143,339</td>
<td>$151,986</td>
</tr>
</tbody>
</table>

Federally sponsored student loans with mandated interest rates and repayment terms are subject to significant restrictions as to their transfer and disposition. Amounts received from the Federal government to fund a portion of the Perkins student loans are ultimately refundable to the Federal government and are classified as government advances for student loans in the consolidated Statement of Financial Position. Due to the nature and terms of student loans funded by the Federal government, and restricted and unrestricted Dartmouth funds, it is not practical to estimate the fair value of such loans. All other receivables are carried at estimated net realizable value.

C. Gifts and Pledges Receivable

Gifts and pledge payments received during the years ended June 30 were as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gifts to support operations</td>
<td>$84,833</td>
<td>$85,584</td>
</tr>
<tr>
<td>Gifts for:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Facilities and student loans</td>
<td>27,473</td>
<td>8,012</td>
</tr>
<tr>
<td>Other restricted uses</td>
<td>38,332</td>
<td>12,875</td>
</tr>
<tr>
<td>Endowment</td>
<td>46,029</td>
<td>143,456</td>
</tr>
<tr>
<td>Split-interest agreements</td>
<td>20,380</td>
<td>6,846</td>
</tr>
<tr>
<td>Total gifts and pledge payments</td>
<td>$217,047</td>
<td>$256,773</td>
</tr>
</tbody>
</table>

Unconditional pledges as of June 30 are expected to be realized in the following periods, discounted at rates ranging from 0.7% to 6.2% (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>In one year or less</td>
<td>$56,519</td>
<td>$53,056</td>
</tr>
<tr>
<td>Between one year and five years</td>
<td>108,097</td>
<td>50,313</td>
</tr>
<tr>
<td>Six years and after</td>
<td>13,183</td>
<td>5,038</td>
</tr>
<tr>
<td>Gross pledges receivable</td>
<td>$177,799</td>
<td>$108,407</td>
</tr>
<tr>
<td>Less: present value discount</td>
<td>(6,915)</td>
<td>(3,700)</td>
</tr>
<tr>
<td>Less: allowance for uncollectible pledges</td>
<td>(6,516)</td>
<td>(7,449)</td>
</tr>
<tr>
<td>Pledges receivable, net</td>
<td>$164,368</td>
<td>$97,258</td>
</tr>
</tbody>
</table>

The change in net pledges receivable is presented as a non-operating activity in the consolidated Statement of Activities.
D. Investments

Dartmouth’s endowment and other investment portfolios include investments in various asset classes, each with different return expectations, risk characteristics, and liquidity provisions.

Fixed Income includes strategies based on capital preservation and predictable yield as well as more opportunistic strategies focused on generating return through price appreciation. These strategies generally include corporate debt securities, government securities, mortgage backed and asset backed securities and other financial instruments. Exposures to these investments include directly held securities as well as investments through commingled funds and derivatives, including fixed income futures and forwards, and interest rate and credit default swaps.

Global Equity includes directly held equity securities and commingled funds, whose managers primarily invest in global public long-only and long/short equity securities with portfolios that are directionally exposed to the market.

Marketable Alternative Strategies includes investments in commingled funds whose managers employ discrete and blended strategies, including long/short equity, absolute return, market neutral, distressed and credit strategies. Funds with marketable alternative strategies generally hold securities or other financial instruments for which a ready market exists, and may include stocks, bonds, put or call options, swaps, futures, currency hedges, and other financial instruments.

Dartmouth also invests in venture capital, private equity, real estate, other real assets, and other debt related strategies through private limited partnerships, which are illiquid. These investments often require the estimation of fair value by the general partner in the absence of readily determinable market values. The private portfolio is based primarily in the United States but includes managers who may invest globally. Real Estate investments also include real estate investment trust securities held through publically traded mutual funds as well as directly held real estate. Other real asset investments include limited partnerships targeting natural resource investments.

Investments at fair value consisted of the following at June 30 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endowment investments</td>
<td>$4,729,487</td>
<td>$4,535,783</td>
</tr>
<tr>
<td>Split-interest agreement investments</td>
<td>133,448</td>
<td>125,245</td>
</tr>
<tr>
<td>Operating and other investments</td>
<td>841,756</td>
<td>886,760</td>
</tr>
<tr>
<td><strong>Total investments</strong></td>
<td><strong>$5,704,691</strong></td>
<td><strong>$5,547,788</strong></td>
</tr>
</tbody>
</table>

The framework for measuring fair value utilizes a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels of the fair value hierarchy are as follows:

Level 1 - Quoted prices (unadjusted) in active markets for identical investments as of the reporting date. The type of investment in Level 1 includes actively listed equities, U.S. treasury securities, and exchange traded and registered funds all held directly by Dartmouth, and excludes listed equities and other securities held indirectly through commingled funds.

Level 2 - Pricing inputs, including broker quotes, are generally those other than exchange quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies. The type of investments in Level 2 includes fixed income securities and derivatives.

Level 3 - Pricing inputs are unobservable for the investment and include situations where there is little, if any, market activity for the investment. The inputs into the determination of fair value require significant management judgment or estimation. The type of investments in Level 3 includes directly held real estate, and other illiquid investments.
In May 2015, the FASB issued amended guidance on the disclosures for investments in certain entities that calculate net asset value per share (or its equivalent). The amendments remove the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value (NAV) per share practical expedient. The amendments also remove the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the NAV per share practical expedient. Rather, those disclosures are limited to investments for which the entity has not elected to measure the fair value using that practical expedient. The guidance is effective for fiscal years beginning after December 15, 2015 and for interim periods within those years. As permitted under the guidance, Dartmouth has elected to early adopt for the fiscal year ended June 30, 2015. In accordance with the guidance, previously reported amounts have been revised to conform with the current presentation.

The inputs or methodology used to value or classify investments for financial reporting purposes is not necessarily an indication of the risk associated with investing in those investments.

The following Fair Value Leveling table summarizes Dartmouth’s assets that are reported at fair value by their fair value hierarchy classification as of June 30, 2015 (in thousands):

<table>
<thead>
<tr>
<th>Assets:</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investments:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$259,514</td>
<td>$</td>
<td>$</td>
<td>$259,514</td>
</tr>
<tr>
<td>Fixed income</td>
<td>391,956</td>
<td>204,863</td>
<td>79</td>
<td>596,898</td>
</tr>
<tr>
<td>Global equity:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>US equity</td>
<td>521,312</td>
<td>-</td>
<td>523</td>
<td>521,835</td>
</tr>
<tr>
<td>International</td>
<td>18,130</td>
<td>-</td>
<td>-</td>
<td>18,130</td>
</tr>
<tr>
<td>Emerging markets</td>
<td>83,232</td>
<td>-</td>
<td>-</td>
<td>83,232</td>
</tr>
<tr>
<td>Real assets:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Real estate</td>
<td>15,981</td>
<td>-</td>
<td>199,028</td>
<td>215,009</td>
</tr>
<tr>
<td>Other real assets</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>2</td>
</tr>
<tr>
<td>Other investments</td>
<td>-</td>
<td>122</td>
<td>1,728</td>
<td>1,850</td>
</tr>
<tr>
<td>Contributions in Advance</td>
<td>32,000</td>
<td>-</td>
<td>-</td>
<td>32,000</td>
</tr>
<tr>
<td>Redemptions Receivable</td>
<td>109,301</td>
<td>-</td>
<td>-</td>
<td>109,301</td>
</tr>
<tr>
<td>Total investments</td>
<td>$1,431,428</td>
<td>$204,985</td>
<td>$201,358</td>
<td>$1,837,771</td>
</tr>
</tbody>
</table>

The following Fair Value Leveling table summarizes Dartmouth’s assets that are reported at fair value by their fair value hierarchy classification as of June 30, 2014 (in thousands):

<table>
<thead>
<tr>
<th>Assets:</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investments:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$246,979</td>
<td>$</td>
<td>$</td>
<td>$246,979</td>
</tr>
<tr>
<td>Fixed income</td>
<td>199,019</td>
<td>177,470</td>
<td>458</td>
<td>376,947</td>
</tr>
<tr>
<td>Global equity:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>US equity</td>
<td>587,876</td>
<td>-</td>
<td>23</td>
<td>587,899</td>
</tr>
<tr>
<td>International</td>
<td>18,014</td>
<td>-</td>
<td>-</td>
<td>18,014</td>
</tr>
<tr>
<td>Emerging markets</td>
<td>48,548</td>
<td>-</td>
<td>-</td>
<td>48,548</td>
</tr>
<tr>
<td>Real assets:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Real estate</td>
<td>17,108</td>
<td>-</td>
<td>203,084</td>
<td>220,192</td>
</tr>
<tr>
<td>Other real assets</td>
<td>75,536</td>
<td>-</td>
<td>-</td>
<td>75,536</td>
</tr>
<tr>
<td>Other investments</td>
<td>-</td>
<td>116</td>
<td>7,683</td>
<td>7,799</td>
</tr>
<tr>
<td>Contribution in Advance</td>
<td>40,000</td>
<td>-</td>
<td>-</td>
<td>40,000</td>
</tr>
<tr>
<td>Redemptions Receivable</td>
<td>135,428</td>
<td>-</td>
<td>-</td>
<td>135,428</td>
</tr>
<tr>
<td>Total investments</td>
<td>$1,368,508</td>
<td>$177,586</td>
<td>$211,248</td>
<td>$1,757,342</td>
</tr>
</tbody>
</table>
The following tables present Dartmouth’s activity for the fiscal years ended June 30, 2015 and 2014 for investments measured at fair value in Level 3 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>Fixed Income</th>
<th>US Equity</th>
<th>Real Assets</th>
<th>Other Investments</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance as of June 30, 2014</td>
<td>$458</td>
<td>$23</td>
<td>$203,084</td>
<td>$7,683</td>
<td>$211,248</td>
</tr>
<tr>
<td>Acquisitions / purchases</td>
<td>-</td>
<td>500</td>
<td>1,062</td>
<td>16</td>
<td>1,578</td>
</tr>
<tr>
<td>Distributions / sales</td>
<td>-</td>
<td>-</td>
<td>(2,069)</td>
<td>(4,824)</td>
<td>(6,893)</td>
</tr>
<tr>
<td>Transfers out</td>
<td>(318)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>(318)</td>
</tr>
<tr>
<td>Investment income and realized gain (loss)</td>
<td>-</td>
<td>-</td>
<td>362</td>
<td>(1,147)</td>
<td>(785)</td>
</tr>
<tr>
<td>Change in unrealized gains (losses) on investments</td>
<td>(61)</td>
<td>-</td>
<td>(3,411)</td>
<td>-</td>
<td>(3,472)</td>
</tr>
<tr>
<td>Balance as of June 30, 2015</td>
<td>$79</td>
<td>$523</td>
<td>$199,028</td>
<td>$1,728</td>
<td>$201,358</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Fixed Income</th>
<th>US Equity</th>
<th>Real Assets</th>
<th>Other Investments</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance as of June 30, 2013</td>
<td>$1</td>
<td>$1</td>
<td>$3,884</td>
<td>$2,073</td>
<td>$5,959</td>
</tr>
<tr>
<td>Acquisitions / purchases</td>
<td>-</td>
<td>-</td>
<td>2,416</td>
<td>5,216</td>
<td>7,632</td>
</tr>
<tr>
<td>Distributions / sales</td>
<td>-</td>
<td>-</td>
<td>(2,838)</td>
<td>(225)</td>
<td>(3,063)</td>
</tr>
<tr>
<td>Transfers in</td>
<td>379</td>
<td>-</td>
<td>193,571</td>
<td>1,583</td>
<td>195,533</td>
</tr>
<tr>
<td>Transfers out</td>
<td>-</td>
<td>22</td>
<td>-</td>
<td>-</td>
<td>22</td>
</tr>
<tr>
<td>Investment return (loss)</td>
<td>-</td>
<td>-</td>
<td>893</td>
<td>(1,067)</td>
<td>(174)</td>
</tr>
<tr>
<td>Unrealized gains (losses) on investments</td>
<td>78</td>
<td>-</td>
<td>5,158</td>
<td>103</td>
<td>5,339</td>
</tr>
<tr>
<td>Balance as of June 30, 2014</td>
<td>$458</td>
<td>$23</td>
<td>$203,084</td>
<td>$7,683</td>
<td>$211,248</td>
</tr>
</tbody>
</table>

Transfers between levels of the fair value hierarchy are reported at the beginning of the reporting period in which they occur. For fiscal year 2015, transfers from Level 3 to Level 2 are primarily due to the increased observability of pricing inputs for certain securities. For fiscal year 2014, transfers from Level 2 to Level 3, are primarily due to the decreased observability of pricing inputs for certain securities, as well as, effective July 1, 2013, Dartmouth considers its directly held real estate investments to be Level 3 investments based on the provision of additional transparency into the observability of inputs.

The following table provides quantitative information about the significant unobservable inputs used in the valuation of directly held real estate as of June 30, 2015 and June 30, 2014. Investments in real estate represent the total asset value of each of the underlying property investments. A reasonable shift in input in any one third party appraisal would likely not result in a significant change in fair value measurement to the directly held real estate portfolio, however, actual results could differ materially from these estimates particularly during periods of investment and/or interest rate volatility.

June 30, 2015:

<table>
<thead>
<tr>
<th>Valuation Technique</th>
<th>Fair Value</th>
<th>Unobservable Inputs</th>
<th>Input Value(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Third party appraisal-income approach &amp; comparable sales</td>
<td>$ 193,964</td>
<td>Capitalization rate</td>
<td>6.50 – 9.00%</td>
</tr>
<tr>
<td>Tax assessed value – adjusted annually</td>
<td>4,438</td>
<td>Discount rate</td>
<td>8.00%</td>
</tr>
<tr>
<td>Cost</td>
<td>626</td>
<td>State/Local equalization ratios</td>
<td>.900 – .983</td>
</tr>
<tr>
<td>Total</td>
<td>$199,028</td>
<td>Not applicable</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

1 The fair value may be determined using multiple valuation techniques.
June 30, 2014:

<table>
<thead>
<tr>
<th>Valuation Technique</th>
<th>Fair Value</th>
<th>Unobservable</th>
<th>Input Value(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Third party appraisal-income approach &amp; comparable sales</td>
<td>$ 183,007</td>
<td>Capitalization rate</td>
<td>6.50 – 9.00%</td>
</tr>
<tr>
<td>Tax assessed value – adjusted annually</td>
<td>19,484</td>
<td>Discount rate</td>
<td>8.00 – 12.00%</td>
</tr>
<tr>
<td>Cost</td>
<td>593</td>
<td>State/Local equalization ratios</td>
<td>.947 – .993</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$ 203,084</strong></td>
<td>Not applicable</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

1 The fair value may be determined using multiple valuation techniques.

The following Fair Value NAV table lists specified investment terms by asset category for Dartmouth’s interest in certain commingled funds and private partnership interests that are reported using NAV as the practical expedient as of June, 30, 2015 (in thousands):

<table>
<thead>
<tr>
<th>Asset Category</th>
<th>Amount</th>
<th>Redemption Terms</th>
<th>Days Notice</th>
<th>Remaining Unfunded Commitment</th>
<th>Remaining Life</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixed income</td>
<td>$ 41,405</td>
<td>Monthly Ranges from quarterly to bi-annual</td>
<td>30 - 40</td>
<td>$ -</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Global equity:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>US equity</td>
<td>689,016</td>
<td>Ranges from monthly to quarterly Ranges from daily</td>
<td>30 – 90</td>
<td>35,000</td>
<td>Not applicable</td>
</tr>
<tr>
<td>International</td>
<td>335,524</td>
<td>to annually Ranges from daily</td>
<td>30 – 180</td>
<td>-</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Emerging markets</td>
<td>151,097</td>
<td>to annually</td>
<td>30 – 180</td>
<td>-</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Marketable alternative strategies</td>
<td>1,146,224</td>
<td>Ranges from quarterly to every three years</td>
<td>30 – 180</td>
<td>-</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Private equity/Venture capital</td>
<td>999,865</td>
<td>Illiquid</td>
<td>Not applicable</td>
<td>393,297</td>
<td>1 - 12 years</td>
</tr>
<tr>
<td>Real assets:</td>
<td>314,892</td>
<td>Illiquid</td>
<td>Not applicable</td>
<td>166,405</td>
<td>1 - 12 years</td>
</tr>
<tr>
<td>Other real assets</td>
<td>188,897</td>
<td>Illiquid</td>
<td>Not applicable</td>
<td>196,910</td>
<td>1 – 20 years</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$ 3,866,920</strong></td>
<td></td>
<td></td>
<td><strong>$ 791,612</strong></td>
<td></td>
</tr>
</tbody>
</table>

1 US equity includes funds that have restrictions on the ability to fully redeem up to five years.
2 Marketable alternative strategies includes funds that have restrictions on the ability to fully redeem up to five years, excluding illiquid securities and special investments.

The following Fair Value NAV table lists specified investment terms by asset category for Dartmouth’s interest in certain commingled funds and private partnership interests that are reported using NAV as the practical expedient as of June, 30, 2014 (in thousands):

<table>
<thead>
<tr>
<th>Asset Category</th>
<th>Amount</th>
<th>Redemption Terms</th>
<th>Days Notice</th>
<th>Remaining Unfunded Commitment</th>
<th>Remaining Life</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixed income</td>
<td>$ 45,783</td>
<td>Monthly Ranges from quarterly to bi-annual</td>
<td>30 - 40</td>
<td>$ -</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Global equity:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>US equity</td>
<td>618,443</td>
<td>Ranges from monthly to quarterly</td>
<td>60 – 90</td>
<td>-</td>
<td>Not applicable</td>
</tr>
<tr>
<td>International</td>
<td>231,936</td>
<td>to quarterly</td>
<td>6 – 60</td>
<td>-</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>
Emerging markets  147,095  Ranges from daily to bi-annual  30 – 120  -  Not applicable
Marketable alternative strategies  1,088,840  Ranges from quarterly to every three years\(^2\)  60 – 180  -  Not applicable

<table>
<thead>
<tr>
<th>Amount</th>
<th>Redemption Terms</th>
<th>Days Notice</th>
<th>Remaining Unfunded Commitment</th>
<th>Remaining Life</th>
</tr>
</thead>
<tbody>
<tr>
<td>Private equity/</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venture capital  1,033,804  Illiquid  Not applicable  310,148  1 - 12 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Real assets:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Real estate  368,133  Illiquid  Not applicable  126,232  1 - 12 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other real assets  256,412  Illiquid  Not applicable  109,430  1 – 20 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total  $3,790,446</td>
<td>$545,810</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^1\) US equity includes funds that have restrictions on the ability to fully redeem up to five years.

\(^2\) Marketable alternative strategies includes funds that have restrictions on the ability to fully redeem up to five years, excluding illiquid securities and special investments.

Investments reported in the Fair Value Leveling and Fair Value NAV tables total $5,704,691 and $5,547,788 and are presented on the consolidated Statement of Financial Position as of June 30, 2015 and 2014, respectively.

The following tables set forth the fair value of Dartmouth’s derivative instruments by contract type as of June 30, 2015 and 2014 and gains/losses related to derivative activities for the years ended June 30, 2015 and 2014 (in thousands):

### June 30, 2015:

<table>
<thead>
<tr>
<th>Notional Exposure</th>
<th>Fair Value(^1)</th>
<th>Net Gain/Loss(^2)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Foreign currency forward contracts</strong></td>
<td>$32,408</td>
<td>$248</td>
</tr>
<tr>
<td><strong>Fixed income futures contracts</strong></td>
<td>56,277</td>
<td>412</td>
</tr>
<tr>
<td><strong>Interest rate swaps</strong></td>
<td>-</td>
<td>3</td>
</tr>
<tr>
<td><strong>Credit default swaps</strong></td>
<td>5,551</td>
<td>203</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$94,236</td>
<td>$866</td>
</tr>
</tbody>
</table>

### June 30, 2014:

<table>
<thead>
<tr>
<th>Notional Exposure</th>
<th>Fair Value(^1)</th>
<th>Net Gain/Loss(^2)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Foreign currency forward contracts</strong></td>
<td>$46,175</td>
<td>$327</td>
</tr>
<tr>
<td><strong>Fixed income futures contracts</strong></td>
<td>25,776</td>
<td>98</td>
</tr>
<tr>
<td><strong>Interest rate swaps</strong></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Credit default swaps</strong></td>
<td>8,421</td>
<td>58</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$80,372</td>
<td>$483</td>
</tr>
</tbody>
</table>

\(^1\) The net fair value of these derivative instruments is included in the consolidated Statement of Financial Position as investments at fair value.

\(^2\) The net gain/loss from these derivative instruments is presented in the operating and non-operating sections of the consolidated Statement of Activities as other operating income and non-operating changes.

Dartmouth enters into foreign currency forward contracts and government bond futures and forwards to efficiently manage portfolio exposures to global currencies and interest rates. These instruments may be used to hedge the portfolio from unwanted currency and interest rate risk, but also to efficiently implement active duration and relative value currency strategies.
Dartmouth College
Notes to Consolidated Financial Statements
For the years ended June 30, 2015 and 2014

Dartmouth is obligated to pledge to the appropriate broker cash or securities to be held as collateral, as determined by exchange margin requirements for futures contracts held. These instruments are valued using market-based prices and are included in Level 2 in the Fair Value Leveling table. At June 30, 2015 and 2014, the fair value of Dartmouth’s pledged collateral on futures contracts for investment purposes was $312,000 and $426,000 respectively and is included in investments on the consolidated Statement of Financial Position.

Dartmouth enters into swap contracts for investment purposes. Interest rate swap contracts are used to efficiently manage portfolio exposures to interest rates. These instruments may be used to hedge the portfolio from unwanted interest rate risk, but also to efficiently implement active duration strategies. These instruments are valued using market-based prices and are included in Level 2 in the Fair Value Leveling table. The fair value of the contracts is included in the consolidated Statement of Financial Position as investments at fair value. The gain on these contracts is presented in the operating and non-operating sections of the consolidated Statement of Activities.

Credit default swaps are used to simulate long or short positions or to reduce credit risk where exposure exists. The buyer of a credit default swap is obligated to pay to the seller a periodic stream of payments over the term of the contract in return for a contingent payment upon occurrence of a contracted credit event. The seller of a credit default swap bears the obligation to pay the buyer upon occurrence of a contracted credit event in return for a periodic stream of fixed payments from the buyer over the term of the contract. These instruments are valued using market-based prices and are included in Level 2 in the Fair Value Leveling table. The fair value of these credit default swap contracts is included in the consolidated Statement of Financial Position as investments at fair value. The net gain/loss on these credit default swap contracts is presented in the operating and non-operating sections of the consolidated Statement of Activities.

E. Endowment

The changes in fair value of net assets held in endowment and similar funds for the years ended June 30 were as follows (in thousands):

<table>
<thead>
<tr>
<th>Endowment net assets, June 30, 2014</th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net investment return:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investment income</td>
<td>6,634</td>
<td>22,045</td>
<td>56</td>
<td>28,735</td>
</tr>
<tr>
<td>Net appreciation</td>
<td>73,410</td>
<td>247,127</td>
<td>645</td>
<td>321,182</td>
</tr>
<tr>
<td>Total investment return</td>
<td>80,044</td>
<td>269,172</td>
<td>701</td>
<td>349,917</td>
</tr>
<tr>
<td>Gifts</td>
<td>141</td>
<td>1,929</td>
<td>43,959</td>
<td>46,024</td>
</tr>
<tr>
<td>Distribution of endowment return to all funds</td>
<td>(48,942)</td>
<td>(165,235)</td>
<td>(48)</td>
<td>(214,225)</td>
</tr>
<tr>
<td>Other changes, net</td>
<td>7,991</td>
<td>(5,185)</td>
<td>10,745</td>
<td>13,551</td>
</tr>
<tr>
<td><strong>Endowment net assets, June 30, 2015</strong></td>
<td>$1,075,885</td>
<td>$2,407,876</td>
<td>$1,179,730</td>
<td>$4,663,491</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Endowment net assets, June 30, 2013</th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net investment return:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investment income</td>
<td>7,224</td>
<td>23,949</td>
<td>-</td>
<td>31,173</td>
</tr>
<tr>
<td>Net appreciation</td>
<td>175,798</td>
<td>568,887</td>
<td>1,595</td>
<td>746,280</td>
</tr>
<tr>
<td>Total investment return</td>
<td>183,022</td>
<td>592,836</td>
<td>1,595</td>
<td>777,453</td>
</tr>
<tr>
<td>Gifts</td>
<td>53</td>
<td>7,779</td>
<td>135,624</td>
<td>143,456</td>
</tr>
<tr>
<td>Distribution of endowment return to all funds</td>
<td>(43,940)</td>
<td>(144,606)</td>
<td>-</td>
<td>(188,546)</td>
</tr>
<tr>
<td>Other changes, net</td>
<td>2,921</td>
<td>(3,446)</td>
<td>2,785</td>
<td>2,260</td>
</tr>
<tr>
<td><strong>Endowment net assets, June 30, 2014</strong></td>
<td>$1,036,651</td>
<td>$2,307,195</td>
<td>$1,124,373</td>
<td>$4,468,219</td>
</tr>
</tbody>
</table>
Included in temporarily restricted endowment net assets at the end of the year is the remaining amount of expendable accumulated appreciation on permanent endowment funds of $2,027,492,000 and $1,927,893,000 at June 30, 2015 and 2014, respectively.

Endowment net assets consist of the following as of June 30, 2015 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donor-restricted endowment funds</td>
<td>$</td>
<td>$2,407,876</td>
<td>$1,179,730</td>
<td>$3,587,606</td>
</tr>
<tr>
<td>Board-designated endowment funds</td>
<td>1,075,885</td>
<td></td>
<td></td>
<td>1,075,885</td>
</tr>
<tr>
<td>Total endowment net assets</td>
<td>$1,103,651</td>
<td>$2,407,876</td>
<td>$1,179,730</td>
<td>$4,663,258</td>
</tr>
</tbody>
</table>

Endowment net assets consist of the following as of June 30, 2014 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donor-restricted endowment funds</td>
<td>$</td>
<td>$2,307,195</td>
<td>$1,124,373</td>
<td>$3,431,568</td>
</tr>
<tr>
<td>Board-designated endowment funds</td>
<td>1,036,651</td>
<td></td>
<td></td>
<td>1,036,651</td>
</tr>
<tr>
<td>Total endowment net assets</td>
<td>$1,074,306</td>
<td>$2,307,195</td>
<td>$1,124,373</td>
<td>$4,504,874</td>
</tr>
</tbody>
</table>

From time to time, the fair values of assets associated with individual donor restricted endowment funds may fall below the level that the donor or UPMIFA requires to retain as a fund of perpetual duration due to market declines. In accordance with GAAP, events of this nature are reported as reductions in unrestricted net assets. As of June 30, 2015 and 2014, there were no endowment funds with a market value less than this required level. A Board of Trustees policy limits the distribution of these funds to current income only, except in cases where the donor directs otherwise.

Dartmouth employs a total return endowment utilization policy that establishes the amount of investment return made available for spending each fiscal year. The amount appropriated for expenditure each year is independent of the actual return for the year, but the appropriated amount cannot exceed the total accumulated return in an individual fund at the time of distribution. The Board approves the formula that determines the amount appropriated from endowment each year. The resulting fiscal 2015 endowment distribution of $214,225,000 represents a 4.8% distribution rate when measured against the previous year’s June 30th endowment market value. Investment return earned in excess of the amount appropriated annually is reinvested in the funds, but can be appropriated in future years in accordance with the utilization policy. The net appreciation on most of the permanently and temporarily restricted endowment funds is reported together with temporarily restricted net assets until such time as all or a portion of the appreciation is appropriated for spending in accordance with the utilization policy and applicable state law.

The overall investment performance objective for the endowment is to generate real (inflation-adjusted) returns net of investment expenses sufficient to support Dartmouth’s current operating needs while maintaining the long-term purchasing power of the endowment. The Investment Committee of the Board of Trustees has determined that a well-diversified mix of assets offers the best opportunity for maximum return with acceptable risk over time. Dartmouth relies on a total return strategy in which investment returns are achieved through both capital appreciation (both realized and unrealized) and current yield (interest and dividends). Investment decisions are made with a view toward maximizing long-term return opportunities while maintaining an acceptable level of investment risk and liquidity.

### F. Land, Buildings, Equipment, and Construction in Progress

Land, buildings, equipment, and construction in progress balances at June 30 were as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Land</td>
<td>$19,158</td>
<td>$19,158</td>
</tr>
<tr>
<td>Buildings</td>
<td>1,175,416</td>
<td>1,147,098</td>
</tr>
<tr>
<td>Land improvements</td>
<td>112,339</td>
<td>109,407</td>
</tr>
</tbody>
</table>
Dartmouth has conditional asset retirement obligations arising from legal obligations to perform certain activities in connection with the retirement, disposal, or abandonment of assets, including asbestos abatement, leasehold improvements, hazardous materials, and equipment disposal and cleanup. The liability was initially recorded at fair value, and is adjusted for accretion expense, and changes in the amount or timing of cash flows. The corresponding asset retirement costs are capitalized as part of the carrying values of the related long-lived assets and depreciated over the useful lives of the assets.

G. Bonds, Mortgages, and Notes Payable

Indebtedness at June 30 consisted of the following (in thousands):

<table>
<thead>
<tr>
<th>New Hampshire Health and Education Facilities Authority (NHHEFA):</th>
<th>Fiscal Year Maturity</th>
<th>Interest Rate</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tax-Exempt Fixed Rate:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Series 2009</td>
<td>2019 – 2039</td>
<td>3.30% - 4.77%</td>
<td>$198,875</td>
<td>$198,875</td>
</tr>
<tr>
<td>Tax-Exempt Variable Rate:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Series 2002</td>
<td>2032</td>
<td>.02% - .12%</td>
<td>101,000</td>
<td>101,000</td>
</tr>
<tr>
<td>Series 2003</td>
<td>2023</td>
<td>.02% - .11%</td>
<td>69,200</td>
<td>76,600</td>
</tr>
<tr>
<td>Series 2007A</td>
<td>2031</td>
<td>.01% - .13%</td>
<td>89,665</td>
<td>89,710</td>
</tr>
<tr>
<td>Series 2007B</td>
<td>2041</td>
<td>.01% - .13%</td>
<td>75,000</td>
<td>75,000</td>
</tr>
<tr>
<td><strong>Subtotal tax-exempt bonds</strong></td>
<td></td>
<td></td>
<td>$533,740</td>
<td>$541,185</td>
</tr>
<tr>
<td>Taxable Bonds:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NHHEFA Variable Rate:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Series 2007C</td>
<td>2041</td>
<td>.07% - .16%</td>
<td>30,000</td>
<td>30,000</td>
</tr>
<tr>
<td>Fixed Rate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Series 2009</td>
<td>2019</td>
<td>4.75%</td>
<td>250,000</td>
<td>250,000</td>
</tr>
<tr>
<td>Series 2012A</td>
<td>2042</td>
<td>4.00%</td>
<td>70,000</td>
<td>70,000</td>
</tr>
<tr>
<td>Series 2012B</td>
<td>2043</td>
<td>3.76%</td>
<td>150,000</td>
<td>150,000</td>
</tr>
<tr>
<td><strong>Subtotal taxable bonds</strong></td>
<td></td>
<td></td>
<td>$500,000</td>
<td>$500,000</td>
</tr>
<tr>
<td><strong>Subtotal bonds</strong></td>
<td></td>
<td></td>
<td>$1,033,740</td>
<td>$1,041,185</td>
</tr>
<tr>
<td>Mortgages on real estate investments:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fixed Rate</td>
<td></td>
<td></td>
<td>47,568</td>
<td>49,003</td>
</tr>
<tr>
<td><strong>Subtotal bonds, mortgages and notes payable</strong></td>
<td></td>
<td></td>
<td>$1,093,908</td>
<td>$1,109,088</td>
</tr>
</tbody>
</table>

Original issue premium, net

| Equipment and software                                         | 315,845 | 292,518 |
| Less: accumulated depreciation                                  | (768,809) | (708,562) |
| Construction in progress                                        | 114,953 | 95,912 |
| **Total net book value**                                        | $968,902 | $955,531 |
Interest expense for the years ended June 30 consists of (in thousands):

Consolidated Statement of Activities:

<table>
<thead>
<tr>
<th>Description</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Endowment Activities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest expense on mortgage and debt used to finance endowment-related real</td>
<td>$2,743</td>
<td>$2,664</td>
</tr>
<tr>
<td>estate projects, presented as a reduction in endowment investment return</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Operating Activities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest expense on debt (including payments on interest rate swap agreements)</td>
<td>24,603</td>
<td>24,462</td>
</tr>
<tr>
<td>used to finance facilities projects, included in “Interest and Amortization” on the consolidated Statement of Operating Expenses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest expense on other operating indebtedness, included in “Interest and Amortization” on the consolidated Statement of Operating Expenses</td>
<td>154</td>
<td>154</td>
</tr>
<tr>
<td><strong>Non-Operating Activities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest expense on debt used to finance student loans, presented as a deduction from other non-operating earnings</td>
<td>1,406</td>
<td>1,406</td>
</tr>
<tr>
<td>Interest expense on other non-operating indebtedness, presented as a deduction from other non-operating earnings</td>
<td>22,126</td>
<td>23,297</td>
</tr>
<tr>
<td><strong>Total interest expense on the consolidated Statement of Activities</strong></td>
<td>$51,032</td>
<td>$51,983</td>
</tr>
</tbody>
</table>

Consolidated Statement of Financial Position:

Interest paid on debt used to finance facilities projects capitalized in connection with various construction projects

$1,214 $199

Scheduled principal payments due for each of the next five years ending June 30 and thereafter are as follows, excluding maturity of commercial paper and unamortized discounts and premiums are (in thousands):

<table>
<thead>
<tr>
<th>June 30</th>
<th>Principal Due</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>$9,154</td>
</tr>
<tr>
<td>2017</td>
<td>27,627</td>
</tr>
<tr>
<td>2018</td>
<td>9,909</td>
</tr>
<tr>
<td>2019</td>
<td>268,209</td>
</tr>
<tr>
<td>2020</td>
<td>10,676</td>
</tr>
<tr>
<td>Thereafter</td>
<td>755,733</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$1,081,308</strong></td>
</tr>
</tbody>
</table>

Principal due after June 30, 2020, includes the following “balloon” payments due on Dartmouth’s indebtedness (in thousands):

<table>
<thead>
<tr>
<th>June 30</th>
<th>Indebtedness</th>
<th>Payment</th>
</tr>
</thead>
<tbody>
<tr>
<td>2027</td>
<td>NHHEFA Series 2007A bonds</td>
<td>$31,820</td>
</tr>
<tr>
<td>2028</td>
<td>NHHEFA Series 2009 bonds</td>
<td>$32,190</td>
</tr>
<tr>
<td>2028</td>
<td>NHHEFA Series 2007A bonds</td>
<td>$52,060</td>
</tr>
<tr>
<td>2029</td>
<td>NHHEFA Series 2009 bonds</td>
<td>$20,000</td>
</tr>
<tr>
<td>2031</td>
<td>NHHEFA Series 2007A bonds</td>
<td>$5,120</td>
</tr>
<tr>
<td>2032</td>
<td>NHHEFA Series 2002 bonds</td>
<td>$101,000</td>
</tr>
<tr>
<td>2036</td>
<td>NHHEFA Series 2007B bonds</td>
<td>$18,000</td>
</tr>
</tbody>
</table>
Dartmouth College
Notes to Consolidated Financial Statements
For the years ended June 30, 2015 and 2014

The estimated fair value of the bonds was approximately $1,069,761,000 and $1,095,409,000 as of June 30, 2015 and 2014, respectively. The fair value for fixed-rate debt is based on estimates of the prevailing market yield and resulting price for each maturity of debt. The market yield is impacted by several factors including credit, length of maturity, coupon, and optional redemption provisions. Variable rate debt is valued at par since the rate is reset frequently and the bonds are puttable by the investor and callable by the borrower at any time. Dartmouth considers this to be a Level 2 measurement.

The NHHEFA bonds are a general obligation collateralized only by Dartmouth’s pledge of full faith and credit and by funds held from time to time by the trustee for the benefit of the holders of the bonds under the respective bond resolutions. Dartmouth has agreed to certain covenants with respect to encumbrance or disposition of its core campus.

During fiscal year 2009, Dartmouth entered into six interest rate swap agreements. Information related to these interest rate swap agreements as of June 30, 2015, including the fixed interest rate paid by Dartmouth and percent of LIBOR BBA (1 month) received on the notional principal, is presented in the table below (in thousands):

<table>
<thead>
<tr>
<th>Expiration Date</th>
<th>Notional Amount</th>
<th>Fixed Interest Rate %</th>
<th>% of LIBOR BBA</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/01/2032</td>
<td>$100,000</td>
<td>3.75</td>
<td>67</td>
</tr>
<tr>
<td>06/01/2041</td>
<td>$100,000</td>
<td>3.73</td>
<td>70</td>
</tr>
<tr>
<td>06/01/2027</td>
<td>$31,930</td>
<td>3.77</td>
<td>72</td>
</tr>
<tr>
<td>06/01/2028</td>
<td>$52,660</td>
<td>3.78</td>
<td>72</td>
</tr>
<tr>
<td>06/01/2042</td>
<td>$100,000</td>
<td>3.73</td>
<td>70</td>
</tr>
<tr>
<td>06/01/2043</td>
<td>$165,000</td>
<td>3.74</td>
<td>70</td>
</tr>
</tbody>
</table>

The fair value of these agreements at June 30, 2015 and 2014, based on various factors contained in the interest rate swap agreements and certain interest rate assumptions, was approximately $167,417,000 and $141,219,000, respectively, and is considered a Level 2 measurement. The increase in the liability of $26,198,000 and $7,997,000 for the years ended June 30, 2015 and 2014, respectively, is presented as a change in unrealized loss in the non-operating section of the consolidated Statement of Activities. Net payments or receipts under the swap agreements associated with facilities debt are reflected as interest expense. These financial instruments involve counter-party credit exposure. Commercial paper consists of notes issued in the short-term taxable market, and is sold at a discount from par. The maturities of individual notes are issued in ranges from one day to no more than 270 days, and fall on average in a range of thirty to ninety days. Dartmouth reports commercial paper at carrying value, which closely approximates fair value for those liabilities.

Dartmouth maintains stand-by bond purchase agreements with financial institutions totaling approximately $364,865,000 to provide alternative liquidity to support its variable rate demand bonds in the event that the bonds cannot be remarketed. Financing obtained through these stand-by credit agreements to fund the repurchase of such bonds would bear interest rates different from those associated with the original bond issues, and mature over a three or a five year period following repurchase. The agreements have various maturity dates between August 2015 and December 2016. There were no amounts outstanding at June 30, 2015 and 2014 under these agreements.

Dartmouth has a $100,000,000 line of credit with a maturity date of December 17, 2015. There have been no borrowings under this line of credit.
H. **Pension and Other Employment Related Obligations**

Liabilities for retirement and postretirement medical benefits, salaries, wages, and other benefits under employment agreements consisted of the following at June 30 (in thousands):

<table>
<thead>
<tr>
<th>Liabilities</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retirement and postretirement benefits</td>
<td>$418,113</td>
<td>$358,284</td>
</tr>
<tr>
<td>Compensated absences, severance plans, and other commitments</td>
<td>$21,907</td>
<td>$20,244</td>
</tr>
<tr>
<td>Self-insured benefits</td>
<td>$11,344</td>
<td>$11,862</td>
</tr>
<tr>
<td><strong>Total employment related obligations</strong></td>
<td><strong>$451,354</strong></td>
<td><strong>$390,390</strong></td>
</tr>
</tbody>
</table>

In fiscal year 1998, Dartmouth revised its pension benefit for staff and non-union service employees, giving each participant a one-time option to either remain in the defined benefit plan or enroll in the defined contribution plan effective January 1, 1998. Staff and non-union service employees hired since that date receive retirement benefits under the defined contribution plan. Effective January 1, 2006, all union employees are enrolled in the defined contribution plan.

Dartmouth’s postretirement medical benefits consist of medical insurance coverage for retirees. Employees hired prior to July 1, 2009 that are 55 or older and have at least ten continuous years of service in a benefits-eligible position immediately prior to retirement are currently eligible for a subsidy toward the purchase of Retiree Medical Benefits. The subsidy amount was based on the employee’s annual salary, age, and years of service as of June 30, 2009. For retirees under the age of 65, the medical insurance options are the same as for active employees. At age 65, the retiree would enroll in the Dartmouth College Medicare Supplement (DCMS) plan. New employees hired on or after July 1, 2009 are eligible to participate in a Retirement Savings Match and are eligible to purchase the retiree group medical insurance at full cost if they qualify at retirement.

Information pertaining to the pension and postretirement benefits at June 30 include (in thousands):

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in benefit obligation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beginning of year</td>
<td>$134,216</td>
<td>$120,696</td>
<td>$336,563</td>
<td>$226,449</td>
<td></td>
</tr>
<tr>
<td>Service cost</td>
<td>2,785</td>
<td>2,538</td>
<td>8,327</td>
<td>5,423</td>
<td></td>
</tr>
<tr>
<td>Interest cost</td>
<td>5,557</td>
<td>5,558</td>
<td>15,633</td>
<td>12,174</td>
<td></td>
</tr>
<tr>
<td>Benefits paid</td>
<td>(8,100)</td>
<td>(7,681)</td>
<td>(6,568)</td>
<td>(5,364)</td>
<td></td>
</tr>
<tr>
<td>Actuarial (gain)/loss</td>
<td>(2,027)</td>
<td>13,105</td>
<td>42,224</td>
<td>97,881</td>
<td></td>
</tr>
<tr>
<td>End of year</td>
<td>$132,431</td>
<td>$134,216</td>
<td>$396,179</td>
<td>$336,563</td>
<td></td>
</tr>
</tbody>
</table>

| Change in estimated fair value of plan assets: |        |        |                         |        |        |
| Beginning of year | $127,229 | $113,931 | - | - |
| Actual return on plan assets | 5,188 | 18,979 | - | - |
| Employer contributions | 4,000 | 2,000 | 6,568 | 5,364 |
| Benefits paid       | (8,100) | (7,681) | (6,568) | (5,364) |
| End of year         | $128,317 | $127,229 | - | - |

| Funded status (plan assets less than benefits obligation) | $ (4,114) | $ (6,987) | $ (396,179) | $ (336,563) |

| Net periodic benefit (income) cost included the following: |        |        |                         |        |        |
| Service cost      | $2,785  | $2,538  | $8,327      | $5,423  |
| Interest cost     | 5,557  | 5,558  | 15,633     | 12,174 |
| Expected return on assets | (7,170) | (6,365) | - | - |
| Amortization of prior service cost (credit) | 240 | 240 | (7,186) | (7,644) |
| Recognized net actuarial loss | 2,293 | 2,364 | 6,093 | - |
| Net periodic benefit cost | $3,705 | $4,335 | $22,867 | $9,953 |

| Weighted-average assumptions: |        |        |                         |        |        |
| Discount rate used to determine net periodic benefit cost | 4.30% | 4.80% | 4.70% | 5.45% |
Expected return on plan assets 6.70% 6.50% - -
Rate of compensation increase 3.00% 3.00% - -
Discount rate used to determine benefit obligations 4.40% 4.30% 4.85% 4.70%

The increase in the post-retirement benefit obligation is primarily due to an increase in future expected claims and updated assumptions about the trends in prescription drug prices and the related Medicare Part D subsidy, which is reflected in the 2015 actuarial loss of $42,224,000.

The estimated net cost that will be amortized into net periodic cost in fiscal 2016 for pension benefits and post-retirement benefits is $1,207,000 and $5,910,000, respectively.

The increase (decrease) in unrestricted net assets resulting from the change in pension and post-retirement benefit obligations consisted of the following (in thousands):

<table>
<thead>
<tr>
<th>Amount</th>
<th>Redemption Terms</th>
<th>Days Notice</th>
<th>Remaining Unfunded Commitment</th>
<th>Remaining Life</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixed income</td>
<td>$ 54,590</td>
<td>Daily</td>
<td>2</td>
<td>$ -</td>
</tr>
<tr>
<td>Global equity</td>
<td>$ 65,661</td>
<td>Daily</td>
<td>2</td>
<td>$ -</td>
</tr>
<tr>
<td>Private equity/ Venture capital</td>
<td>$ 2,896</td>
<td>Illiquid</td>
<td>Not applicable</td>
<td>463</td>
</tr>
<tr>
<td>Total</td>
<td>$ 123,147</td>
<td></td>
<td></td>
<td>$ 463</td>
</tr>
</tbody>
</table>

In addition to the investments disclosed above, the Plan also holds $5,170,000 in cash and cash equivalents at June 30, 2015, which is classified as a Level 1 investment in the fair value hierarchy.

The following table lists specified investment terms by asset category for defined benefit pension plan investments in certain commingled funds and private partnership interests that are reported using NAV as the practical expedient as of June 30, 2014 (in thousands):

<table>
<thead>
<tr>
<th>Amount</th>
<th>Redemption Terms</th>
<th>Days Notice</th>
<th>Remaining Unfunded Commitment</th>
<th>Remaining Life</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fixed income</td>
<td>$ 90,210</td>
<td>Daily</td>
<td>2</td>
<td>$ -</td>
</tr>
<tr>
<td>Global equity</td>
<td>$ 32,345</td>
<td>Daily</td>
<td>2</td>
<td>$ -</td>
</tr>
<tr>
<td>Private equity/ Venture capital</td>
<td>$ 3,777</td>
<td>Illiquid</td>
<td>Not applicable</td>
<td>580</td>
</tr>
<tr>
<td>Total</td>
<td>$ 126,332</td>
<td></td>
<td></td>
<td>$ 580</td>
</tr>
</tbody>
</table>
In addition to the investments disclosed above, the Plan also held $897,000 in cash and cash equivalents at June 30, 2014, which is classified as a Level 1 investment in the fair value hierarchy.

The overall investment strategy of the defined benefit pension plan (the Plan) is to utilize an asset mix that is designed to meet the near and longer term benefit payment obligations of the Plan. Over time, the asset mix may include global equity and fixed income exposures. Global equity exposure is designed to capture the equity market performance of developed markets while fixed income exposure provides a predictable yield as well as a hedge against changing interest rates by holding corporate bonds and other financial instruments. Other types of investments may include private equity, venture capital, and other private real asset partnerships that employ different underlying strategies. Outside investment advisors are utilized to manage the Plan assets and are selected based on their investment style, philosophy, and past performance. Dartmouth’s investment office is responsible for managing the asset allocation and investment risk management of the Plan.

Dartmouth makes annual contributions to maintain funding for the defined benefit plan on an actuarially recommended basis. Dartmouth currently expects to contribute $4 million to the defined benefit plan in fiscal year 2016.

Benefit payments, which reflect expected future service, as appropriate, are expected to be paid in each of the next five years ending June 30 and thereafter as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>Pension Benefits</th>
<th>Postretirement Benefits</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>$11,300</td>
<td>$8,400</td>
</tr>
<tr>
<td>2017</td>
<td>9,400</td>
<td>9,700</td>
</tr>
<tr>
<td>2018</td>
<td>9,400</td>
<td>10,900</td>
</tr>
<tr>
<td>2019</td>
<td>9,400</td>
<td>13,200</td>
</tr>
<tr>
<td>2020</td>
<td>9,400</td>
<td>14,700</td>
</tr>
<tr>
<td>Years 2021-2025</td>
<td>46,100</td>
<td>94,700</td>
</tr>
</tbody>
</table>

Assumed health care cost trend rates have a significant effect on the estimated amounts reported for the postretirement benefit plan. The medical cost trend rates for pre-age 65 and post-age 65 retirees, respectively, are assumed to be 7.1% and 7.0% in year 2016, decrease gradually to 5% and 5% in fiscal year 2023, respectively, and remain level thereafter. Dartmouth’s estimate of postretirement benefit expense and obligations also reflects the impact of the Medicare Prescription Drug Improvement and Modernization Act, which provides for tax-free subsidies to employers that offer retiree medical benefit plans with qualifying drug coverage.

A one percentage point increase (decrease) in assumed health care cost trend rates would have the following effect (in thousands):

- Increase (decrease) in total of service and interest cost components $6,073 $(4,691)
- Increase (decrease) in postretirement benefit obligation $78,514 $(61,391)

Dartmouth also maintains defined contribution retirement plans for its employees. These benefits are individually funded and are subject to various vesting requirements. Under these arrangements, Dartmouth makes contributions to individual self-directed retirement investment accounts for the participants. These contributions for the years ended June 30, 2015 and 2014 were $25,170,000 and $24,862,000, respectively. Dartmouth also maintains deferred compensation plans. The liabilities for the plans are included in pension and other employment related obligations in the consolidated Statement of Financial Position.

I. Other Operating Income

The major components of other operating income for the years ended June 30 were as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical School clinical services and other support</td>
<td>$54,267</td>
<td>$55,244</td>
</tr>
<tr>
<td>Foreign study and continuing education programs</td>
<td>13,158</td>
<td>13,317</td>
</tr>
</tbody>
</table>
Student activities and other program revenues 11,729 11,037
Athletics revenues 4,526 4,387
Hopkins Center and Hood Museum revenues 1,372 1,525
Other revenues 21,671 17,444
Investment income 18,341 49,602
Total other operating income $125,064 $152,556

J. Net Assets

Additional information pertaining to Dartmouth’s net assets at June 30 is presented below (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating funds</td>
<td>$ 356,275</td>
<td>$ 66,228</td>
<td>-</td>
<td>$ 422,503</td>
</tr>
<tr>
<td>Pledges</td>
<td>-</td>
<td>137,601</td>
<td>26,767</td>
<td>164,368</td>
</tr>
<tr>
<td>Postretirement and pension benefit obligations</td>
<td>(400,293)</td>
<td>-</td>
<td>-</td>
<td>(400,293)</td>
</tr>
<tr>
<td>Third-party charitable trusts</td>
<td>-</td>
<td>5,674</td>
<td>4,010</td>
<td>9,684</td>
</tr>
<tr>
<td>Facilities and capital</td>
<td>347,886</td>
<td>37,613</td>
<td>-</td>
<td>385,499</td>
</tr>
<tr>
<td>Interest rate swap agreements</td>
<td>(167,417)</td>
<td>-</td>
<td>-</td>
<td>(167,417)</td>
</tr>
<tr>
<td>Student loan funds</td>
<td>20,761</td>
<td>22,754</td>
<td>-</td>
<td>43,515</td>
</tr>
<tr>
<td>Other non-operating activities</td>
<td>79,091</td>
<td>44,813</td>
<td>-</td>
<td>123,904</td>
</tr>
<tr>
<td>Life income, annuity, and similar funds</td>
<td>-</td>
<td>50,399</td>
<td>32,808</td>
<td>83,207</td>
</tr>
<tr>
<td>Endowment funds</td>
<td>1,075,885</td>
<td>2,407,876</td>
<td>1,179,730</td>
<td>4,663,491</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>$1,312,188</strong></td>
<td><strong>$2,772,958</strong></td>
<td><strong>$1,243,315</strong></td>
<td><strong>$5,328,461</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Permanently Restricted</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating funds</td>
<td>$ 350,234</td>
<td>$ 69,862</td>
<td>-</td>
<td>$ 420,096</td>
</tr>
<tr>
<td>Pledges</td>
<td>-</td>
<td>81,460</td>
<td>15,798</td>
<td>97,258</td>
</tr>
<tr>
<td>Postretirement and pension benefit obligations</td>
<td>(343,550)</td>
<td>-</td>
<td>-</td>
<td>(343,550)</td>
</tr>
<tr>
<td>Third-party charitable trusts</td>
<td>-</td>
<td>6,096</td>
<td>3,816</td>
<td>9,912</td>
</tr>
<tr>
<td>Facilities and capital</td>
<td>336,815</td>
<td>23,808</td>
<td>-</td>
<td>360,623</td>
</tr>
<tr>
<td>Interest rate swap agreements</td>
<td>(141,219)</td>
<td>-</td>
<td>-</td>
<td>(141,219)</td>
</tr>
<tr>
<td>Student loan funds</td>
<td>21,434</td>
<td>21,913</td>
<td>-</td>
<td>43,347</td>
</tr>
<tr>
<td>Other non-operating activities</td>
<td>89,598</td>
<td>9,873</td>
<td>-</td>
<td>99,471</td>
</tr>
<tr>
<td>Life income, annuity, and similar funds</td>
<td>-</td>
<td>41,785</td>
<td>36,008</td>
<td>77,793</td>
</tr>
<tr>
<td>Endowment funds</td>
<td>1,036,651</td>
<td>2,407,876</td>
<td>1,124,373</td>
<td>4,663,491</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>$1,349,963</strong></td>
<td><strong>$2,561,992</strong></td>
<td><strong>$1,179,995</strong></td>
<td><strong>$5,091,950</strong></td>
</tr>
</tbody>
</table>

K. Commitments and Contingencies

Outstanding commitments on uncompleted construction contracts total $28,156,000 at June 30, 2015.

All funds expended by Dartmouth in connection with government sponsored grants and contracts are subject to audit by governmental agencies. The ultimate liability, if any, from such audits, is not expected to have a material adverse effect on Dartmouth’s financial position.

In conducting its activities, Dartmouth from time to time is the subject of various claims and also has claims against others. The
ultimate resolution of such claims is not expected to have either a material adverse or favorable effect on Dartmouth’s financial position.

L. Related Party Transactions

Members of Dartmouth’s Board of Trustees and senior management may, from time to time, be associated, either directly or indirectly, with companies doing business with Dartmouth. Dartmouth has a written conflict of interest policy that requires annual reporting by each Trustee, as well as senior management. Additionally, Dartmouth has a policy on Pecuniary Benefit Transactions and Related Party Investments. This policy supplements the Dartmouth College Conflict of Interest Policy with regard to pecuniary benefit transactions, as defined by New Hampshire law, including but not limited to Dartmouth’s investment in investment vehicles in which Trustees have a financial interest. These policies include, among other things, that no member of the Board of Trustees can participate in any decision in which he or she (or an immediate family member) has a material financial interest. When such relationships exist, measures are taken to mitigate any actual or perceived conflict, including requiring that such transactions be conducted at arm’s length, for good and sufficient consideration, based on terms that are fair and reasonable to and for the benefit of Dartmouth, and in accordance with applicable conflict of interest laws.

M. Subsequent Events

In August 2015, Dartmouth College refunded $101,000,000 NHHEFA Series 2002 and $89,700,000 NHHEFA Series 2007A variable rate demand bonds and replaced them with a floating rate direct placement of debt with a bank. This private placement has a ten year term, is not puttable by the lender, and can be called by Dartmouth at any time. The $30,000,000 NHHEFA Series 2007C taxable variable rate demand bonds were also refunded at the same time and replaced with taxable commercial paper notes.

For purposes of determining the effects of other subsequent events on these consolidated financial statements, management has evaluated events subsequent to June 30, 2015 and through October 19, 2015, the date on which the consolidated financial statements were issued, and has concluded that there were no other subsequent events requiring adjustment or disclosure.
# Dartmouth College Schedule of Expenditures of Federal Awards
## Year Ended June 30, 2015

<table>
<thead>
<tr>
<th>Federal Program</th>
<th>Cluster Title/CFDA Number</th>
<th>Project Name</th>
<th>Award Number/Pass-through Identification Number</th>
<th>Funding Source</th>
<th>Pass-Through Entity</th>
<th>Total Expenditures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research and Development Cluster:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>American Recovery and Reinvestment Act:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trans-NSF Recovery Act Research Support</td>
<td>47.082</td>
<td>Geomicrobiology</td>
<td>ANT-0838896</td>
<td>Direct</td>
<td>$1,124</td>
<td></td>
</tr>
<tr>
<td>Trans-NIH Recovery Act Research Support</td>
<td>93.701</td>
<td>Toxin-Entotoxin</td>
<td>R01AI079598</td>
<td>Direct</td>
<td>(92)</td>
<td></td>
</tr>
<tr>
<td>Trans-NIH Recovery Act Research Support</td>
<td>93.701</td>
<td>Isis</td>
<td>R01HD049762</td>
<td>Direct</td>
<td>(6,300)</td>
<td></td>
</tr>
<tr>
<td>ARRA - Strategic Health IT Advanced Research Projects (SHARPS)</td>
<td>93.728</td>
<td>SHARPS</td>
<td>2010-03958-11</td>
<td>Pass-Through</td>
<td>(95)</td>
<td>89,433</td>
</tr>
</tbody>
</table>

**American Recovery and Reinvestment Act total**: $84,165

### DEPARTMENT OF AGRICULTURE

<table>
<thead>
<tr>
<th>Cluster Title/CFDA Number</th>
<th>Project Name</th>
<th>Award Number/Pass-through Identification Number</th>
<th>Funding Source</th>
<th>Pass-Through Entity</th>
<th>Total Expenditures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agriculture and Food Research Initiative (AFRI)</td>
<td>10.310</td>
<td>Subcontinental Variation</td>
<td>2009-65104-05731</td>
<td>Direct</td>
<td>10,489</td>
</tr>
<tr>
<td>USDA AFRI AST</td>
<td>10.310</td>
<td>USDA AFRI AST</td>
<td>2015-67021-23278</td>
<td>Direct</td>
<td>31,590</td>
</tr>
<tr>
<td>Forestry Research</td>
<td>10.652</td>
<td>Vernal Pools</td>
<td>14-088</td>
<td>Pass Through</td>
<td>(65)</td>
</tr>
<tr>
<td>Forest Health Protection</td>
<td>10.680</td>
<td>Forest Health Grant</td>
<td>12-DC-1142004-287</td>
<td>Direct</td>
<td>1,065</td>
</tr>
<tr>
<td>Forest Health Protection</td>
<td>10.680</td>
<td>Structure and Fuel</td>
<td>14-CA-1142004-295</td>
<td>Direct</td>
<td>11,730</td>
</tr>
<tr>
<td>Unknown</td>
<td>10.9XX</td>
<td>culvert install/rep</td>
<td>EQIF 2014-7414281400</td>
<td>Direct</td>
<td>(8)</td>
</tr>
<tr>
<td>Unknown</td>
<td>10.XXX</td>
<td>USDA SPB population</td>
<td>00-CF-10310-100-107</td>
<td>Direct</td>
<td>3,093</td>
</tr>
<tr>
<td>Unknown</td>
<td>10.XXX</td>
<td>Forest insect USDA</td>
<td>12-DC-113327622-441</td>
<td>Direct</td>
<td>65,091</td>
</tr>
<tr>
<td>Unknown</td>
<td>10.XXX</td>
<td>Joint Venture #2</td>
<td>13-JV-11330143-027</td>
<td>Direct</td>
<td>11,401</td>
</tr>
<tr>
<td>Unknown</td>
<td>10.XXX</td>
<td>Landscape and Climate Change</td>
<td>09-JV-124237-124</td>
<td>Direct</td>
<td>19,211</td>
</tr>
</tbody>
</table>

**DEPARTMENT OF COMMERCE**: $79,863

<table>
<thead>
<tr>
<th>Cluster Title/CFDA Number</th>
<th>Project Name</th>
<th>Award Number/Pass-through Identification Number</th>
<th>Funding Source</th>
<th>Pass-Through Entity</th>
<th>Total Expenditures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unknown</td>
<td>11.609</td>
<td>Design and optimization</td>
<td>60NABIR13D210</td>
<td>Direct</td>
<td>41,661</td>
</tr>
</tbody>
</table>

**DEPARTMENT OF DEFENSE**

<table>
<thead>
<tr>
<th>Cluster Title/CFDA Number</th>
<th>Project Name</th>
<th>Award Number/Pass-through Identification Number</th>
<th>Funding Source</th>
<th>Pass-Through Entity</th>
<th>Total Expenditures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unknown</td>
<td>12.000</td>
<td>Neuroimaging Acquisition</td>
<td>1036186</td>
<td>Pass Through</td>
<td>(90)</td>
</tr>
<tr>
<td>Basic and Applied Scientific Research</td>
<td>12.300</td>
<td>Bayesian Knowledge</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(78)</td>
</tr>
<tr>
<td>Basic and Applied Scientific Research</td>
<td>12.300</td>
<td>Attacking Tumors</td>
<td>FA8750-09-1-0213</td>
<td>Direct</td>
<td>59,093</td>
</tr>
<tr>
<td>Basic and Applied Scientific Research</td>
<td>12.300</td>
<td>Improving CSIR Skills</td>
<td>FA8750-12-2-0258</td>
<td>Direct</td>
<td>1,395,931</td>
</tr>
<tr>
<td>Basic and Applied Scientific Research</td>
<td>12.300</td>
<td>Modular Social Intelligence</td>
<td>N00014-14-1-0693</td>
<td>Direct</td>
<td>280,648</td>
</tr>
<tr>
<td>Basic and Applied Scientific Research</td>
<td>12.300</td>
<td>Brain Circuit YR4</td>
<td>N00014-10-1-0013</td>
<td>Direct</td>
<td>171,942</td>
</tr>
<tr>
<td>Basic and Applied Scientific Research</td>
<td>12.300</td>
<td>sensory_processing</td>
<td>N00014-13-1-0298</td>
<td>Direct</td>
<td>280,169</td>
</tr>
<tr>
<td>Basic and Applied Scientific Research</td>
<td>12.300</td>
<td>Seasonal Evolution</td>
<td>N00014-14-1-0176</td>
<td>Direct</td>
<td>60,000</td>
</tr>
<tr>
<td>Basic and Applied Scientific Research</td>
<td>12.300</td>
<td>ONR Navy Hearing</td>
<td>N00014-14-1-0290</td>
<td>Direct</td>
<td>408,151</td>
</tr>
<tr>
<td>Basic and Applied Scientific Research</td>
<td>12.300</td>
<td>Reinforcement Learning</td>
<td>N00014-14-1-0458</td>
<td>Direct</td>
<td>8,355</td>
</tr>
<tr>
<td>Basic and Applied Scientific Research</td>
<td>12.300</td>
<td>Seasonal Evolution of Floe</td>
<td>N00014-14-1-0582</td>
<td>Direct</td>
<td>20,742</td>
</tr>
<tr>
<td>Basic and Applied Scientific Research</td>
<td>12.300</td>
<td>Re-Inforcement Learning</td>
<td>N00014-15-1-2154</td>
<td>Direct</td>
<td>7,741</td>
</tr>
<tr>
<td>Basic and Applied Scientific Research</td>
<td>12.300</td>
<td>Preventing/Isolation</td>
<td>N00244-14-1-0021</td>
<td>Direct</td>
<td>164,677</td>
</tr>
<tr>
<td>Military Medical Research and Development</td>
<td>12.420</td>
<td>PAR</td>
<td>f#sREaVJ-P200519959</td>
<td>Pass Through</td>
<td>(76)</td>
</tr>
<tr>
<td>Military Medical Research and Development</td>
<td>12.420</td>
<td>Predicting Disease Progression</td>
<td>00096718</td>
<td>Pass Through</td>
<td>(110)</td>
</tr>
<tr>
<td>Military Medical Research and Development</td>
<td>12.420</td>
<td>MR-EPT for Prostate</td>
<td>W81XWH-13-1-0127</td>
<td>Direct</td>
<td>200,164</td>
</tr>
<tr>
<td>Military Medical Research and Development</td>
<td>12.420</td>
<td>Mycobione Modifiers</td>
<td>W81XWH-14-1-0224</td>
<td>Direct</td>
<td>44,788</td>
</tr>
<tr>
<td>Military Medical Research and Development</td>
<td>12.420</td>
<td>Brain Connectivity in MS</td>
<td>W81XWH-14-1-0582</td>
<td>Direct</td>
<td>201,652</td>
</tr>
<tr>
<td>Military Medical Research and Development</td>
<td>12.420</td>
<td>Nanoparticle-based contrast</td>
<td>W81XWH-15-1-0102</td>
<td>Direct</td>
<td>9,672</td>
</tr>
<tr>
<td>Military Medical Research and Development</td>
<td>12.420</td>
<td>Repair in Multiple Sclerosis</td>
<td>W81XWH-09-1-0460</td>
<td>Direct</td>
<td>363,259</td>
</tr>
<tr>
<td>Military Medical Research and Development</td>
<td>12.420</td>
<td>Tk2 mouse strain</td>
<td>W81XWH-11-1</td>
<td>Direct</td>
<td>13,962</td>
</tr>
<tr>
<td>Military Medical Research and Development</td>
<td>12.420</td>
<td>Compartment Syndrome</td>
<td>3416</td>
<td>Direct</td>
<td>17,924</td>
</tr>
<tr>
<td>Basic Scientific Research</td>
<td>12.431</td>
<td>Cyber Defense</td>
<td>E2030472</td>
<td>Pass Through</td>
<td>(30)</td>
</tr>
<tr>
<td>Basic Scientific Research</td>
<td>12.431</td>
<td>PTSD/TBI</td>
<td>1409174</td>
<td>Pass Through</td>
<td>(98)</td>
</tr>
<tr>
<td>Basic Scientific Research</td>
<td>12.431</td>
<td>SHuCS Phase 2</td>
<td>2013-0034701</td>
<td>Pass Through</td>
<td>(95)</td>
</tr>
<tr>
<td>Basic Scientific Research</td>
<td>12.431</td>
<td>SiSiGe Quantum Dots</td>
<td>419K812</td>
<td>Pass Through</td>
<td>(116)</td>
</tr>
</tbody>
</table>

29
<table>
<thead>
<tr>
<th>Federal Program</th>
<th>Cluster Title/CFDA Number</th>
<th>Project Name</th>
<th>Award Number/Pass-through Identification Number</th>
<th>Funding Source</th>
<th>Pass-Through Entity</th>
<th>Total Expenditures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Scientific Research</td>
<td>12.431</td>
<td>Anomolies-Cluttered_rev</td>
<td>W911NF-08-1-0385</td>
<td>Direct</td>
<td></td>
<td>127,795</td>
</tr>
<tr>
<td>Basic Scientific Research</td>
<td>12.431</td>
<td>Metamorphism of Dry Snow</td>
<td>W911NF-11-1-0497</td>
<td>Direct</td>
<td></td>
<td>48,548</td>
</tr>
<tr>
<td>Basic Scientific Research</td>
<td>12.431</td>
<td>DUREP</td>
<td>W911NF-13-1-0294</td>
<td>Direct</td>
<td></td>
<td>(78)</td>
</tr>
<tr>
<td>Basic Scientific Research</td>
<td>12.431</td>
<td>Limited Electrometry</td>
<td>W911NF-13-1-0377</td>
<td>Direct</td>
<td></td>
<td>217,904</td>
</tr>
<tr>
<td>Air Force Defense Research Sciences Program</td>
<td>12.800</td>
<td>RIQUEST</td>
<td>30004</td>
<td>Pass Through</td>
<td>(78)</td>
<td>77</td>
</tr>
<tr>
<td>Air Force Defense Research Sciences Program</td>
<td>12.800</td>
<td>RIQUEST YR2</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(78)</td>
<td>60,566</td>
</tr>
<tr>
<td>Air Force Defense Research Sciences Program</td>
<td>12.800</td>
<td>Drivers of Thermal</td>
<td>15-012</td>
<td>Pass Through</td>
<td>(102)</td>
<td>23,428</td>
</tr>
<tr>
<td>Air Force Defense Research Sciences Program</td>
<td>12.800</td>
<td>Cyber Intelligence</td>
<td>2014054629</td>
<td>Pass Through</td>
<td>(109)</td>
<td>90,221</td>
</tr>
<tr>
<td>Air Force Defense Research Sciences Program</td>
<td>12.800</td>
<td>Dynamic Social Model</td>
<td>2014054388</td>
<td>Pass Through</td>
<td>(109)</td>
<td>36,014</td>
</tr>
<tr>
<td>Air Force Defense Research Sciences Program</td>
<td>12.800</td>
<td>Dynamic Info</td>
<td>FA9550-11-1-0166</td>
<td>Direct</td>
<td></td>
<td>147,228</td>
</tr>
<tr>
<td>Mathematical Sciences Grants Program</td>
<td>12.901</td>
<td>Consecutive Patterns</td>
<td>H98230-14-1-0125</td>
<td>Direct</td>
<td></td>
<td>19,997</td>
</tr>
<tr>
<td>Information Security Grants</td>
<td>12.902</td>
<td>IASP 2012</td>
<td>H98230-12-1-0434</td>
<td>Direct</td>
<td></td>
<td>11,888</td>
</tr>
<tr>
<td>Research and Technology Development</td>
<td>12.910</td>
<td>Memory Enhancement</td>
<td>564000</td>
<td>Pass Through</td>
<td>(104)</td>
<td>258,095</td>
</tr>
<tr>
<td>Research and Technology Development</td>
<td>12.910</td>
<td>Genetic Memory</td>
<td>H80011-15-1-0002</td>
<td>Direct</td>
<td></td>
<td>150,093</td>
</tr>
<tr>
<td>Unknown</td>
<td>12.XXX</td>
<td>APT Platelet CLIN0001</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(1)</td>
<td>64,481</td>
</tr>
<tr>
<td>Unknown</td>
<td>12.XXX</td>
<td>DOD Navy_Baker</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(2)</td>
<td>24,786</td>
</tr>
<tr>
<td>Unknown</td>
<td>12.XXX</td>
<td>CPP eGMP CLIN 0001 - 34.5%</td>
<td>Dartmouth-13-01</td>
<td>Pass Through</td>
<td>(17)</td>
<td>1,693,319</td>
</tr>
<tr>
<td>Unknown</td>
<td>12.XXX</td>
<td>Validation of eGMP</td>
<td>Dartmouth-09-01</td>
<td>Pass Through</td>
<td>(17)</td>
<td>41,920</td>
</tr>
<tr>
<td>Unknown</td>
<td>12.XXX</td>
<td>Ear Canal Geometry</td>
<td>66231</td>
<td>Pass Through</td>
<td>(21)</td>
<td>43,263</td>
</tr>
<tr>
<td>Unknown</td>
<td>12.XXX</td>
<td>DARPA</td>
<td>70438</td>
<td>Pass Through</td>
<td>(21)</td>
<td>875</td>
</tr>
<tr>
<td>Unknown</td>
<td>12.XXX</td>
<td>CHP Dose Escalation</td>
<td>0047-1062-EPP-DHMC</td>
<td>Pass Through</td>
<td>(26)</td>
<td>60,965</td>
</tr>
<tr>
<td>Unknown</td>
<td>12.XXX</td>
<td>Noncontact Laser Uit</td>
<td>PO7000267034</td>
<td>Pass Through</td>
<td>(48)</td>
<td>48,680</td>
</tr>
<tr>
<td>Unknown</td>
<td>12.XXX</td>
<td>Intra-Osseous Tools</td>
<td>CACU-12012014</td>
<td>Pass Through</td>
<td>(71)</td>
<td>74,185</td>
</tr>
<tr>
<td>Unknown</td>
<td>12.XXX</td>
<td>Bioprosthesys</td>
<td>10317739</td>
<td>Pass Through</td>
<td>(90)</td>
<td>47,811</td>
</tr>
<tr>
<td>Unknown</td>
<td>12.XXX</td>
<td>BL-MCAL: SAFE-TBI</td>
<td>10320526</td>
<td>Pass Through</td>
<td>(90)</td>
<td>153,418</td>
</tr>
<tr>
<td>Unknown</td>
<td>12.XXX</td>
<td>Advanced Emf Models</td>
<td>W911IQ-12-C-0014</td>
<td>Direct</td>
<td></td>
<td>9,250,436</td>
</tr>
</tbody>
</table>

**VETERAN'S ADMINISTRATION**

Intergovernmental Personnel Act (IPA) Mobility Program | 27.011 | VAQ5 - SQUIRE Proj | N/A | Direct | | 1,965 |
| Intergovernmental Personnel Act (IPA) Mobility Program | 27.011 | IPA Hamblens Grant FY14 | 405D54001 | Direct | | 4,605 |
| Intergovernmental Personnel Act (IPA) Mobility Program | 27.011 | Nicholson IPA | 405D74007 | Direct | | 5,176 |
| Intergovernmental Personnel Act (IPA) Mobility Program | 27.011 | IPA Hamblens FY15 | 405D54000 | Direct | | 7,737 |
| Intergovernmental Personnel Act (IPA) Mobility Program | 27.011 | Surveillance of AK1 | 405D54007 | Direct | | 26,019 |
| Intergovernmental Personnel Act (IPA) Mobility Program | 27.011 | Li JPA | N/A | Direct | | 7,902 |
| Intergovernmental Personnel Act (IPA) Mobility Program | 27.011 | IPA 2015 | N/A | Direct | | 7,449 |
| Intergovernmental Personnel Act (IPA) Mobility Program | 27.011 | VA IPA Chesnut | VA IPA Chesnut | Direct | | 2,749 |
| | | | | | | **63,601** |

**NATIONAL AERONAUTICS AND SPACE ADMINISTRATION**

Unknown | 43.000 | EFSAC | X5336545104 | Pass Through | (48) | 133,492 |
| Unknown | 43.000 | Ring Current | 107457 | Pass Through | (43) | 11,650 |
| Unknown | 43.000 | EPScR II | 13-049 | Pass Through | (102) | 45,619 |
| Unknown | 43.000 | EPScR Space Eyes Yr 2 | 13-065 | Pass Through | (102) | 117,606 |
| Unknown | 43.000 | Pharmacodyamic | 14-072 | Pass Through | (102) | 61,423 |
| Unknown | 43.000 | Emission, transport | 14-085 | Pass Through | (102) | 43,086 |
| Science | 43.001 | RBSP-ECT | 10-092 | Pass Through | (102) | 124,927 |
| Science | 43.001 | Obscured Quasars | 1001478 | Pass Through | (117) | 65,828 |
| Science | 43.001 | Ion & Electron Veloc | 1549737 | Pass Through | (93) | 51,666 |
| Science | 43.001 | Twin Clusters | G02-13150A | Direct | | 98 |
| Science | 43.001 | Foundations of Complex Life Yr 2 | 5710003372 | Pass Through | (48) | 59,936 |
| Science | 43.001 | Magnetic Structure | 113961 | Pass Through | (43) | 49,646 |
| Science | 43.001 | E-Region Turbulence | 4500001613 | Pass Through | (10) | 35,089 |
| Science | 43.001 | RBSP Mission YR2 | NNX08AM58G | Direct | | 993,854 |
| Science | 43.001 | CryoSat-2 | NNX10AG22G | Direct | | 67,010 |
## Dartmouth College

### Schedule of Expenditures of Federal Awards

**Year Ended June 30, 2015**

<table>
<thead>
<tr>
<th>Federal Program</th>
<th>Cluster Title/CFDA Number</th>
<th>Project Name</th>
<th>Award Number/Pass-through Identification Number</th>
<th>Funding Source</th>
<th>Pass-Through Entity</th>
<th>Total Expenditures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Science</td>
<td>43.001</td>
<td>CryoSat 2</td>
<td>NNX10AP04G</td>
<td>Direct</td>
<td></td>
<td>30,719</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>MHD Modeling</td>
<td>NNX10AQ60G</td>
<td>Direct</td>
<td></td>
<td>194,932</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>Ejecta Jets</td>
<td>HST-GO-12300.01-A</td>
<td>Direct</td>
<td></td>
<td>24,863</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>Dynamics of Magnetosphere</td>
<td>NNX11AP09G</td>
<td>Direct</td>
<td></td>
<td>255,189</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>Icebridge Data</td>
<td>NNX12AB73G</td>
<td>Direct</td>
<td></td>
<td>80,678</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>Sounding Ricket Payload System</td>
<td>NNX12AF56G</td>
<td>Direct</td>
<td></td>
<td>52,321</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>CAFER</td>
<td>NNX12AJ44G</td>
<td>Direct</td>
<td></td>
<td>127,339</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>Young Solar Wind</td>
<td>HST-GO-12986.02-A</td>
<td>Direct</td>
<td></td>
<td>1,481</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>Iron in SN 1885</td>
<td>HST-GO-12809.01-A</td>
<td>Direct</td>
<td></td>
<td>12,758</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>Cyclotron Waves</td>
<td>NNX13AD69G</td>
<td>Direct</td>
<td></td>
<td>120,722</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>Fast, Low Entropy</td>
<td>NNX13AF82G</td>
<td>Direct</td>
<td></td>
<td>21,555</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>RENU2</td>
<td>NNX13A90G</td>
<td>Direct</td>
<td></td>
<td>77,715</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>ExoPlanet Atmosphere</td>
<td>NNX13AR41G</td>
<td>Direct</td>
<td></td>
<td>19,997</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>Winds of Red Giants</td>
<td>HST-GO-13462.02-A</td>
<td>Direct</td>
<td></td>
<td>20,576</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>STIS Spectra</td>
<td>HST-GO-13471.01-A</td>
<td>Direct</td>
<td></td>
<td>16,691</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>Outer Heliosphere</td>
<td>NNX14AC10G</td>
<td>Direct</td>
<td></td>
<td>89,190</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>Reconnecting Regions</td>
<td>NNX14AC38G</td>
<td>Direct</td>
<td></td>
<td>21,973</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>ISINGlass</td>
<td>NNX14AH07G</td>
<td>Direct</td>
<td></td>
<td>342,330</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>Magnetotail</td>
<td>NNX14AN52G</td>
<td>Direct</td>
<td></td>
<td>118,869</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>UFL Wave Geo Storms YR1</td>
<td>NNX15AF54G</td>
<td>Direct</td>
<td></td>
<td>14,934</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>Dartmouth Greenhouse 6</td>
<td>1492210</td>
<td>Pass Through</td>
<td>(41)</td>
<td>8,746</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>Luminous Obscured Quasars</td>
<td>1471850</td>
<td>Pass Through</td>
<td>(41)</td>
<td>8,342</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>Early Detection YR3</td>
<td>1507622</td>
<td>Pass Through</td>
<td>(41)</td>
<td>79,620</td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>Greenhouse 7</td>
<td>Pass Through</td>
<td>Pass Through</td>
<td>(41)</td>
<td>17,927</td>
</tr>
</tbody>
</table>

**NATIONAL SCIENCE FOUNDATION**

| Mathematical and Physical Sciences | 47.049 | Rodriguez SEES NSF | CHE-1313932 | Direct | 195,504 |
| Biological Sciences              | 47.074 | NSF Mapping         | 4011-19822  | Direct | 363,116 |
| Biological Sciences              | 47.074 | Analysis of Gene Networks | NSF40391 | Direct | 938,030 |
| Biological Sciences              | 47.074 | Aridibiosis 2010: Analysis CTN | 5-54963 | Direct | 222,344 |
| Biological Sciences              | 47.074 | UNC sub Rice grant  | 5037375     | Direct | 364,032 |
| Biological Sciences              | 47.074 | Tauhe V-Tech        | 49066-19715 | Direct | 11,241  |
| Biological Sciences              | 47.074 | Animal Recognition  | DBI-0754773 | Direct | (222)   |
| Biological Sciences              | 47.074 | Memory System       | IIOS-0922075 | Direct | (2,747) |
| Biological Sciences              | 47.074 | MRE AIRSI           | DBI-1039423 | Direct | (3,984) |
| Biological Sciences              | 47.074 | TRMS: Genetic Analysis | IOS-1029865 | Direct | 911,673 |
| Biological Sciences              | 47.074 | Biofilm Development II | MCB-1158229 | Direct | 131,691 |
| Biological Sciences              | 47.074 | Septin Organization | MCB-123878  | Direct | 197,686 |
| Biological Sciences              | 47.074 | Irwin Gezon DDIG NSF | DEB-1311257 | Direct | 3,637   |
| Biological Sciences              | 47.074 | Irwin Toxic Bee     | DEB-1254817 | Direct | 46,662  |
| Biological Sciences              | 47.074 | Olga Simons Fdnt Dept | IOS-2579480 | Direct | 44,389  |
| Biological Sciences              | 47.074 | Reciprocal Regs     | IOS-1257722 | Direct | 142,326 |
| Biological Sciences              | 47.074 | Context dependency  | DEB-1354616 | Direct | 82,163  |
| Biological Sciences              | 47.074 | Schaller EAGER      | IOS-1405593 | Direct | 49,242  |
| Biological Sciences              | 47.074 | Bucci NSF BIO       | IOS-1353317 | Direct | 53,576  |
| Biological Sciences              | 47.074 | Ramsa DDIG         | DEB-1406779 | Direct | 2,118   |
| Biological Sciences              | 47.074 | Lany Ayres DDIG     | DEB-1406149 | Direct | 11,361  |
| Biological Sciences              | 47.074 | Integrating NSF    | IOS-1456290 | Direct | 77,740  |
| Biological Sciences              | 47.074 | Two-Comp Pathway - Particpnt | IOS-145687 | Direct | 8,140   |
| Biological Sciences              | 47.070 | NSF Infrastructure  | ACI-1345952 | Direct | 19,481  |
| Computer and Information Science and Engineering | 47.070 | Student Travel     | CNS-1505091 | Direct | 9,800   |
| Computer and Information Science and Engineering | 47.070 | CRI-IAD Digital Imaging Lab | CNS-0708209 | Direct | (86)    |
| Computer and Information Science and Engineering | 47.070 | CAREER Image Retrieval | IIS-0599243 | Direct | 89,876  |
| Computer and Information Science and Engineering | 47.070 | Small Collab Res    | IIS-1017231 | Direct | 11,932  |
| Computer and Information Science and Engineering | 47.070 | PC3: Last-mile Healthcare | CNS-1143548 | Direct | 10,026  |
| Computer and Information Science and Engineering | 47.070 | Communication Comp  | CCF-1217375 | Direct | 186,921 |
| Computer and Information Science and Engineering | 47.070 | Robotic Manipulation | IIS-1217447 | Direct | 113,071 |

**Total: 3,620,096**
## Dartmouth College
### Schedule of Expenditures of Federal Awards
#### Year Ended June 30, 2015

<table>
<thead>
<tr>
<th>Federal Program</th>
<th>Cluster Title/CFDA Number</th>
<th>Project Name</th>
<th>Award Number/Pass-through Identification Number</th>
<th>Funding Source</th>
<th>Pass-Through Entity</th>
<th>Total Expenditures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Computer and Information Science and Engineering</td>
<td>47.070</td>
<td>Frontier:trustworthy</td>
<td>CNS-1329686</td>
<td>Direct</td>
<td>698,298</td>
<td></td>
</tr>
<tr>
<td>Computer and Information Science and Engineering</td>
<td>47.070</td>
<td>Mobile Health (ISTI)</td>
<td>CNS-1314281</td>
<td>Direct</td>
<td>443,914</td>
<td></td>
</tr>
<tr>
<td>Computer and Information Science and Engineering</td>
<td>47.070</td>
<td>Cardiac Device</td>
<td>IIS-1416497</td>
<td>Direct</td>
<td>74,610</td>
<td></td>
</tr>
<tr>
<td>Computer and Information Science and Engineering</td>
<td>47.070</td>
<td>DataGIT</td>
<td>IIS-1429999</td>
<td>Direct</td>
<td>148,485</td>
<td></td>
</tr>
<tr>
<td>Computer and Information Science and Engineering</td>
<td>47.070</td>
<td>NSF EAGER</td>
<td>IIS-1451632</td>
<td>Direct</td>
<td>57,795</td>
<td></td>
</tr>
<tr>
<td>Computer and Information Science and Engineering</td>
<td>47.070</td>
<td>Bits in the Light</td>
<td>CNS-1421528</td>
<td>Direct</td>
<td>47,133</td>
<td></td>
</tr>
<tr>
<td>Education and Human Resources</td>
<td>47.075</td>
<td>Cyber Corps Initiative 0% IDC</td>
<td>14-2-120379-94802</td>
<td>Pass Through</td>
<td>(112)</td>
<td>53,385</td>
</tr>
<tr>
<td>Education and Human Resources</td>
<td>47.076</td>
<td>Climate Shift Champlain Basin</td>
<td>25399</td>
<td>Pass Through</td>
<td>(113)</td>
<td>18,550</td>
</tr>
<tr>
<td>Education and Human Resources</td>
<td>47.076</td>
<td>Flanagan EAGER NSF</td>
<td>HRD-1137483</td>
<td>Direct</td>
<td>40,497</td>
<td></td>
</tr>
<tr>
<td>Education and Human Resources</td>
<td>47.076</td>
<td>REAL</td>
<td>DRL-1420836</td>
<td>Direct</td>
<td>74,010</td>
<td></td>
</tr>
<tr>
<td>Education and Human Resources</td>
<td>47.076</td>
<td>GRFP</td>
<td>DGE-1313911</td>
<td>Direct</td>
<td>569,116</td>
<td></td>
</tr>
<tr>
<td>Engineering Grants</td>
<td>47.041</td>
<td>Solar Power Receiver</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(67)</td>
<td>2,647</td>
</tr>
<tr>
<td>Engineering Grants</td>
<td>47.041</td>
<td>Ethics</td>
<td>14-2-120662-94802</td>
<td>Pass Through</td>
<td>(112)</td>
<td>22,317</td>
</tr>
<tr>
<td>Engineering Grants</td>
<td>47.041</td>
<td>Nanostructured FeNiMnAl</td>
<td>CMII-1063732</td>
<td>Direct</td>
<td>69,940</td>
<td></td>
</tr>
<tr>
<td>Engineering Grants</td>
<td>47.041</td>
<td>Cognitive Signal Processing</td>
<td>IIP-1112753</td>
<td>Direct</td>
<td>73,721</td>
<td></td>
</tr>
<tr>
<td>Engineering Grants</td>
<td>47.041</td>
<td>Power-aware Sensor Interfacing</td>
<td>ECCS-1128478</td>
<td>Direct</td>
<td>79,667</td>
<td></td>
</tr>
<tr>
<td>Engineering Grants</td>
<td>47.041</td>
<td>Ice-templated Mater</td>
<td>CMII-1200008</td>
<td>Direct</td>
<td>123,229</td>
<td></td>
</tr>
<tr>
<td>Engineering Grants</td>
<td>47.041</td>
<td>Avalanche UV Detect</td>
<td>ECCS-1231701</td>
<td>Direct</td>
<td>122,858</td>
<td></td>
</tr>
<tr>
<td>Engineering Grants</td>
<td>47.041</td>
<td>High Power</td>
<td>ECCS-1309905</td>
<td>Direct</td>
<td>145,611</td>
<td></td>
</tr>
<tr>
<td>Engineering Grants</td>
<td>47.041</td>
<td>Highly-Integrated</td>
<td>ECCS-1407725</td>
<td>Direct</td>
<td>67,325</td>
<td></td>
</tr>
<tr>
<td>Engineering Grants</td>
<td>47.041</td>
<td>Power One IC</td>
<td>1406588</td>
<td>Direct</td>
<td>1,247</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>JSEP</td>
<td>PLR-1506155</td>
<td>Direct</td>
<td>8,386</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>Chukchi Sea</td>
<td>AGS-1340932</td>
<td>Direct</td>
<td>146,164</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>SuperDARN</td>
<td>ATM-0839356</td>
<td>Direct</td>
<td>11,259</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>Dayside Magnetosphere</td>
<td>AGS-1009072</td>
<td>Direct</td>
<td>11,259</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>Testing Mechanisms</td>
<td>EAR-1003460</td>
<td>Direct</td>
<td>30,359</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>Fishscale</td>
<td>GEO-1010280</td>
<td>Direct</td>
<td>311,795</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>Radiation Belt</td>
<td>AGS-1023325</td>
<td>Direct</td>
<td>81,892</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>Whistler Chorus</td>
<td>AGS-1155934</td>
<td>Direct</td>
<td>54,764</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>HYDROCLIMATE</td>
<td>AGS-1204035</td>
<td>Direct</td>
<td>111,002</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>Remote Sensing</td>
<td>AGS-1145719</td>
<td>Direct</td>
<td>69,277</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>Multi-Method</td>
<td>EAR-1223600</td>
<td>Direct</td>
<td>65,272</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>Rverzon</td>
<td>EAR-1222705</td>
<td>Direct</td>
<td>10,046</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>Magnetospheric Mass Density</td>
<td>AGS-1105962</td>
<td>Direct</td>
<td>53,607</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>Brine Network</td>
<td>PLR-1304134</td>
<td>Direct</td>
<td>287,397</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>Ice Shelf Lat Margin</td>
<td>PLR-124915</td>
<td>Direct</td>
<td>123,001</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>SHINE</td>
<td>AGS-1259433</td>
<td>Direct</td>
<td>34,048</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>Ice Drilling Prog Office</td>
<td>PLR-1327315</td>
<td>Direct</td>
<td>5,015,106</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>GEM</td>
<td>AGS-1404599</td>
<td>Direct</td>
<td>69,671</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>Collab: Combining Ar</td>
<td>PLR-1417436</td>
<td>Direct</td>
<td>60,579</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>GreenTRACS</td>
<td>PLR-1417678</td>
<td>Direct</td>
<td>3,742</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>Thompson-NSF</td>
<td>PLR-1444788</td>
<td>Direct</td>
<td>10,075</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>Bolide Signature</td>
<td>PLR-1413795</td>
<td>Direct</td>
<td>13,597</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>SuperDARN 2</td>
<td>1341925</td>
<td>Direct</td>
<td>5,833</td>
<td></td>
</tr>
<tr>
<td>Geosciences</td>
<td>47.050</td>
<td>SPICE</td>
<td>PLR-1443336</td>
<td>Direct</td>
<td>13,217</td>
<td></td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>CBMS Conference</td>
<td>DMS-1347163</td>
<td>Direct</td>
<td>37,968</td>
<td></td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Conference</td>
<td>DMS-1461679</td>
<td>Direct</td>
<td>35,011</td>
<td></td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Conformal Switching</td>
<td>CHE-0953693</td>
<td>Direct</td>
<td>174,129</td>
<td></td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Metal-Catalized Synthesis</td>
<td>CHE-1011818</td>
<td>Direct</td>
<td>(1)</td>
<td></td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>NSF_Cataclysmic Binaries</td>
<td>AST-1008217</td>
<td>Direct</td>
<td>52,244</td>
<td></td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Phosphorothioate</td>
<td>CHE-1052824</td>
<td>Direct</td>
<td>83,377</td>
<td></td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Polymer Glasses 2</td>
<td>1304658</td>
<td>Direct</td>
<td>39,978</td>
<td></td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Theory of Quantum/Classical</td>
<td>DMR-1104790</td>
<td>Direct</td>
<td>24,730</td>
<td></td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Pseudorandomness</td>
<td>PHY-110403</td>
<td>Direct</td>
<td>72,081</td>
<td></td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Quantum Noise VR 4</td>
<td>DMR-110482</td>
<td>Direct</td>
<td>56,848</td>
<td></td>
</tr>
<tr>
<td>Federal Program</td>
<td>Cluster Title/CFDA Number</td>
<td>Project Name</td>
<td>Award Number/Pass-through Identification Number</td>
<td>Funding Source</td>
<td>Pass-Through Entity</td>
<td>Total Expenditures</td>
</tr>
<tr>
<td>-----------------</td>
<td>---------------------------</td>
<td>--------------</td>
<td>-----------------------------------------------</td>
<td>----------------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Cosmic Fields</td>
<td>PHY-1068027</td>
<td>Direct</td>
<td></td>
<td>58,602</td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Random Walk</td>
<td>DMS-1162172</td>
<td>Direct</td>
<td></td>
<td>72,858</td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Stellar Evolution</td>
<td>AST-1211384</td>
<td>Direct</td>
<td></td>
<td>99,335</td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Understand Laves</td>
<td>DMR-1206240</td>
<td>Direct</td>
<td></td>
<td>92,433</td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Nest-generation</td>
<td>DMR-1216146</td>
<td>Direct</td>
<td></td>
<td>66,574</td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>SDSS and WISE</td>
<td>AAST-1211096</td>
<td>Direct</td>
<td></td>
<td>92,382</td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Centralizer Algebra</td>
<td>DMS-1162101</td>
<td>Direct</td>
<td></td>
<td>18,555</td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>CAREER: Low- Temperat</td>
<td>DMR-1255066</td>
<td>Direct</td>
<td></td>
<td>114,630</td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Molecular Machines</td>
<td>CHE-1253385</td>
<td>Direct</td>
<td></td>
<td>148,572</td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Voight NSF CAREER</td>
<td>DMS-1346989</td>
<td>Direct</td>
<td></td>
<td>71,207</td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Metal-Protein 2013</td>
<td>CHE-1308598</td>
<td>Direct</td>
<td></td>
<td>119,429</td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Metal-Catalyzed Syn</td>
<td>CHE-1265758</td>
<td>Direct</td>
<td></td>
<td>135,093</td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Comb Rep Theory</td>
<td>DMS-130512</td>
<td>Direct</td>
<td></td>
<td>26,532</td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Voight Number Theory</td>
<td>DMS-1430032</td>
<td>Direct</td>
<td></td>
<td>33,381</td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Polymer Glass III</td>
<td>DMR-1403757</td>
<td>Direct</td>
<td></td>
<td>78,161</td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Index Theory 2014</td>
<td>DMS-1442357</td>
<td>Direct</td>
<td></td>
<td>42,776</td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>NMR Surface</td>
<td>CHE-1410524</td>
<td>Direct</td>
<td></td>
<td>91,483</td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>NSF EARS</td>
<td>AST-1443945</td>
<td>Direct</td>
<td></td>
<td>6,054</td>
</tr>
<tr>
<td>Mathematical and Physical Sciences</td>
<td>47.049</td>
<td>Recursion Theory</td>
<td>DMS-1458061</td>
<td>Direct</td>
<td></td>
<td>9,357</td>
</tr>
<tr>
<td>Office of Experimental Program to Stimulate Competitive Research</td>
<td>47.081</td>
<td>Albert RET stipd/travel meals</td>
<td>PZ 12-044</td>
<td>Pass Through</td>
<td>(102)</td>
<td>285,999</td>
</tr>
<tr>
<td>Office of International Science and Engineering</td>
<td>47.079</td>
<td>PIRE: ICETRICS</td>
<td>S1315A-F</td>
<td>Pass Through</td>
<td>(70)</td>
<td>24,374</td>
</tr>
<tr>
<td>Polar Programs</td>
<td>47.078</td>
<td>McMurdo LTER IV</td>
<td>1548198</td>
<td>Pass Through</td>
<td>(93)</td>
<td>54,085</td>
</tr>
<tr>
<td>Polar Programs</td>
<td>47.078</td>
<td>IDPO</td>
<td>ANT-0841308</td>
<td>Direct</td>
<td></td>
<td>9,413</td>
</tr>
<tr>
<td>Polar Programs</td>
<td>47.078</td>
<td>Strain-Induced Fabric</td>
<td>ARC-1022972</td>
<td>Direct</td>
<td></td>
<td>33,546</td>
</tr>
<tr>
<td>Polar Programs</td>
<td>47.078</td>
<td>Pan-Arctic</td>
<td>ARC-1020322</td>
<td>Direct</td>
<td></td>
<td>97,297</td>
</tr>
<tr>
<td>Polar Programs</td>
<td>47.078</td>
<td>Roosevelt Island</td>
<td>ANT-0943466</td>
<td>Direct</td>
<td></td>
<td>29,272</td>
</tr>
<tr>
<td>Polar Programs</td>
<td>47.078</td>
<td>Greenland Ice Sheet Campaigns</td>
<td>ARC-0802343</td>
<td>Direct</td>
<td></td>
<td>46,725</td>
</tr>
<tr>
<td>Polar Programs</td>
<td>47.078</td>
<td>Fine Structure</td>
<td>ANT-1043230</td>
<td>Direct</td>
<td></td>
<td>14,873</td>
</tr>
<tr>
<td>Polar Programs</td>
<td>47.078</td>
<td>Bromide Snow Sea Ice Zone</td>
<td>ANT-1043145</td>
<td>Direct</td>
<td></td>
<td>16,294</td>
</tr>
<tr>
<td>Polar Programs</td>
<td>47.078</td>
<td>NW Greenland</td>
<td>ARC-1107411</td>
<td>Direct</td>
<td></td>
<td>123,931</td>
</tr>
<tr>
<td>Polar Programs</td>
<td>47.078</td>
<td>Summit Station</td>
<td>ARC-1042358</td>
<td>Direct</td>
<td></td>
<td>49,483</td>
</tr>
<tr>
<td>Polar Programs</td>
<td>47.078</td>
<td>The Effects of Solub</td>
<td>ANT-1144141</td>
<td>Direct</td>
<td></td>
<td>112,761</td>
</tr>
<tr>
<td>Polar Programs</td>
<td>47.078</td>
<td>Collab.- Tel Ice</td>
<td>ANT-1141817</td>
<td>Direct</td>
<td></td>
<td>81,866</td>
</tr>
<tr>
<td>Polar Programs</td>
<td>47.078</td>
<td>AGO Network</td>
<td>ANT-1141817</td>
<td>Direct</td>
<td></td>
<td>86,088</td>
</tr>
<tr>
<td>Social, Behavioral, and Economic Sciences</td>
<td>47.075</td>
<td>Cox Indiana U sub</td>
<td>PO1403545/BL1443920DC</td>
<td>Pass Through</td>
<td>(37)</td>
<td>11,986</td>
</tr>
<tr>
<td>Social, Behavioral, and Economic Sciences</td>
<td>47.075</td>
<td>DDR</td>
<td>BCS-110372</td>
<td>Direct</td>
<td></td>
<td>3,570</td>
</tr>
<tr>
<td>Social, Behavioral, and Economic Sciences</td>
<td>47.075</td>
<td>German collaboration</td>
<td>BCS-1129764</td>
<td>Direct</td>
<td></td>
<td>449</td>
</tr>
<tr>
<td>Social, Behavioral, and Economic Sciences</td>
<td>47.075</td>
<td>Irene</td>
<td>BCS-1222323</td>
<td>Direct</td>
<td></td>
<td>82,892</td>
</tr>
<tr>
<td>Social, Behavioral, and Economic Sciences</td>
<td>47.075</td>
<td>categorical percepts</td>
<td>BCS-1157121</td>
<td>Direct</td>
<td></td>
<td>31,440</td>
</tr>
<tr>
<td>Social, Behavioral, and Economic Sciences</td>
<td>47.075</td>
<td>English Dialect</td>
<td>BCS-1251324</td>
<td>Direct</td>
<td></td>
<td>31,696</td>
</tr>
<tr>
<td>Social, Behavioral, and Economic Sciences</td>
<td>47.075</td>
<td>Agricultural Extensi</td>
<td>BCS-1262774</td>
<td>Direct</td>
<td></td>
<td>39,614</td>
</tr>
<tr>
<td>Social, Behavioral, and Economic Sciences</td>
<td>47.075</td>
<td>Soc Dim of Dam Rem (Off)</td>
<td>BCS-1263519</td>
<td>Direct</td>
<td></td>
<td>68,510</td>
</tr>
<tr>
<td>Social, Behavioral, and Economic Sciences</td>
<td>47.075</td>
<td>Craft Specialization</td>
<td>BCS-1424312</td>
<td>Direct</td>
<td></td>
<td>5,385</td>
</tr>
<tr>
<td>Social, Behavioral, and Economic Sciences</td>
<td>47.075</td>
<td>Reading Intervention</td>
<td>BCS-1420006</td>
<td>Direct</td>
<td></td>
<td>18,900</td>
</tr>
<tr>
<td>Social, Behavioral, and Economic Sciences</td>
<td>47.075</td>
<td>Rengmitca</td>
<td>BCS-1360731</td>
<td>Direct</td>
<td></td>
<td>12,533</td>
</tr>
</tbody>
</table>

**ENVIRONMENTAL PROTECTION AGENCY**

| Science To Achieve Results (STAR) Research Program | 66.509 | CEHDPRECD Core A | RD83544201 | Direct | | 690,267 |

<p>| Total | 16,413,032 | 690,267 |</p>
<table>
<thead>
<tr>
<th>Federal Program</th>
<th>Cluster Title/CFDA Number</th>
<th>Project Name</th>
<th>Award Number/Pass-through Identification Number</th>
<th>Funding Source</th>
<th>Pass-Through Entity</th>
<th>Total Expenditures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Office of Science Financial Assistance Program</td>
<td>81.049</td>
<td>Global 3D</td>
<td>DE-SC0010508</td>
<td>Direct</td>
<td></td>
<td>107,692</td>
</tr>
<tr>
<td>Office of Science Financial Assistance Program</td>
<td>81.049</td>
<td>Cosmic Frontier</td>
<td>DE-SC0010386</td>
<td>Direct</td>
<td></td>
<td>199,342</td>
</tr>
<tr>
<td>University Coal Research</td>
<td>81.057</td>
<td>Laves Phase-Strength</td>
<td>DE-EE008857</td>
<td>Direct</td>
<td></td>
<td>108,995</td>
</tr>
<tr>
<td>Electricity Delivery and Energy Reliability, Research, Development and Analysis</td>
<td>81.122</td>
<td>Cybertrust II</td>
<td>2010-01251-01</td>
<td>Pass Through</td>
<td>(95)</td>
<td>192,994</td>
</tr>
<tr>
<td>Electricity Delivery and Energy Reliability, Research, Development and Analysis</td>
<td>81.122</td>
<td>Hardened platforms</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(77)</td>
<td>123,878</td>
</tr>
<tr>
<td>Unknown</td>
<td>81.XXX</td>
<td>Integrated Simulation</td>
<td>08-028</td>
<td>Pass Through</td>
<td>(102)</td>
<td>82,748</td>
</tr>
<tr>
<td>Unknown</td>
<td>81.XXX</td>
<td>BioEnergy Sci Ctr 2</td>
<td>400115284</td>
<td>Direct</td>
<td>(5)</td>
<td>2,124,623</td>
</tr>
<tr>
<td>Unknown</td>
<td>81.XXX</td>
<td>Soil To Seed</td>
<td>DE-FG02-06ER1580</td>
<td>Direct</td>
<td></td>
<td>4,991</td>
</tr>
<tr>
<td>Unknown</td>
<td>81.XXX</td>
<td>Structure/Property Two Phase</td>
<td>DE-FG02-07ER4392</td>
<td>Direct</td>
<td></td>
<td>176,511</td>
</tr>
<tr>
<td><strong>DEPARTMENT OF EDUCATION</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3,121,774</td>
</tr>
<tr>
<td>National Institute on Disability and Rehabilitation Program</td>
<td>84.133</td>
<td>Research and Training Ctr YR4</td>
<td>450001127</td>
<td>Pass Through</td>
<td>(10)</td>
<td>6,571</td>
</tr>
<tr>
<td>National Institute on Disability and Rehabilitation Program</td>
<td>84.133</td>
<td>Howard: C.I.D.D.: NIERR</td>
<td>0008512-1080054351</td>
<td>Pass Through</td>
<td>(33)</td>
<td>25,602</td>
</tr>
<tr>
<td>National Institute on Disability and Rehabilitation Program</td>
<td>84.133</td>
<td>Sustaining IPS</td>
<td>H133G110161</td>
<td>Direct</td>
<td></td>
<td>88,373</td>
</tr>
<tr>
<td>National Institute on Disability and Rehabilitation Program</td>
<td>84.133</td>
<td>WorkingWell</td>
<td>H133G140889</td>
<td>Direct</td>
<td></td>
<td>69,153</td>
</tr>
<tr>
<td>National Institute on Disability and Rehabilitation Program</td>
<td>84.133B</td>
<td>BU Ctr Grant-NIDRR</td>
<td>450001753</td>
<td>Pass Through</td>
<td>(10)</td>
<td>51,779</td>
</tr>
<tr>
<td>National Institute on Disability and Rehabilitation Program</td>
<td>84.133B</td>
<td>RCT UMass-NIDRR</td>
<td>WA00253991/RFS2015115</td>
<td>Pass Through</td>
<td>(97)</td>
<td>25,774</td>
</tr>
<tr>
<td>Unknown</td>
<td>84.XXX</td>
<td>NCER-RDTeachEff</td>
<td>108074-5025571</td>
<td>Pass Through</td>
<td>(32)</td>
<td>85,095</td>
</tr>
<tr>
<td><strong>DEPARTMENT OF HEALTH AND HUMAN SERVICES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>402,492</td>
</tr>
<tr>
<td>ACL National Institute on Disability, Independent Living, and Rehabilitation Research</td>
<td>93.433</td>
<td>Field-Initiated Program DHHS</td>
<td>90IF0017-01-00</td>
<td>Direct</td>
<td></td>
<td>28,174</td>
</tr>
<tr>
<td>ACL National Institute on Disability, Independent Living, and Rehabilitation Research</td>
<td>93.433</td>
<td>Field-Initiated Nicholson</td>
<td>90IF0069-01-00</td>
<td>Direct</td>
<td></td>
<td>53,925</td>
</tr>
<tr>
<td>ACL National Institute on Disability, Independent Living, and Rehabilitation Research</td>
<td>93.433</td>
<td>Field-Initiated Lord</td>
<td>90DP0052-01-00</td>
<td>Direct</td>
<td></td>
<td>112,757</td>
</tr>
<tr>
<td>Affordable Care Act (ACA) Public Health Training Centers Program</td>
<td>93.516</td>
<td>PHTC</td>
<td>450001665</td>
<td>Pass Through</td>
<td>(10)</td>
<td>38,792</td>
</tr>
<tr>
<td>Aging Research</td>
<td>93.866</td>
<td>Econ of HBW</td>
<td>33-4135-05-Dartmouth</td>
<td>Pass Through</td>
<td>(57)</td>
<td>98,488</td>
</tr>
<tr>
<td>Aging Research</td>
<td>93.866</td>
<td>Behavior Activation YRS</td>
<td>00-19000-501001</td>
<td>Pass Through</td>
<td>(84)</td>
<td>22,783</td>
</tr>
<tr>
<td>Aging Research</td>
<td>93.866</td>
<td>Adm Core A 13</td>
<td>2P01AG019703-11</td>
<td>Direct</td>
<td></td>
<td>1,795,313</td>
</tr>
<tr>
<td>Aging Research</td>
<td>93.866</td>
<td>Metabolism in Alzheimer's</td>
<td>R01AG037609</td>
<td>Direct</td>
<td></td>
<td>324,519</td>
</tr>
<tr>
<td>Aging Research</td>
<td>93.866</td>
<td>Expressions in older</td>
<td>R01AG035028</td>
<td>Direct</td>
<td></td>
<td>186,303</td>
</tr>
<tr>
<td>Aging Research</td>
<td>93.866</td>
<td>Hip Fracture YR YR4</td>
<td>SR0002920</td>
<td>Pass Through</td>
<td>(90)</td>
<td>14,090</td>
</tr>
<tr>
<td>Aging Research</td>
<td>93.866</td>
<td>Skin Symptoms</td>
<td>R03AG042363</td>
<td>Direct</td>
<td></td>
<td>9,773</td>
</tr>
<tr>
<td>Aging Research</td>
<td>93.866</td>
<td>Pension Wealth</td>
<td>R03AG045161-01</td>
<td>Direct</td>
<td></td>
<td>7,104</td>
</tr>
<tr>
<td>Aging Research</td>
<td>93.866</td>
<td>Diffusion Grant</td>
<td>1L01AG046830</td>
<td>Direct</td>
<td></td>
<td>1,119,242</td>
</tr>
<tr>
<td>Alcohol Research Programs</td>
<td>93.273</td>
<td>Cognitive Decline</td>
<td>R21AA020279</td>
<td>Direct</td>
<td></td>
<td>96,008</td>
</tr>
<tr>
<td>Alcohol Research Programs</td>
<td>93.273</td>
<td>Web-Based CBT YR3</td>
<td>622D</td>
<td>Pass Through</td>
<td>(58)</td>
<td>6,414</td>
</tr>
<tr>
<td>Alcohol Research Programs</td>
<td>93.273</td>
<td>Prenat ethanol</td>
<td>R21AA020279</td>
<td>Direct</td>
<td></td>
<td>4,338</td>
</tr>
<tr>
<td>Alcohol Research Programs</td>
<td>93.273</td>
<td>Adolescent Alcohol Abuse</td>
<td>R01AA016917</td>
<td>Direct</td>
<td></td>
<td>12,905</td>
</tr>
<tr>
<td>Federal Program</td>
<td>Cluster Title/CFDA Number</td>
<td>Project Name</td>
<td>Award Number/Pass-through Identification Number</td>
<td>Funding Source</td>
<td>Pass-Through Entity</td>
<td>Total Expenditures</td>
</tr>
<tr>
<td>---------------------------------------------</td>
<td>---------------------------</td>
<td>-------------------------------------------</td>
<td>-------------------------------------------------</td>
<td>---------------</td>
<td>---------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Alcohol Research Programs</td>
<td>93.273</td>
<td>Alcohol Marketing</td>
<td>R01AA01021347</td>
<td>Direct</td>
<td></td>
<td>10,000</td>
</tr>
<tr>
<td>Alcohol Research Programs</td>
<td>93.273</td>
<td>New Media Alcohol Marketing</td>
<td>K23AA021154</td>
<td>Direct</td>
<td></td>
<td>5,137</td>
</tr>
<tr>
<td>Alcohol Research Programs</td>
<td>93.273</td>
<td>Ethanol in Utro</td>
<td>R01AA023410</td>
<td>Direct</td>
<td></td>
<td>4,692</td>
</tr>
<tr>
<td>Alcohol Research Programs</td>
<td>93.273</td>
<td>EU-German Research</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>2,692</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>R01AI025984</td>
<td>RSV DT-prefusion F</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>102,855</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Molecular Mechanism</td>
<td>18,584</td>
<td>Direct</td>
<td></td>
<td>125,031</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Antagonizing miRNAs</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>59,059</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Innate Immunity</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Innate Immunity Y2R</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>59,059</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Harvard animal costs</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Validating Human VISTA</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Safe Anti-CD154 Antibodies</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Immuno with Rexinoids</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>170,708</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Online Measurement YR11</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Online Measurement YR11</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Disco platform YR5 (comp sci)</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>23,928</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>MGH-NIH</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Murine GVHD</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>S. aureus</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Commensal Polysaccharide</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Adaptive Immune Eff YR5</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Hormones Regulation</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Chemokines in Auto</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Pyrimidine Synthesis YR11</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Cognate Activation YR 19</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Biodensefense Research yrt</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Lactobacilli MIP YR5</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>GraRS in resistance</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Genetic Dissection Toxoplasma</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>P. aeruginus Colonies</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>NIG EBBG</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Vibrio Cholerae - Segment 2</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Genetic Determinants 2</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Menstrual HIV</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Myeloid and Lymphoid-23</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>GALT Mediated Protection</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>HIV Immunogen</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>VISTA, a Novel Regulator</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Hypothesis Adaptation</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Toxoplasma Gondii</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Gonidi G Ra Protein</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>T cell murine</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Role of CshA and CshB</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>PH Domain Regulation</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>cdiGMPII Regulation II</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>C. albicans Mediator</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Hypox Adaption</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Hierarchy FY2015</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Retinoic Acid</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Hormone Reg Microbic Yr 1</td>
<td>R01AI025984</td>
<td>Direct</td>
<td></td>
<td>1,858</td>
</tr>
<tr>
<td>Federal Program</td>
<td>Cluster Title/CFDA Number</td>
<td>Project Name</td>
<td>Award Number/Pass-through Identification Number</td>
<td>Funding Source</td>
<td>Pass-Through Entity</td>
<td>Total Expenditures</td>
</tr>
<tr>
<td>------------------------------------------------------</td>
<td>----------------------------</td>
<td>-------------------------------------</td>
<td>-------------------------------------------------</td>
<td>---------------</td>
<td>---------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Arthritis, Musculoskeletal and Skin Diseases Research</td>
<td>93.855</td>
<td>C. Albicans Cdk8</td>
<td>R21AI115253</td>
<td>Direct</td>
<td></td>
<td>5,388</td>
</tr>
<tr>
<td>Arthritis, Musculoskeletal and Skin Diseases Research</td>
<td>93.846</td>
<td>NIAMS: CORT YR3</td>
<td>4500001432</td>
<td>Pass Through</td>
<td>(10)</td>
<td>61,080</td>
</tr>
<tr>
<td>Arthritis, Musculoskeletal and Skin Diseases Research</td>
<td>93.846</td>
<td>NIAMS: Core Center YR3</td>
<td>4500001434</td>
<td>Pass Through</td>
<td>(10)</td>
<td>21,041</td>
</tr>
<tr>
<td>Arthritis, Musculoskeletal and Skin Diseases Research</td>
<td>93.846</td>
<td>NIAMS: Core Center YR4</td>
<td>4500001680</td>
<td>Pass Through</td>
<td>(10)</td>
<td>108,061</td>
</tr>
<tr>
<td>Arthritis, Musculoskeletal and Skin Diseases Research</td>
<td>93.846</td>
<td>NIAMS: Core Center YR3  Proc.</td>
<td>4500001683</td>
<td>Pass Through</td>
<td>(10)</td>
<td>211,258</td>
</tr>
<tr>
<td>Arthritis, Musculoskeletal and Skin Diseases Research</td>
<td>93.846</td>
<td>Phase II</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(14)</td>
<td>102,553</td>
</tr>
<tr>
<td>Arthritis, Musculoskeletal and Skin Diseases Research</td>
<td>93.846</td>
<td>Joint Replacements</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(20)</td>
<td>35,802</td>
</tr>
<tr>
<td>Arthritis, Musculoskeletal and Skin Diseases Research</td>
<td>93.846</td>
<td>Subaward # 232514</td>
<td></td>
<td>Pass Through</td>
<td>(22)</td>
<td>9,179</td>
</tr>
<tr>
<td>Arthritis, Musculoskeletal and Skin Diseases Research</td>
<td>93.846</td>
<td>Quality of Life in Scoliosis</td>
<td>WU-10-157</td>
<td>Pass Through</td>
<td>(122)</td>
<td>66,714</td>
</tr>
<tr>
<td>Arthritis, Musculoskeletal and Skin Diseases Research</td>
<td>93.846</td>
<td>Low Back Pain YR15</td>
<td>U10AR045444</td>
<td>Direct</td>
<td></td>
<td>121,816</td>
</tr>
<tr>
<td>Arthritis, Musculoskeletal and Skin Diseases Research</td>
<td>93.846</td>
<td>RA Biomarkers</td>
<td>R21AR006164</td>
<td>Direct</td>
<td></td>
<td>17,784</td>
</tr>
<tr>
<td>Arthritis, Musculoskeletal and Skin Diseases Research</td>
<td>93.846</td>
<td>Develop Proj Yr 2</td>
<td>1F60AR062799-01</td>
<td>Direct</td>
<td></td>
<td>1,438,929</td>
</tr>
<tr>
<td>Arthritis, Musculoskeletal and Skin Diseases Research</td>
<td>93.846</td>
<td>Macrophage Scleroder</td>
<td>R56AR006385</td>
<td>Direct</td>
<td></td>
<td>71,242</td>
</tr>
<tr>
<td>Arthritis, Musculoskeletal and Skin Diseases Research</td>
<td>93.846</td>
<td>ccNEMO</td>
<td>R03AR061630</td>
<td>Direct</td>
<td></td>
<td>36,197</td>
</tr>
<tr>
<td>Arthritis, Musculoskeletal and Skin Diseases Research</td>
<td>93.846</td>
<td>Molecular Biomarkers</td>
<td>R21AR098035</td>
<td>Direct</td>
<td></td>
<td>8,413</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.360</td>
<td>Radiation TEETH</td>
<td>HH501002011000024C</td>
<td>Direct</td>
<td></td>
<td>(300)</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.360</td>
<td>Radiation TEETH-Option #1</td>
<td>HH501002011000024C</td>
<td>Direct</td>
<td></td>
<td>2,303,657</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>MBL NIH suite</td>
<td>45997</td>
<td>Pass Through</td>
<td>(46)</td>
<td>52,055</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Computational Genetics YR3</td>
<td>P1C-Dartmouth-1112-1073-51-01</td>
<td>Pass Through</td>
<td>(72)</td>
<td>110,623</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Mechanistic Analysis</td>
<td>HS0356</td>
<td>Pass Through</td>
<td>(85)</td>
<td>2,570</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Filamentous Fungi YR10</td>
<td>P01GM0808087</td>
<td>Direct</td>
<td></td>
<td>123,957</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Mrna In Yeast 25-28</td>
<td>R01GM030398</td>
<td>Direct</td>
<td></td>
<td>5,061</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Sister Chromatin Cohesion</td>
<td>R01GM097864</td>
<td>Direct</td>
<td></td>
<td>189,111</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Asynchronous Mitosis</td>
<td>R01GM081506</td>
<td>Direct</td>
<td></td>
<td>237,521</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Fine Tuning Kinesin</td>
<td>R01GM097079</td>
<td>Direct</td>
<td></td>
<td>280,962</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Funct deimmunization</td>
<td>R01GM089897</td>
<td>Direct</td>
<td></td>
<td>292,494</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Cytochrome c</td>
<td>R01GM089852</td>
<td>Direct</td>
<td></td>
<td>296,694</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Natural variation</td>
<td>R01GM078536</td>
<td>Direct</td>
<td></td>
<td>288,644</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Mitotic size control</td>
<td>R01GM097774</td>
<td>Direct</td>
<td></td>
<td>339,815</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Clock Control Gomes YR23</td>
<td>R01GM083336</td>
<td>Direct</td>
<td></td>
<td>706,010</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Brinkerhoff</td>
<td>P01GM0103415</td>
<td>Direct</td>
<td></td>
<td>1,034,965</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>COPP1-dependent-YR16</td>
<td>R37GM0602549</td>
<td>Direct</td>
<td></td>
<td>520,059</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>INI1BRE YR4</td>
<td>P30GM010358</td>
<td>Direct</td>
<td></td>
<td>2,858,283</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>A. Rogers COBRE</td>
<td>P20GM0103534</td>
<td>Direct</td>
<td></td>
<td>1,755,698</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Chromosome pairing</td>
<td>GM099462</td>
<td>Direct</td>
<td></td>
<td>823</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Neutrophor Clock YR27</td>
<td>R01GM034985</td>
<td>Direct</td>
<td></td>
<td>775,451</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Mitotic Spindle YR17</td>
<td>R37GM0605152</td>
<td>Direct</td>
<td></td>
<td>578,829</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>CME Admin Core</td>
<td>P20GM0104416</td>
<td>Direct</td>
<td></td>
<td>2,356,266</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Metacellcyle</td>
<td>R01GM082066-09</td>
<td>Direct</td>
<td></td>
<td>804,723</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Biology at Dartmouth YR16</td>
<td>2T32GM0808704</td>
<td>Direct</td>
<td></td>
<td>405,199</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Protein Compartment-38A1</td>
<td>Preward</td>
<td>Direct</td>
<td></td>
<td>864,980</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>INF2 &amp; mitochondria</td>
<td>R01GM089800</td>
<td>Direct</td>
<td></td>
<td>469,216</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Admin Core Yr 1</td>
<td>P01GM016394</td>
<td>Direct</td>
<td></td>
<td>1,126,970</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Bacterial-Fungal Interactions</td>
<td>R01GM084929</td>
<td>Direct</td>
<td></td>
<td>440,124</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Mammalian Formins - 10A1</td>
<td>R01GM112048</td>
<td>Direct</td>
<td></td>
<td>319,132</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>cycloloka-b-iodoles</td>
<td>R01GM111638</td>
<td>Direct</td>
<td></td>
<td>302,018</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>CF Microbiome</td>
<td>R01GM112050</td>
<td>Direct</td>
<td></td>
<td>186,665</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>Filopodia Assembly</td>
<td>R01GM109965</td>
<td>Direct</td>
<td></td>
<td>84,491</td>
</tr>
<tr>
<td>Federal Program</td>
<td>Cluster Title/CFDA Number</td>
<td>Project Name</td>
<td>Award Number/Pass-through Identification Number</td>
<td>Funding Source</td>
<td>Pass-Through Entity</td>
<td>Total Expenditures</td>
</tr>
<tr>
<td>------------------------------------------------------</td>
<td>---------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>-------------------------------------------------</td>
<td>------------------------</td>
<td>---------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Blood Diseases and Resources Research</td>
<td>93.839</td>
<td>Recruitment, DNA Prep Yr 4</td>
<td>M10A10692 (A07741)</td>
<td>Pass Through</td>
<td>(127)</td>
<td>(7,660)</td>
</tr>
<tr>
<td>Blood Diseases and Resources Research</td>
<td>93.839</td>
<td>MLL Function YR6</td>
<td>R01HL000036</td>
<td>Direct</td>
<td></td>
<td>46,364</td>
</tr>
<tr>
<td>Cancer Biology Research</td>
<td>93.393</td>
<td>Med College WI sub</td>
<td>PO # 1532593</td>
<td>Pass Through</td>
<td>(51)</td>
<td>941</td>
</tr>
<tr>
<td>Cancer Biology Research</td>
<td>93.393</td>
<td>Hedgehog Signaling YR3</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(100)</td>
<td>10,804</td>
</tr>
<tr>
<td>Cancer Biology Research</td>
<td>93.393</td>
<td>The P530 YR2</td>
<td>VUMC-4070</td>
<td>Pass Through</td>
<td>(119)</td>
<td>12,080</td>
</tr>
<tr>
<td>Cancer Biology Research</td>
<td>93.393</td>
<td>The P540 YR3</td>
<td>VUMC-4070</td>
<td>Pass Through</td>
<td>(119)</td>
<td>54,677</td>
</tr>
<tr>
<td>Cancer Biology Research</td>
<td>93.393</td>
<td>Evolution of ovarian cancer</td>
<td>24581-02-365</td>
<td>Direct</td>
<td></td>
<td>19,164</td>
</tr>
<tr>
<td>Cancer Biology Research</td>
<td>93.396</td>
<td>The P450 YR4</td>
<td>PRE-AWARD</td>
<td>Direct</td>
<td></td>
<td>5,222</td>
</tr>
<tr>
<td>Cancer Biology Research</td>
<td>93.396</td>
<td>Invasive Behavior YR 08</td>
<td>R01CA077267</td>
<td>Direct</td>
<td></td>
<td>65,209</td>
</tr>
<tr>
<td>Cancer Biology Research</td>
<td>93.396</td>
<td>Polymorphisms in Cancer</td>
<td>R01CA080320</td>
<td>Direct</td>
<td></td>
<td>327,715</td>
</tr>
<tr>
<td>Cancer Biology Research</td>
<td>93.396</td>
<td>APC Tumor Suppressor-YR6</td>
<td>R01CA105388</td>
<td>Direct</td>
<td></td>
<td>372,809</td>
</tr>
<tr>
<td>Cancer Biology Research</td>
<td>93.396</td>
<td>Mechanisms of Concom YR6</td>
<td>R01CA120777</td>
<td>Direct</td>
<td></td>
<td>270,544</td>
</tr>
<tr>
<td>Cancer Biology Research</td>
<td>93.396</td>
<td>Role of Protein S14 Yr 10</td>
<td>2801CA126618-10A1</td>
<td>Direct</td>
<td></td>
<td>276,689</td>
</tr>
<tr>
<td>Cancer Biology Research</td>
<td>93.396</td>
<td>Combinational Therapy Melanoma</td>
<td>R03CA188418</td>
<td>Direct</td>
<td></td>
<td>11,149</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Measure Overuse of Hc Yr 2</td>
<td>109109</td>
<td>Pass Through</td>
<td>(11)</td>
<td>29,032</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>ACR-WOR YR2</td>
<td>109272</td>
<td>Pass Through</td>
<td>(11)</td>
<td>21,316</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>NHS: Ca in Women</td>
<td>111034</td>
<td>Pass Through</td>
<td>(11)</td>
<td>134,304</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Vitamin D3, Immunomodulation</td>
<td>T179442</td>
<td>Pass Through</td>
<td>(25)</td>
<td>12,843</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Gut Barrier Function</td>
<td>T299757</td>
<td>Pass Through</td>
<td>(25)</td>
<td>18,079</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Vitamin D3, ImmunomodulationY2</td>
<td>PRE-AWARD</td>
<td>Pass Through</td>
<td>(25)</td>
<td>3,045</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Telomeres YR3</td>
<td>788667</td>
<td>Pass Through</td>
<td>(29)</td>
<td>23,619</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Telomeres YR3 supplement</td>
<td>788690</td>
<td>Pass Through</td>
<td>(29)</td>
<td>7,082</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Telomeres YR4</td>
<td>789534</td>
<td>Pass Through</td>
<td>(29)</td>
<td>18,635</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Telomeres YR4</td>
<td>810611</td>
<td>Pass Through</td>
<td>(29)</td>
<td>91,028</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Risk-based cancer screen YR 3</td>
<td>CA15452-03</td>
<td>Pass Through</td>
<td>(31)</td>
<td>200,432</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>RRBC - Project YR3</td>
<td>CA15452-03-Dartmouth-Onega</td>
<td>Pass Through</td>
<td>(31)</td>
<td>122,286</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>PCORI</td>
<td>2013169197</td>
<td>Pass Through</td>
<td>(31)</td>
<td>17,667</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>BBCC - Core B YR3</td>
<td>CA15452-03-Dartmouth-Onega</td>
<td>Pass Through</td>
<td>(31)</td>
<td>7,449</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Risk-based Cancer Screen YR 4</td>
<td>CA15452-04</td>
<td>Pass Through</td>
<td>(31)</td>
<td>299,033</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>RRBC - Core B YR4</td>
<td>PO02014188879</td>
<td>Pass Through</td>
<td>(31)</td>
<td>72,168</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>RRBC - Project YR4</td>
<td>PO02014188879</td>
<td>Pass Through</td>
<td>(31)</td>
<td>66,250</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>PCORI YR2</td>
<td>2013169197</td>
<td>Pass Through</td>
<td>(31)</td>
<td>26,683</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Social Networks</td>
<td>150144-50761-0004</td>
<td>Pass Through</td>
<td>(32)</td>
<td>24,050</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>CCFR YR2</td>
<td>6077226-110835-K</td>
<td>Pass Through</td>
<td>(80)</td>
<td>55,941</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Arsenic-Induced Skin CA YR12</td>
<td>44706-A</td>
<td>Pass Through</td>
<td>(92)</td>
<td>7,873</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Arsenic-Induced Skin CA YR13</td>
<td>44706-A</td>
<td>Pass Through</td>
<td>(92)</td>
<td>55,861</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Self Control YR5</td>
<td>Z107872496</td>
<td>Pass Through</td>
<td>(94)</td>
<td>48,199</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Vit D Sub-Account YR1</td>
<td>5-33528</td>
<td>Pass Through</td>
<td>(103)</td>
<td>77,526</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>FPS3 Sub YR4</td>
<td>5-39087</td>
<td>Pass Through</td>
<td>(103)</td>
<td>22,184</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>VitD Sub-Account YR2</td>
<td>50032286</td>
<td>Pass Through</td>
<td>(103)</td>
<td>908,084</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Mol Mech NRF2 Yr 4</td>
<td>0019106 (120429-3)</td>
<td>Pass Through</td>
<td>(105)</td>
<td>10,116</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>GSRM</td>
<td>0009805A</td>
<td>Pass Through</td>
<td>(110)</td>
<td>15,860</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>MDACC sub Lung</td>
<td>0002207-3000395344</td>
<td>Pass Through</td>
<td>(111)</td>
<td>32,193</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>MDACC sub Lung Yr 2</td>
<td>2207</td>
<td>Pass Through</td>
<td>(111)</td>
<td>10,731</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Double Reading</td>
<td>659975</td>
<td>Pass Through</td>
<td>(115)</td>
<td>54,670</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Technology &amp; Double Reading</td>
<td>724576</td>
<td>Pass Through</td>
<td>(115)</td>
<td>161,963</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Southern Community YR2</td>
<td>VUMC-40616</td>
<td>Pass Through</td>
<td>(119)</td>
<td>(1,452)</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Southern Community YR3</td>
<td>VUMC-40616</td>
<td>Pass Through</td>
<td>(119)</td>
<td>16,822</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>NH Colon Registry</td>
<td>HHSN261210400595P</td>
<td>Direct</td>
<td></td>
<td>186,041</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Adolescent Smoking YR10</td>
<td>R01CA077026</td>
<td>Direct</td>
<td></td>
<td>21,348</td>
</tr>
</tbody>
</table>
## Dartmouth College

### Schedule of Expenditures of Federal Awards

#### Year Ended June 30, 2015

<table>
<thead>
<tr>
<th>Federal Program</th>
<th>Cluster Title/CFDA Number</th>
<th>Project Name</th>
<th>Award Number/Pass-through Identification Number</th>
<th>Funding Source</th>
<th>Pass-Through Entity</th>
<th>Total Expenditures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Effectors Myc Function</td>
<td>R01CA055248</td>
<td>Direct</td>
<td></td>
<td>134,934</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Colon Survival</td>
<td>R01CA131141</td>
<td>Direct</td>
<td></td>
<td>9,814</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Image Breast Cancer YR10</td>
<td>R01CA069544</td>
<td>Direct</td>
<td></td>
<td>264</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Surveillance YR 6</td>
<td>R01CA103642</td>
<td>Direct</td>
<td></td>
<td>18,116</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Retinoid Ca Prv Mech YR11</td>
<td>R01CA087546</td>
<td>Direct</td>
<td></td>
<td>10,960</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Preop Mammo</td>
<td>R01CA139505</td>
<td>Direct</td>
<td></td>
<td>532,988</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Skin Cancer in NH</td>
<td>R01CA057494</td>
<td>Direct</td>
<td></td>
<td>503,124</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>NCI-D.S. for S.C.</td>
<td>R21CA138863</td>
<td>Direct</td>
<td></td>
<td>129,682</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Admin Core YR4</td>
<td>U19CA148127</td>
<td>Direct</td>
<td></td>
<td>1,076,564</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>MicroRNA</td>
<td>R21CA175553</td>
<td>Direct</td>
<td></td>
<td>146,700</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Blinding</td>
<td>R01CA178272</td>
<td>Direct</td>
<td></td>
<td>84,194</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>RCT of MDSS for Smok</td>
<td>R01CA168778</td>
<td>Direct</td>
<td></td>
<td>527,864</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Morden_NCI_R03_Resub</td>
<td>R03CA167723</td>
<td>Direct</td>
<td></td>
<td>62,786</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>TRICL Admin Core</td>
<td>U19CA148127</td>
<td>Direct</td>
<td></td>
<td>246,862</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Genomewide Study</td>
<td>R01CA149462</td>
<td>Direct</td>
<td></td>
<td>741,769</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Adolescent Smoking YR15-18</td>
<td>R01CA077026</td>
<td>Direct</td>
<td></td>
<td>696,861</td>
</tr>
<tr>
<td>Cancer Centers Support Grants</td>
<td>93.397</td>
<td>GI Sore YR4</td>
<td>3020191972</td>
<td>Pass Through</td>
<td>(101)</td>
<td>23,440</td>
</tr>
<tr>
<td>Cancer Centers Support Grants</td>
<td>93.397</td>
<td>GI SPORE YR5</td>
<td>PRE-AWARD</td>
<td>Pass Through</td>
<td>(101)</td>
<td>109,861</td>
</tr>
<tr>
<td>Cancer Centers Support Grants</td>
<td>93.397</td>
<td>SPORE MDA YR2</td>
<td>91818</td>
<td>Pass Through</td>
<td>(111)</td>
<td>2,836</td>
</tr>
<tr>
<td>Cancer Centers Support Grants</td>
<td>93.397</td>
<td>Dragnev Leadership Yr 36</td>
<td>P30CA023108</td>
<td>Direct</td>
<td></td>
<td>12,175</td>
</tr>
<tr>
<td>Cancer Centers Support Grants</td>
<td>93.397</td>
<td>CCNE - Administrative YR4</td>
<td>U54CA151662</td>
<td>Direct</td>
<td></td>
<td>1,923,653</td>
</tr>
<tr>
<td>Cancer Centers Support Grants</td>
<td>93.397</td>
<td>Test_PROSPR_breast Proj YR 3</td>
<td>U54CA163307</td>
<td>Direct</td>
<td></td>
<td>945,744</td>
</tr>
<tr>
<td>Cancer Centers Support Grants</td>
<td>93.397</td>
<td>Admin FY14</td>
<td>P30CA023108</td>
<td>Direct</td>
<td></td>
<td>1,534,151</td>
</tr>
<tr>
<td>Cancer Control</td>
<td>93.399</td>
<td>Topography and Genetics YR2</td>
<td>BHCIAH 1P50CA148110-00S1</td>
<td>Pass Through</td>
<td>(7)</td>
<td>29,827</td>
</tr>
<tr>
<td>Cancer Control</td>
<td>93.399</td>
<td>S0221 Continuous vs Schedule</td>
<td>CA37249</td>
<td>Direct</td>
<td></td>
<td>9,726</td>
</tr>
<tr>
<td>Cancer Detection and Diagnosis Research</td>
<td>93.394</td>
<td>Developing DOSI Tech</td>
<td>2014-3024</td>
<td>Pass Through</td>
<td>(88)</td>
<td>32,712</td>
</tr>
<tr>
<td>Cancer Detection and Diagnosis Research</td>
<td>93.394</td>
<td>GLNE YR5</td>
<td>5100047</td>
<td>Pass Through</td>
<td>(103)</td>
<td>80,480</td>
</tr>
<tr>
<td>Cancer Detection and Diagnosis Research</td>
<td>93.394</td>
<td>Optical Imaging Fuse</td>
<td>R01CA139449</td>
<td>Direct</td>
<td></td>
<td>59,739</td>
</tr>
<tr>
<td>Cancer Detection and Diagnosis Research</td>
<td>93.394</td>
<td>Intraoperative surgi</td>
<td>R01CA143020</td>
<td>Direct</td>
<td></td>
<td>270,417</td>
</tr>
<tr>
<td>Cancer Detection and Diagnosis Research</td>
<td>93.394</td>
<td>Brain Tumor Resection</td>
<td>R01CA139324</td>
<td>Direct</td>
<td></td>
<td>373,291</td>
</tr>
<tr>
<td>Cancer Detection and Diagnosis Research</td>
<td>93.394</td>
<td>Kabeche Supplement</td>
<td>R01CA135260</td>
<td>Direct</td>
<td></td>
<td>403,210</td>
</tr>
<tr>
<td>Cancer Detection and Diagnosis Research</td>
<td>93.394</td>
<td>Fluorescence Imaging YR6</td>
<td>R01CA109558</td>
<td>Direct</td>
<td></td>
<td>131,800</td>
</tr>
<tr>
<td>Cancer Detection and Diagnosis Research</td>
<td>93.394</td>
<td>Molecular-Guided Surgery</td>
<td>R25CA174713</td>
<td>Direct</td>
<td></td>
<td>632,965</td>
</tr>
<tr>
<td>Cancer Detection and Diagnosis Research</td>
<td>93.394</td>
<td>MRI fluorescence tom</td>
<td>R01CA184354</td>
<td>Direct</td>
<td></td>
<td>357,118</td>
</tr>
<tr>
<td>Cancer Detection and Diagnosis Research</td>
<td>93.394</td>
<td>NIR tomography</td>
<td>R01CA176086</td>
<td>Direct</td>
<td></td>
<td>384,299</td>
</tr>
<tr>
<td>Cancer Detection and Diagnosis Research</td>
<td>93.394</td>
<td>New Cancer Target</td>
<td>1R21CA177781</td>
<td>Direct</td>
<td></td>
<td>229,224</td>
</tr>
<tr>
<td>Cancer Detection and Diagnosis Research</td>
<td>93.394</td>
<td>Image-Guided Surgery</td>
<td>R21CA182956</td>
<td>Direct</td>
<td></td>
<td>151,504</td>
</tr>
<tr>
<td>Cancer Detection and Diagnosis Research</td>
<td>93.394</td>
<td>Optical Scanning</td>
<td>R01CA192803</td>
<td>Direct</td>
<td></td>
<td>494,536</td>
</tr>
<tr>
<td>Cancer Detection and Diagnosis Research</td>
<td>93.394</td>
<td>Core 1 - Admin</td>
<td>P01CA190193</td>
<td>Direct</td>
<td></td>
<td>10,596</td>
</tr>
<tr>
<td>Cancer Detection and Diagnosis Research</td>
<td>93.394</td>
<td>Train Quantitative YR 3</td>
<td>R25CA134286</td>
<td>Direct</td>
<td></td>
<td>123,276</td>
</tr>
<tr>
<td>Cancer Research Manpower</td>
<td>93.398</td>
<td>Microwave Imaging Nevadjuvant</td>
<td>1R01CA191227</td>
<td>Direct</td>
<td></td>
<td>7,622</td>
</tr>
<tr>
<td>Cancer Research Manpower</td>
<td>93.398</td>
<td>Quant Optical Biomar</td>
<td>K25CA164248</td>
<td>Direct</td>
<td></td>
<td>147,545</td>
</tr>
<tr>
<td>Cancer Research Manpower</td>
<td>93.398</td>
<td>Train Quantitative YR 6</td>
<td>R25CA134286</td>
<td>Direct</td>
<td></td>
<td>141,735</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>PVIICO</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(14)</td>
<td>3,874</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>Dampering CAR</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(14)</td>
<td>63,485</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>Children's Oncology Grp -Chop</td>
<td>P20CA134356</td>
<td>Pass Through</td>
<td>(8)</td>
<td>71,753</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>Mesylate in Gists YR7</td>
<td>1618607</td>
<td>Pass Through</td>
<td>(28)</td>
<td>(4,893)</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>CITN-06</td>
<td>799972</td>
<td>Pass Through</td>
<td>(29)</td>
<td>2,744</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>CITN-06 Yr 2</td>
<td>816302</td>
<td>Pass Through</td>
<td>(29)</td>
<td>2,407</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>CITNO4_W13204</td>
<td>0000789863-207806</td>
<td>Pass Through</td>
<td>(29)</td>
<td>(801)</td>
</tr>
<tr>
<td>Federal Program</td>
<td>Cluster Title/CFDA Number</td>
<td>Project Name</td>
<td>Award Number/Pass-through Identification Number</td>
<td>Funding Source</td>
<td>Pass-Through Entity</td>
<td>Total Expenditures</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>---------------------------</td>
<td>-------------------------------</td>
<td>-----------------------------------------------</td>
<td>----------------</td>
<td>---------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>W1008</td>
<td>MS1T-11</td>
<td>Pass Through</td>
<td>(42)</td>
<td>325</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>Online Measurement YR12</td>
<td>225634</td>
<td>Pass Through</td>
<td>(47)</td>
<td>92,362</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>Online Measurement YR12</td>
<td>225638</td>
<td>Pass Through</td>
<td>(47)</td>
<td>82,791</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>Targeting Pancreatic Cancer04</td>
<td>60344794</td>
<td>Pass Through</td>
<td>(49)</td>
<td>144,666</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>Targeting Pancreatic Cancer 05</td>
<td>60344762</td>
<td>Pass Through</td>
<td>(49)</td>
<td>68,501</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>Statin Choice Implem</td>
<td>6371477</td>
<td>Pass Through</td>
<td>(52)</td>
<td>46,808</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>Optical Spectrum</td>
<td>G02486</td>
<td>Pass Through</td>
<td>(59)</td>
<td>21,963</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>Intraoperative Guidance</td>
<td>60039916</td>
<td>Pass Through</td>
<td>(68)</td>
<td>19,729</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>Role of STAT3</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(124)</td>
<td>33,022</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>ABNER</td>
<td>N/A</td>
<td>Direct</td>
<td></td>
<td>282</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>A021202 Carcinoid Tumors</td>
<td>NH102</td>
<td>Direct</td>
<td></td>
<td>1,211</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>E1609 High Risk Melanoma</td>
<td>N/A</td>
<td>Direct</td>
<td></td>
<td>10,097</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>Ret Ac Para and PrLe</td>
<td>R01CA002275</td>
<td>Direct</td>
<td></td>
<td>202,359</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>Effects of PTEN</td>
<td>R00CA142899</td>
<td>Direct</td>
<td></td>
<td>206,165</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>R00</td>
<td>4800CA140948</td>
<td>Direct</td>
<td></td>
<td>288,971</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>NGK2D-specific BiTE cancer</td>
<td>1801CA164178</td>
<td>Direct</td>
<td></td>
<td>340,448</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>CC Checkpoint</td>
<td>R01CA117874</td>
<td>Direct</td>
<td></td>
<td>114,140</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>PV-1 as a Novel Target</td>
<td>R21CA175592</td>
<td>Direct</td>
<td></td>
<td>164,729</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>Anti-PV1 Therapy</td>
<td>R21CA172983</td>
<td>Direct</td>
<td></td>
<td>163,493</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>NMDA Pancreatic</td>
<td>R21CA167329</td>
<td>Direct</td>
<td></td>
<td>1,564</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>G175 Carbo/Paclit ov Cancer</td>
<td>27469-34</td>
<td>Direct</td>
<td>(1)</td>
<td>277,690</td>
</tr>
<tr>
<td>Cancer Treatment Research</td>
<td>93.395</td>
<td>A021202 Carcinoid Tumors</td>
<td>U10CA180854</td>
<td>Direct</td>
<td></td>
<td>3,041</td>
</tr>
<tr>
<td>Cardiovascular Diseases Research</td>
<td>93.837</td>
<td>Therapy for Atherosclerosis</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(14)</td>
<td>23,871</td>
</tr>
<tr>
<td>Cardiovascular Diseases Research</td>
<td>93.837</td>
<td>MI Therapeutics YR3</td>
<td>2RRHL07464-02A1</td>
<td>Pass Through</td>
<td>(23)</td>
<td>1,564</td>
</tr>
<tr>
<td>Cardiovascular Diseases Research</td>
<td>93.837</td>
<td>EXACT-HF</td>
<td>177794</td>
<td>Pass Through</td>
<td>(23)</td>
<td>2,388</td>
</tr>
<tr>
<td>Cardiovascular Diseases Research</td>
<td>93.837</td>
<td>GUIDE-IT</td>
<td>179452</td>
<td>Pass Through</td>
<td>(25)</td>
<td>37,417</td>
</tr>
<tr>
<td>Cardiovascular Diseases Research</td>
<td>93.837</td>
<td>Mechanisms YR2</td>
<td>T390617</td>
<td>Pass Through</td>
<td>(25)</td>
<td>46,679</td>
</tr>
<tr>
<td>Cardiovascular Diseases Research</td>
<td>93.837</td>
<td>RBC Transfusions YR2</td>
<td>T286230</td>
<td>Pass Through</td>
<td>(32)</td>
<td>23,101</td>
</tr>
<tr>
<td>Cardiovascular Diseases Research</td>
<td>93.837</td>
<td>Long Term Outcomes</td>
<td>150103.570564.00003</td>
<td>Pass Through</td>
<td>(32)</td>
<td>24,451</td>
</tr>
<tr>
<td>Cardiovascular Diseases Research</td>
<td>93.837</td>
<td>Vasomotor Control</td>
<td>34552-A</td>
<td>Pass Through</td>
<td>(64)</td>
<td>71,938</td>
</tr>
<tr>
<td>Cardiovascular Diseases Research</td>
<td>93.837</td>
<td>Dopamine and Angiotensin YR2</td>
<td>150122.570574.0311</td>
<td>Pass Through</td>
<td>(114)</td>
<td>20,653</td>
</tr>
<tr>
<td>Cardiovascular Diseases Research</td>
<td>93.837</td>
<td>Mechanisms YR3</td>
<td>PRE-AWARD</td>
<td>Direct</td>
<td></td>
<td>3,317</td>
</tr>
<tr>
<td>Cardiovascular Diseases Research</td>
<td>93.837</td>
<td>Quality of Life</td>
<td>K23HL092160</td>
<td>Direct</td>
<td></td>
<td>7,292</td>
</tr>
<tr>
<td>Cardiovascular Diseases Research</td>
<td>93.837</td>
<td>Understanding Variation</td>
<td>K23HL095676</td>
<td>Direct</td>
<td></td>
<td>115,506</td>
</tr>
<tr>
<td>Cardiovascular Diseases Research</td>
<td>93.837</td>
<td>Self Reg R21</td>
<td>R21HL114092</td>
<td>Direct</td>
<td>(353)</td>
<td>353,672</td>
</tr>
<tr>
<td>Cardiovascular Diseases Research</td>
<td>93.837</td>
<td>Analysis Of Acat</td>
<td>R01HL090306</td>
<td>Direct</td>
<td></td>
<td>364,721</td>
</tr>
<tr>
<td>Cardiovascular Diseases Research</td>
<td>93.837</td>
<td>Biomarkers/Readmission</td>
<td>R01HL119664</td>
<td>Direct</td>
<td></td>
<td>353,672</td>
</tr>
<tr>
<td>Cardiovascular Diseases Research</td>
<td>93.837</td>
<td>ACAT and Disease</td>
<td>F32HL124953</td>
<td>Direct</td>
<td></td>
<td>40,327</td>
</tr>
<tr>
<td>Centers for Disease Control and</td>
<td>93.283</td>
<td>Cancer Enhancement YR25</td>
<td>PO 1 1024261</td>
<td>Direct</td>
<td></td>
<td>616,507</td>
</tr>
<tr>
<td>Prevention_Investigations and Technical Assistance Centers for Disease Control and</td>
<td>93.283</td>
<td>CDC NHBDP YR5</td>
<td>U50DD00607</td>
<td>Direct</td>
<td></td>
<td>94,688</td>
</tr>
<tr>
<td>Prevention_Investigations and Technical Assistance Centers for Disease Control and</td>
<td>93.283</td>
<td>CDC NHBDP YR6</td>
<td>U50DD00607</td>
<td>Direct</td>
<td></td>
<td>63,221</td>
</tr>
<tr>
<td>Prevention_Investigations and Technical Assistance Centers for Research and Demonstration for Health Promotion and Disease Prevention</td>
<td>93.135</td>
<td>ALS CDC Project</td>
<td>10-2014-59046</td>
<td>Direct</td>
<td></td>
<td>317,194</td>
</tr>
<tr>
<td>Prevention_Investigations and Technical Assistance Centers for Research and Demonstration for Health Promotion and Disease Prevention</td>
<td>93.135</td>
<td>HOBSCHOTCH YR 2</td>
<td>3U48DP019035-0552</td>
<td>Direct</td>
<td></td>
<td>50,352</td>
</tr>
<tr>
<td>Prevention_Investigations and Technical Assistance Centers for Research and Demonstration for Health Promotion and Disease Prevention</td>
<td>93.135</td>
<td>CDC/PBC Core</td>
<td>U48DP005018</td>
<td>Direct</td>
<td></td>
<td>508,433</td>
</tr>
</tbody>
</table>
### Dartmouth College

**Schedule of Expenditures of Federal Awards**  
**Year Ended June 30, 2015**

<table>
<thead>
<tr>
<th>Federal Program</th>
<th>Cluster Title/CFDA Number</th>
<th>Project Name</th>
<th>Award Number/Pass-through Identification Number</th>
<th>Funding Source</th>
<th>Pass-Through Entity</th>
<th>Total Expenditures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Child Health and Human Development Extramural Research</td>
<td>93.865</td>
<td>Improving Preterm Outcomes YR3</td>
<td>3266</td>
<td>Pass Through</td>
<td>(9)</td>
<td>3,005</td>
</tr>
<tr>
<td>Child Health and Human Development Extramural Research</td>
<td>93.865</td>
<td>CHAART</td>
<td>4429-5</td>
<td>Pass Through</td>
<td>(10)</td>
<td>19,745</td>
</tr>
<tr>
<td>Child Health and Human Development Extramural Research</td>
<td>93.865</td>
<td>WHAART</td>
<td>4500000689</td>
<td>Pass Through</td>
<td>(10)</td>
<td>24,642</td>
</tr>
<tr>
<td>Child Health and Human Development Extramural Research</td>
<td>93.865</td>
<td>WHAART YR 5</td>
<td>PRE-AWARD</td>
<td>Pass Through</td>
<td>(10)</td>
<td>9,779</td>
</tr>
<tr>
<td>Child Health and Human Development Extramural Research</td>
<td>93.865</td>
<td>Ventral Medula/SIDS Yr 17</td>
<td>RSTFD0000582456</td>
<td>Pass Through</td>
<td>(15)</td>
<td>508,403</td>
</tr>
<tr>
<td>Child Health and Human Development Extramural Research</td>
<td>93.865</td>
<td>Vent Medulla SIDS Yr 18</td>
<td>Pre Award</td>
<td>Pass Through</td>
<td>(32)</td>
<td>34,827</td>
</tr>
<tr>
<td>Child Health and Human Development Extramural Research</td>
<td>93.865</td>
<td>Treat YR 5</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(79)</td>
<td>41,234</td>
</tr>
<tr>
<td>Child Health and Human Development Extramural Research</td>
<td>93.865</td>
<td>Treat YR2</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(79)</td>
<td>39,552</td>
</tr>
<tr>
<td>Child Health and Human Development Extramural Research</td>
<td>93.865</td>
<td>PHACS - Tulane</td>
<td>TUL-HSC-466-13/14</td>
<td>Pass Through</td>
<td>(83)</td>
<td>2,038</td>
</tr>
<tr>
<td>Child Health and Human Development Extramural Research</td>
<td>93.865</td>
<td>PHACS-Tulane Yr 2</td>
<td>TUL-HSC-567-14/15</td>
<td>Pass Through</td>
<td>(84)</td>
<td>18,449</td>
</tr>
<tr>
<td>Child Health and Human Development Extramural Research</td>
<td>93.865</td>
<td>Mobility Disabilitie</td>
<td>6147954/RFS2013101</td>
<td>Pass Through</td>
<td>(98)</td>
<td>6,108</td>
</tr>
<tr>
<td>Child Health and Human Development Extramural Research</td>
<td>93.865</td>
<td>Risk Prediction Model</td>
<td>1301522</td>
<td>Pass Through</td>
<td>(108)</td>
<td>10,745</td>
</tr>
<tr>
<td>Child Health and Human Development Extramural Research</td>
<td>93.865</td>
<td>Maat And Meth In Tbi</td>
<td>R01HD047242</td>
<td>Direct</td>
<td></td>
<td>85,897</td>
</tr>
<tr>
<td>Child Health and Human Development Extramural Research</td>
<td>93.865</td>
<td>Early Pregnancy-yr6</td>
<td>R01HD049762</td>
<td>Direct</td>
<td></td>
<td>(1,250)</td>
</tr>
<tr>
<td>Child Health and Human Development Extramural Research</td>
<td>93.865</td>
<td>The Upper Airway YR5</td>
<td>R01HD042707</td>
<td>Direct</td>
<td></td>
<td>(2,774)</td>
</tr>
<tr>
<td>Child Health and Human Development Extramural Research</td>
<td>93.865</td>
<td>Food Marketing</td>
<td>R01HD071021</td>
<td>Direct</td>
<td></td>
<td>632,272</td>
</tr>
<tr>
<td>Child Health and Human Development Extramural Research</td>
<td>93.865</td>
<td>Thyroxine Prohormone</td>
<td>R21HD072526</td>
<td>Direct</td>
<td></td>
<td>61,534</td>
</tr>
<tr>
<td>Child Health and Human Development Extramural Research</td>
<td>93.865</td>
<td>Teens &amp; Type 1 Diabetes</td>
<td>1DP3HD0764602</td>
<td>Direct</td>
<td></td>
<td>570,016</td>
</tr>
<tr>
<td>Child Health and Human Development Extramural Research</td>
<td>93.865</td>
<td>R21</td>
<td>R21HD076007</td>
<td>Direct</td>
<td></td>
<td>152,425</td>
</tr>
<tr>
<td>Child Health and Human Development Extramural Research</td>
<td>93.865</td>
<td>Anytime Fitness</td>
<td>R21HD074995</td>
<td>Direct</td>
<td></td>
<td>189,836</td>
</tr>
<tr>
<td>Diabetes, Digestive, and Kidney Diseases Extramural Research</td>
<td>93.847</td>
<td>Mediated FSGS YR4</td>
<td>1024387</td>
<td>Pass Through</td>
<td>(6)</td>
<td>(166)</td>
</tr>
<tr>
<td>Diabetes, Digestive, and Kidney Diseases Extramural Research</td>
<td>93.847</td>
<td>Mediated FSGS YR5</td>
<td>1027777</td>
<td>Pass Through</td>
<td>(6)</td>
<td>54,804</td>
</tr>
</tbody>
</table>

---

**Total Expenditures:**

- **Federal Program:**
  - Child Health and Human Development Extramural Research: 3,005
  - CHAART: 19,745
  - WHAART: 24,642
  - WHAART YR 5: 9,779
  - Ventral Medula/SIDS Yr 17: 508,403
  - Vent Medulla SIDS Yr 18: 34,827
  - Treat YR 5: 41,234
  - Treat YR2: 39,552
  - PHACS - Tulane: 2,038
  - PHACS-Tulane Yr 2: 18,449
  - Mobility Disabilitie: 6,108
  - Risk Prediction Model: 10,745
  - Maat And Meth In Tbi: 85,897
  - Early Pregnancy-yr6: 1,250
  - The Upper Airway YR5: 2,774
  - Food Marketing: 632,272
  - Thyroxine Prohormone: 61,534
  - Teens & Type 1 Diabetes: 570,016
  - R21: 152,425
  - Anytime Fitness: 189,836
  - Mediated FSGS YR4: 166
  - Mediated FSGS YR5: 54,804
<table>
<thead>
<tr>
<th>Federal Program</th>
<th>Cluster Title/CFDA Number</th>
<th>Project Name</th>
<th>Award Number/Pass-through Identification Number</th>
<th>Funding Source</th>
<th>Pass-Through Entity</th>
<th>Total Expenditures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes, Digestive, and Kidney Diseases Extramural Research</td>
<td>93.847</td>
<td>MERIT UC Revised Yr 1</td>
<td>5-31662</td>
<td>Pass Through</td>
<td>(103)</td>
<td>9,461</td>
</tr>
<tr>
<td>Diabetes, Digestive, and Kidney Diseases Extramural Research</td>
<td>93.847</td>
<td>EUS Diagnosis</td>
<td>K23DK088832</td>
<td>Direct</td>
<td></td>
<td>135,063</td>
</tr>
<tr>
<td>Diabetes, Digestive, and Kidney Diseases Extramural Research</td>
<td>93.847</td>
<td>Renal Function &amp; Disease YR34</td>
<td>T32DK007301</td>
<td>Direct</td>
<td></td>
<td>182,973</td>
</tr>
<tr>
<td>Diabetes, Digestive, and Kidney Diseases Extramural Research</td>
<td>93.847</td>
<td>CAL preclinical</td>
<td>R01DK101541</td>
<td>Direct</td>
<td></td>
<td>383,139</td>
</tr>
<tr>
<td>Disabilities Prevention</td>
<td>93.184</td>
<td>Hemophilia Complications</td>
<td>WA015403/18F2014118</td>
<td>Pass Through</td>
<td>(98)</td>
<td>8,520</td>
</tr>
<tr>
<td>Innovations to Improve Human Health</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discovery and Applied Research for Technological Innovations to Improve Human Health</td>
<td>93.286</td>
<td>Imaging Islets</td>
<td>R01EB007456</td>
<td>Direct</td>
<td>(2)</td>
<td>1,995</td>
</tr>
<tr>
<td>Discovery and Applied Research for Technological Innovations to Improve Human Health</td>
<td>93.286</td>
<td>Optimization</td>
<td>R21EB016241</td>
<td>Direct</td>
<td></td>
<td>193,043</td>
</tr>
<tr>
<td>Discovery and Applied Research for Technological Innovations to Improve Human Health</td>
<td>93.286</td>
<td>Handheld Scanner</td>
<td>R21EB016189</td>
<td>Direct</td>
<td></td>
<td>124,528</td>
</tr>
<tr>
<td>Discovery and Applied Research for Technological Innovations to Improve Human Health</td>
<td>93.286</td>
<td>4D Radiation Therapy</td>
<td>R21EB017559</td>
<td>Direct</td>
<td></td>
<td>264,894</td>
</tr>
<tr>
<td>Discovery and Applied Research for Technological Innovations to Improve Human Health</td>
<td>93.286</td>
<td>Pororo and Viscoelastic</td>
<td>R01EB018230</td>
<td>Direct</td>
<td></td>
<td>263,176</td>
</tr>
<tr>
<td>Discovery and Applied Research for Technological Innovations to Improve Human Health</td>
<td>93.286</td>
<td>Probes and Methods</td>
<td>R01EB004031</td>
<td>Direct</td>
<td></td>
<td>370,715</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>Marijuana Sleep YR3</td>
<td>200T60994</td>
<td>Pass Through</td>
<td>(43)</td>
<td>37,963</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>Abstinence-Contingent</td>
<td>200T58271</td>
<td>Pass Through</td>
<td>(43)</td>
<td>12,122</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>NIDA Trials U10</td>
<td>400579</td>
<td>Pass Through</td>
<td>(50)</td>
<td>19,469</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>Maternal Smoking Yr 4</td>
<td>7108865</td>
<td>Pass Through</td>
<td>(54)</td>
<td>31,361</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>Maternal Smoking Yr 5</td>
<td>Pre Award</td>
<td>Pass Through</td>
<td>(54)</td>
<td>5,946</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>DPTSAMT YR3</td>
<td>631C</td>
<td>Pass Through</td>
<td>(58)</td>
<td>32,841</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>DPTSAMT YR4</td>
<td>631D</td>
<td>Pass Through</td>
<td>(58)</td>
<td>45,189</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>Oregon Family CM</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(69)</td>
<td>20,950</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>Computerized Therapy</td>
<td>2000 G SD265</td>
<td>Pass Through</td>
<td>(89)</td>
<td>40,391</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>UVM-Anhedonia</td>
<td>24027</td>
<td>Pass Through</td>
<td>(113)</td>
<td>158,778</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>UVM-Anhedonia YR2</td>
<td>PRE-AWARD</td>
<td>Pass Through</td>
<td>(113)</td>
<td>191,136</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>I-Tech YR2</td>
<td>416K080</td>
<td>Pass Through</td>
<td>(116)</td>
<td>272</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>I-Tech YR3</td>
<td>416K080</td>
<td>Pass Through</td>
<td>(116)</td>
<td>61,504</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>Family Smoking YR3</td>
<td>s954</td>
<td>Pass Through</td>
<td>(123)</td>
<td>82,336</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>Content Coding Ad Hoc</td>
<td>8954.02.77.03</td>
<td>Pass Through</td>
<td>(123)</td>
<td>18,900</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>FAAH-Inhibitor YR3</td>
<td>M12A11475 (A08819)</td>
<td>Pass Through</td>
<td>(127)</td>
<td>12,338</td>
</tr>
<tr>
<td>Federal Program</td>
<td>Cluster Title/CFDA Number</td>
<td>Project Name</td>
<td>Award Number/Pass-through Identification Number</td>
<td>Funding Source</td>
<td>Pass-Through Entity</td>
<td>Total Expenditures</td>
</tr>
<tr>
<td>-------------------------------------------------</td>
<td>---------------------------</td>
<td>-------------------------------------</td>
<td>-------------------------------------------------</td>
<td>----------------</td>
<td>---------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>STTR-Phase II</td>
<td>N/A</td>
<td>Direct</td>
<td></td>
<td>85,379</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>0. Foundation Paper</td>
<td>s954</td>
<td>Direct</td>
<td></td>
<td>85,462</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>Integrated CBT</td>
<td>R01DA030102</td>
<td>Direct</td>
<td></td>
<td>128,186</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>Community Addiction Treatment</td>
<td>R01DA036750</td>
<td>Direct</td>
<td></td>
<td>43,810</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>Nicotinic Acetylcholine</td>
<td>R01DA036788</td>
<td>Direct</td>
<td></td>
<td>237,772</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>Admin YR4</td>
<td>P3DA029926</td>
<td>Direct</td>
<td></td>
<td>1,074,611</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>Adolescent Substance Abuse</td>
<td>R21DA032442</td>
<td>Direct</td>
<td></td>
<td>23,001</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>Tobacco MJ</td>
<td>R01DA032243</td>
<td>Direct</td>
<td></td>
<td>324,654</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>CLOCS Study</td>
<td>R01DA032533</td>
<td>Direct</td>
<td></td>
<td>666,444</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>Neural Predictors of Self-Reg.</td>
<td>2R01DA022582-06</td>
<td>Direct</td>
<td></td>
<td>520,818</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>Adolescent MJ Use-12A1</td>
<td>R01DA0375186</td>
<td>Direct</td>
<td></td>
<td>564,353</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>Cannabis Schizophrenia Reward</td>
<td>DA034699</td>
<td>Direct</td>
<td></td>
<td>534,384</td>
</tr>
<tr>
<td>Drug Abuse and Addiction Research Programs</td>
<td>93.279</td>
<td>Co-Occurring Disorders</td>
<td>DA037202</td>
<td>Direct</td>
<td></td>
<td>237,610</td>
</tr>
<tr>
<td>Emergency Medical Services for Children</td>
<td>93.127</td>
<td>EMSC YR10</td>
<td>H33MC06727</td>
<td>Direct</td>
<td></td>
<td>34,726</td>
</tr>
<tr>
<td>Environmental Health</td>
<td>93.113</td>
<td>VICTER_SUB</td>
<td>1094771-2-57490</td>
<td>Direct</td>
<td></td>
<td>171,297</td>
</tr>
<tr>
<td>Environmental Health</td>
<td>93.113</td>
<td>Genetics-of Arsenic Metabolism</td>
<td>F0355558-A</td>
<td>Direct</td>
<td></td>
<td>16,974</td>
</tr>
<tr>
<td>Environmental Health</td>
<td>93.113</td>
<td>Arsenic Metabolism YR2</td>
<td>F0355558-A</td>
<td>Direct</td>
<td></td>
<td>2,318</td>
</tr>
<tr>
<td>Environmental Health</td>
<td>93.113</td>
<td>R21 Arsenic</td>
<td>R21ES020936</td>
<td>Direct</td>
<td></td>
<td>962</td>
</tr>
<tr>
<td>Environmental Health</td>
<td>93.113</td>
<td>NIH Methylmercury</td>
<td>ES021950</td>
<td>Direct</td>
<td></td>
<td>326,431</td>
</tr>
<tr>
<td>Environmental Health</td>
<td>93.113</td>
<td>Admin supplement</td>
<td>P01ES022832</td>
<td>Direct</td>
<td></td>
<td>981,478</td>
</tr>
<tr>
<td>Environmental Health</td>
<td>93.113</td>
<td>Imprinting</td>
<td>R01ES022223</td>
<td>Direct</td>
<td></td>
<td>980,904</td>
</tr>
<tr>
<td>Environmental Health</td>
<td>93.113</td>
<td>Prenatal Diagnoses</td>
<td>K99ES024144</td>
<td>Direct</td>
<td></td>
<td>62,141</td>
</tr>
<tr>
<td>Environmental Health</td>
<td>93.113</td>
<td>Low-dose arsenic impacts</td>
<td>F22ES025082</td>
<td>Direct</td>
<td></td>
<td>26,082</td>
</tr>
<tr>
<td>Extramural Research Programs in the Neurosciences and Neurological Disorders</td>
<td>93.853</td>
<td>JCV-induced PML Proj#3 YR05</td>
<td>304</td>
<td>Pass Through</td>
<td>(75)</td>
<td>14,571</td>
</tr>
<tr>
<td>Extramural Research Programs in the Neurosciences and Neurological Disorders</td>
<td>93.853</td>
<td>STEADY-PD III</td>
<td>60036745 DC</td>
<td>Pass Through</td>
<td>(66)</td>
<td>268</td>
</tr>
<tr>
<td>Extramural Research Programs in the Neurosciences and Neurological Disorders</td>
<td>93.853</td>
<td>STEADY-PD III 2015</td>
<td>60036745 DC</td>
<td>Pass Through</td>
<td>(66)</td>
<td>977</td>
</tr>
<tr>
<td>Extramural Research Programs in the Neurosciences and Neurological Disorders</td>
<td>93.853</td>
<td>Stenting Trial</td>
<td>99-705</td>
<td>Pass Through</td>
<td>(99)</td>
<td>2,625</td>
</tr>
<tr>
<td>Extramural Research Programs in the Neurosciences and Neurological Disorders</td>
<td>93.853</td>
<td>DRAVET YR2</td>
<td>28377 SUB51601</td>
<td>Pass Through</td>
<td>(113)</td>
<td>18,478</td>
</tr>
<tr>
<td>Extramural Research Programs in the Neurosciences and Neurological Disorders</td>
<td>93.853</td>
<td>Dravet yr 3</td>
<td>28377 SUB51601</td>
<td>Pass Through</td>
<td>(113)</td>
<td>10,764</td>
</tr>
<tr>
<td>Extramural Research Programs in the Neurosciences and Neurological Disorders</td>
<td>93.853</td>
<td>Parkinson Disease FY13 LS-1</td>
<td>26913SUB51363</td>
<td>Pass Through</td>
<td>(113)</td>
<td>5,736</td>
</tr>
<tr>
<td>Extramural Research Programs in the Neurosciences and Neurological Disorders</td>
<td>93.853</td>
<td>Iris Yr 15</td>
<td>M1OA10508</td>
<td>Pass Through</td>
<td>(127)</td>
<td>59,357</td>
</tr>
<tr>
<td>Extramural Research Programs in the Neurosciences and Neurological Disorders</td>
<td>93.853</td>
<td>IRIS Yr 14</td>
<td>A09394 M1OA10508</td>
<td>Pass Through</td>
<td>(127)</td>
<td>6,236</td>
</tr>
<tr>
<td>Extramural Research Programs in the Neurosciences and Neurological Disorders</td>
<td>93.853</td>
<td>TBI Biomechanics</td>
<td>R01NS055020</td>
<td>Direct</td>
<td></td>
<td>232,774</td>
</tr>
<tr>
<td>Extramural Research Programs in the Neurosciences and Neurological Disorders</td>
<td>93.853</td>
<td>Coregistered Fluores</td>
<td>R01NS055274</td>
<td>Direct</td>
<td></td>
<td>23,993</td>
</tr>
<tr>
<td>Extramural Research Programs in the Neurosciences and Neurological Disorders</td>
<td>93.853</td>
<td>Spatial Cognition YR 15-19</td>
<td>R01NS053907</td>
<td>Direct</td>
<td></td>
<td>372,792</td>
</tr>
<tr>
<td>Federal Program</td>
<td>Cluster Title/CFDA Number</td>
<td>Project Name</td>
<td>Award Number/Pass-through Identification Number</td>
<td>Funding Source</td>
<td>Pass-Through Entity</td>
<td>Total Expenditures</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------------</td>
<td>----------------------------</td>
<td>---------------------------------------------</td>
<td>-------------------------------------------------</td>
<td>---------------</td>
<td>---------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Extramural Research Programs in the Neurosciences and Neurological Disorders</td>
<td>93.853</td>
<td>Temporal Lobe Epilepsy</td>
<td>R01NS074450</td>
<td>Direct</td>
<td></td>
<td>356,099</td>
</tr>
<tr>
<td>Extramural Research Programs in the Neurosciences and Neurological Disorders</td>
<td>93.853</td>
<td>HYBRID Diffusion Imaging</td>
<td>R21NS075791</td>
<td>Direct</td>
<td></td>
<td>142,868</td>
</tr>
<tr>
<td>Extramural Research Programs in the Neurosciences and Neurological Disorders</td>
<td>93.853</td>
<td>Measuring Material P</td>
<td>R21NS078607</td>
<td>Direct</td>
<td></td>
<td>122,415</td>
</tr>
<tr>
<td>Extramural Research Programs in the Neurosciences and Neurological Disorders</td>
<td>93.853</td>
<td>Prion Strains YR10</td>
<td>R01NS046478</td>
<td>Direct</td>
<td></td>
<td>451,729</td>
</tr>
<tr>
<td>Extramural Research Programs in the Neurosciences and Neurological Disorders</td>
<td>93.853</td>
<td>Ischemic Stroke</td>
<td>R21NS082585</td>
<td>Direct</td>
<td></td>
<td>239,492</td>
</tr>
<tr>
<td>Extramural Research Programs in the Neurosciences and Neurological Disorders</td>
<td>93.853</td>
<td>Coregistered Fluorescence</td>
<td>R01NS052274</td>
<td>Direct</td>
<td></td>
<td>472,688</td>
</tr>
<tr>
<td>Food and Drug Administration Research</td>
<td>93.103</td>
<td>NE Pedi Device Conso</td>
<td>NEPDC-002</td>
<td>Pass Through</td>
<td>(61)</td>
<td>24,985</td>
</tr>
<tr>
<td>Food and Drug Administration Research</td>
<td>93.103</td>
<td>NE Pedi Device Consor YR 2</td>
<td>NEPDC-002</td>
<td>Pass Through</td>
<td>(61)</td>
<td>24,979</td>
</tr>
<tr>
<td>Global AIDS</td>
<td>93.067</td>
<td>SHARE IT Yr 2</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(56)</td>
<td>22,618</td>
</tr>
<tr>
<td>Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease</td>
<td>93.918</td>
<td>Ryan White EIS YR12</td>
<td>H76HA00812</td>
<td>Direct</td>
<td></td>
<td>285,169</td>
</tr>
<tr>
<td>Health Care Innovation Awards (HCIA)</td>
<td>93.610</td>
<td>Improving Quality YR2</td>
<td>50059-DAR-02</td>
<td>Pass Through</td>
<td>(27)</td>
<td>16,444</td>
</tr>
<tr>
<td>Health Care Innovation Awards (HCIA)</td>
<td>93.610</td>
<td>Improving Quality YR3</td>
<td>50059-DAR-03</td>
<td>Pass Through</td>
<td>(27)</td>
<td>109,913</td>
</tr>
<tr>
<td>Health Care Innovation Awards (HCIA)</td>
<td>93.610</td>
<td>Health Homes</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(120)</td>
<td>(183)</td>
</tr>
<tr>
<td>Health Care Innovation Awards (HCIA)</td>
<td>93.610</td>
<td>Health Homes YR3</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(120)</td>
<td>65,572</td>
</tr>
<tr>
<td>Centers: PPHF - Affordable Care Act Projects</td>
<td>93.542</td>
<td>Reducing Disp. Research YR5</td>
<td>U48DP001935</td>
<td>Direct</td>
<td></td>
<td>102,747</td>
</tr>
<tr>
<td>Human Genome Research</td>
<td>93.172</td>
<td>Chromosomal Instability</td>
<td>FT05513</td>
<td>Pass Through</td>
<td>(92)</td>
<td>31,914</td>
</tr>
<tr>
<td>Human Genome Research</td>
<td>93.172</td>
<td>Chromosomal Instability YR2</td>
<td>PRE-AWARD</td>
<td>Pass Through</td>
<td>(92)</td>
<td>2,360</td>
</tr>
<tr>
<td>International Research and Research Training</td>
<td>93.989</td>
<td>OSP at Muhimbili Sup Yr 3</td>
<td>G11TW005977</td>
<td>Direct</td>
<td></td>
<td>109,441</td>
</tr>
<tr>
<td>Lung Diseases Research</td>
<td>93.838</td>
<td>Habi-Flnt</td>
<td>74159</td>
<td>Pass Through</td>
<td>(15)</td>
<td>17,809</td>
</tr>
<tr>
<td>Lung Diseases Research</td>
<td>93.838</td>
<td>Pedi ICU</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(104)</td>
<td>8,196</td>
</tr>
<tr>
<td>Lung Diseases Research</td>
<td>93.838</td>
<td>Pseudomonas-Host</td>
<td>R01HL074175</td>
<td>Direct</td>
<td></td>
<td>18,394</td>
</tr>
<tr>
<td>Lung Diseases Research</td>
<td>93.838</td>
<td>Control Of Breathing YR29-33</td>
<td>R01HL026066</td>
<td>Direct</td>
<td></td>
<td>23,973</td>
</tr>
<tr>
<td>Lung Diseases Research</td>
<td>93.838</td>
<td>CSF The Central Control Yr 3</td>
<td>R01HL026066</td>
<td>Direct</td>
<td></td>
<td>294,664</td>
</tr>
<tr>
<td>Maternal and Child Health Federal Consolidated Programs</td>
<td>93.110</td>
<td>CNRC YR3</td>
<td>29592-Dartmouth 2</td>
<td>Pass Through</td>
<td>(113)</td>
<td>11,389</td>
</tr>
<tr>
<td>Maternal and Child Health Federal Consolidated Programs</td>
<td>93.110</td>
<td>Psychosocial Aspects YR8</td>
<td>T2MC07472-</td>
<td>Direct</td>
<td></td>
<td>14,761</td>
</tr>
<tr>
<td>Medical Library Assistance</td>
<td>93.879</td>
<td>Bioinformatics Strat</td>
<td>IN4697237DC</td>
<td>Pass Through</td>
<td>(37)</td>
<td>39,298</td>
</tr>
<tr>
<td>Medical Library Assistance</td>
<td>93.879</td>
<td>Bioinformatics Strategies sub</td>
<td>PRE-AWARD</td>
<td>Pass Through</td>
<td>(104)</td>
<td>22,460</td>
</tr>
<tr>
<td>Medical Library Assistance</td>
<td>93.879</td>
<td>Machine Learning 5-9</td>
<td>R01LM090112</td>
<td>Direct</td>
<td></td>
<td>214,584</td>
</tr>
<tr>
<td>Medical Library Assistance</td>
<td>93.879</td>
<td>Bioinformatics Strategies 5-9</td>
<td>R01LM030989</td>
<td>Direct</td>
<td></td>
<td>229,923</td>
</tr>
<tr>
<td>Medical Library Assistance</td>
<td>93.879</td>
<td>Bioinformatics Hoen</td>
<td>K01LM011985</td>
<td>Direct</td>
<td></td>
<td>94,403</td>
</tr>
<tr>
<td>Mental Health National Research Service Awards for Research Training</td>
<td>93.282</td>
<td>T32-Geriatric YR10</td>
<td>T32MH073553</td>
<td>Direct</td>
<td></td>
<td>350,616</td>
</tr>
<tr>
<td>Federal Program</td>
<td>Cluster Title/CFDA Number</td>
<td>Project Name</td>
<td>Award Number/Pass-through Identification Number</td>
<td>Funding Source</td>
<td>Pass-Through Entity</td>
<td>Total Expenditures</td>
</tr>
<tr>
<td>-----------------</td>
<td>---------------------------</td>
<td>--------------</td>
<td>-----------------------------------------------</td>
<td>---------------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Allegheny TF-CBT YR2</td>
<td>PRE-AWARD</td>
<td>Pass Through</td>
<td>(3)</td>
<td>52,474</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>McGuirk R01 SE Renewal</td>
<td>450000977</td>
<td>Pass Through</td>
<td>(10)</td>
<td>40,149</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Photovoice</td>
<td>450001758</td>
<td>Pass Through</td>
<td>(10)</td>
<td>12,835</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Early Life Stress</td>
<td>9225-8340</td>
<td>Pass Through</td>
<td>(13)</td>
<td>25,939</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Early Life Stress Yr 2</td>
<td>9225-8340</td>
<td>Pass Through</td>
<td>(13)</td>
<td>8,646</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Adherence and Empower YR3</td>
<td>SA453-1102-6157</td>
<td>Pass Through</td>
<td>(35)</td>
<td>8,231</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>PTSD and Addiction Disorder</td>
<td>4546</td>
<td>Pass Through</td>
<td>(76)</td>
<td>4,027</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Intervention</td>
<td>22605</td>
<td>Pass Through</td>
<td>(113)</td>
<td>12,835</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Sustained PTSD Treatment</td>
<td>M13A11533 (A00085)</td>
<td>Pass Through</td>
<td>(127)</td>
<td>21,664</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Tech Assisted Assess</td>
<td>9064-8340</td>
<td>Direct</td>
<td></td>
<td>14,049</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Fitness With SMI</td>
<td>R01MH078052</td>
<td>Direct</td>
<td></td>
<td>14,799</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Anatomic Studies</td>
<td>R01MH092982</td>
<td>Direct</td>
<td></td>
<td>53,932</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Statewide Intervention</td>
<td>R01MH089811</td>
<td>Direct</td>
<td></td>
<td>366,309</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Biomarkers of TRD</td>
<td>R01MH091100</td>
<td>Direct</td>
<td></td>
<td>312,680</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>BRAINS</td>
<td>R01MH094609</td>
<td>Direct</td>
<td></td>
<td>378,762</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Prefrontal-amygdala YR5</td>
<td>R01MH080716</td>
<td>Direct</td>
<td></td>
<td>358,701</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Mobile Text</td>
<td>7R34MH093162</td>
<td>Direct</td>
<td></td>
<td>87,057</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Impact of Pten</td>
<td>R01MH097949</td>
<td>Direct</td>
<td></td>
<td>401,421</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Mobile System</td>
<td>R34MH103095</td>
<td>Direct</td>
<td></td>
<td>198,458</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Neuromod cortical</td>
<td>R01MH099054</td>
<td>Direct</td>
<td></td>
<td>383,109</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Exercise to Prevent Depression</td>
<td>K32MH098025</td>
<td>Direct</td>
<td></td>
<td>(298)</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>EUROKA</td>
<td>R01MH103148</td>
<td>Direct</td>
<td></td>
<td>172,303</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Home Care for SMI</td>
<td>1R24MH0102794</td>
<td>Direct</td>
<td></td>
<td>140,724</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Implementation R01</td>
<td>R01MH102255</td>
<td>Direct</td>
<td></td>
<td>581,727</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Telehealth for SMI</td>
<td>R01MH104555</td>
<td>Direct</td>
<td></td>
<td>78,214</td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Postdoc NRS3</td>
<td>F32MH06178</td>
<td>Direct</td>
<td></td>
<td>13,070</td>
</tr>
<tr>
<td>Microbiology and Infectious Diseases Research</td>
<td>93.856</td>
<td>UAB BAA CMX Study</td>
<td>00406257-017</td>
<td>Pass Through</td>
<td>(87)</td>
<td>1,658</td>
</tr>
<tr>
<td>Microbiology and Infectious Diseases Research</td>
<td>93.856</td>
<td>UAB BAA 1</td>
<td>00406261-014</td>
<td>Pass Through</td>
<td>(87)</td>
<td>19,869</td>
</tr>
<tr>
<td>Microbiology and Infectious Diseases Research</td>
<td>93.856</td>
<td>CORE A ADMIN YR4</td>
<td>U19A091173</td>
<td>Direct</td>
<td></td>
<td>3,364,355</td>
</tr>
<tr>
<td>National Center for Advancing Translational Sciences</td>
<td>93.350</td>
<td>NIH SBR</td>
<td>(NIHES22C20140046C)</td>
<td>Pass Through</td>
<td>(14)</td>
<td>53,290</td>
</tr>
<tr>
<td>National Center for Advancing Translational Sciences</td>
<td>93.350</td>
<td>Academic Industry Core YR3</td>
<td>ULTRR001086</td>
<td>Direct</td>
<td></td>
<td>3,859,467</td>
</tr>
<tr>
<td>National Center for Advancing Translational Sciences</td>
<td>93.350</td>
<td>Colla Yr 1</td>
<td>K1LTRR001088</td>
<td>Direct</td>
<td></td>
<td>801,690</td>
</tr>
<tr>
<td>National Translational Research Program Community of Practice (NISP CoP)</td>
<td>93.852</td>
<td>Cognitive Deficits</td>
<td>28375LUS31600</td>
<td>Pass Through</td>
<td>(113)</td>
<td>14,134</td>
</tr>
<tr>
<td>NIEHS Superfund Hazardous Substances, Basic Research and Education</td>
<td>93.143</td>
<td>Administration Yr 19</td>
<td>2P42ES007373</td>
<td>Direct</td>
<td></td>
<td>1,973,547</td>
</tr>
<tr>
<td>Nursing Research</td>
<td>93.361</td>
<td>Design &amp; Analysis</td>
<td>R01NR014915</td>
<td>Direct</td>
<td></td>
<td>66,358</td>
</tr>
<tr>
<td>Oral Diseases and Disorders Research</td>
<td>93.121</td>
<td>mRNA</td>
<td>R01DE022772</td>
<td>Direct</td>
<td></td>
<td>589,184</td>
</tr>
<tr>
<td>Research and Training in Complementary and Integrative Health</td>
<td>93.213</td>
<td>Vitamin A YR5</td>
<td>R01AT005832</td>
<td>Direct</td>
<td></td>
<td>421</td>
</tr>
<tr>
<td>Research and Training in Complementary and Integrative Health</td>
<td>93.213</td>
<td>Alternative Medicine Market</td>
<td>K01AT006162</td>
<td>Direct</td>
<td></td>
<td>17,240</td>
</tr>
<tr>
<td>Research and Training in Complementary and Integrative Health</td>
<td>93.213</td>
<td>Chiro costs</td>
<td>R21AT008287</td>
<td>Direct</td>
<td></td>
<td>182,280</td>
</tr>
<tr>
<td>Research Infrastructure Programs</td>
<td>93.351</td>
<td>TIRF SIG</td>
<td>S10OD010330</td>
<td>Direct</td>
<td></td>
<td>(142)</td>
</tr>
<tr>
<td>Research Infrastructure Programs</td>
<td>93.351</td>
<td>Gladfelter equip NIH</td>
<td>1S10OD018046</td>
<td>Direct</td>
<td></td>
<td>348,581</td>
</tr>
<tr>
<td>Research on Healthcare Costs, Quality and Outcomes</td>
<td>93.226</td>
<td>Privacy in Practice-EHRs</td>
<td>NIH-T52</td>
<td>Pass Through</td>
<td>(86)</td>
<td>4,772</td>
</tr>
<tr>
<td>Research on Healthcare Costs, Quality and Outcomes</td>
<td>93.226</td>
<td>Privacy in Practice-EHRs TS2</td>
<td>NIH-T52</td>
<td>Pass Through</td>
<td>(86)</td>
<td>188</td>
</tr>
<tr>
<td>Federal Program</td>
<td>Cluster Title/CFDA Number</td>
<td>Project Name</td>
<td>Award Number/Pass-through Identification Number</td>
<td>Funding Source</td>
<td>Pass-Through Entity</td>
<td>Total Expenditures</td>
</tr>
<tr>
<td>------------------------------------------------------</td>
<td>---------------------------</td>
<td>------------------------------------</td>
<td>-------------------------------------------------</td>
<td>---------------</td>
<td>---------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Research on Healthcare Costs, Quality and Outcomes</td>
<td>93.226</td>
<td>Ambulatory Surgery Centers</td>
<td>3001694180</td>
<td>Pass Through</td>
<td>(101)</td>
<td>4,820</td>
</tr>
<tr>
<td>Research on Healthcare Costs, Quality and Outcomes</td>
<td>93.226</td>
<td>Pt Sfty &amp; Kidney Injury YR5</td>
<td>K01HS018443</td>
<td>Direct</td>
<td></td>
<td>66,214</td>
</tr>
<tr>
<td>Research on Healthcare Costs, Quality and Outcomes</td>
<td>93.226</td>
<td>Randomized Active Step YR3</td>
<td>R01HS018459</td>
<td>Direct</td>
<td></td>
<td>360,279</td>
</tr>
<tr>
<td>Research on Healthcare Costs, Quality and Outcomes</td>
<td>93.226</td>
<td>Bartels K-12 YR2</td>
<td>1K22HS021695-01</td>
<td>Direct</td>
<td></td>
<td>471,615</td>
</tr>
<tr>
<td>Research on Healthcare Costs, Quality and Outcomes</td>
<td>93.226</td>
<td>Tool Evaluation Yr 2</td>
<td>1R01HS021747</td>
<td>Direct</td>
<td></td>
<td>344,236</td>
</tr>
<tr>
<td>Research on Healthcare Costs, Quality and Outcomes</td>
<td>93.226</td>
<td>Leveraging Health IT</td>
<td>R21HS021581</td>
<td>Direct</td>
<td></td>
<td>132,713</td>
</tr>
<tr>
<td>Research Related to Deafness and Communication</td>
<td>93.173</td>
<td>Hearing Loss</td>
<td>R01DC089972</td>
<td>Direct</td>
<td></td>
<td>277,754</td>
</tr>
<tr>
<td>Disorders</td>
<td>93.173</td>
<td>Auditory HIV</td>
<td>R01DC014369</td>
<td>Direct</td>
<td></td>
<td>272,233</td>
</tr>
<tr>
<td>Trans-NIH Recovery Act Research Support</td>
<td>93.701</td>
<td>POINT Trial</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(24)</td>
<td>11,480</td>
</tr>
<tr>
<td>Trans-NIH Recovery Act Research Support</td>
<td>93.701</td>
<td>EMMES VRC</td>
<td>3501-001</td>
<td>Pass Through</td>
<td>(24)</td>
<td>4,867</td>
</tr>
<tr>
<td>Trans-NIH Research Support</td>
<td>93.310</td>
<td>Colla_NBH_R21_33</td>
<td>1R21AG044251-01</td>
<td>Direct</td>
<td></td>
<td>52,581</td>
</tr>
<tr>
<td>Trans-NIH Research Support</td>
<td>93.310</td>
<td>Colla_NBH_R21_33</td>
<td>1R21AG044251-01</td>
<td>Direct</td>
<td></td>
<td>42,423</td>
</tr>
<tr>
<td>University Centers for Excellence in Developmental</td>
<td>93.632</td>
<td>Univ Program in NH-YR25</td>
<td>13-055B</td>
<td>Pass Through</td>
<td>(102)</td>
<td>3,582</td>
</tr>
<tr>
<td>Cancer Cause and Prevention Research</td>
<td>93.393</td>
<td>Cyclin D As Target YR5-9</td>
<td>R01CA111422</td>
<td>Direct</td>
<td></td>
<td>8,826</td>
</tr>
<tr>
<td>Biomedical Research and Research Training</td>
<td>93.859</td>
<td>G Protein</td>
<td>R01GM054082</td>
<td>Direct</td>
<td></td>
<td>1,250</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.937</td>
<td>Distance to Food</td>
<td>R01HL109263</td>
<td>Direct</td>
<td></td>
<td>250,423</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>RadioProbe</td>
<td>75406</td>
<td>Pass Through</td>
<td>(21)</td>
<td>1,065</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>Schizophrenic Ep YR3</td>
<td>DMS01-NON-ARRA</td>
<td>Pass Through</td>
<td>(27)</td>
<td>18,581</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>BCSCDR YR3</td>
<td>HHSN261201100031C-Dartmouth</td>
<td>Pass Through</td>
<td>(34)</td>
<td>42,547</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>PCOR</td>
<td>13ED5K0169</td>
<td>Pass Through</td>
<td>(34)</td>
<td>131,401</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>Using Handheld Computers YR5</td>
<td>20099032</td>
<td>Pass Through</td>
<td>(43)</td>
<td>15,800</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>EM/SAXS fusion</td>
<td>200228702</td>
<td>Pass Through</td>
<td>(43)</td>
<td>138,757</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>CPP YR 2</td>
<td>J5I/CHI 6904</td>
<td>Pass Through</td>
<td>(44)</td>
<td>22,786</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>GHESEKO CTU YR3</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(45)</td>
<td>14,409</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>Image Guided Drug Delivery</td>
<td>217706</td>
<td>Pass Through</td>
<td>(47)</td>
<td>113,017</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>Dar CTU</td>
<td>Westf &amp; 6101-S-Subcontract</td>
<td>Pass Through</td>
<td>(56)</td>
<td>56,181</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>DAR CTU supplement</td>
<td>5-23280</td>
<td>Pass Through</td>
<td>(106)</td>
<td>14,264</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>Pediatric ReVax Study</td>
<td>U01-DK061055</td>
<td>Pass Through</td>
<td>(107)</td>
<td>17,091</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>Trialnet</td>
<td>25992-Dartmouth-3</td>
<td>Pass Through</td>
<td>(113)</td>
<td>14,911</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>HF PRO Measure</td>
<td>N/A</td>
<td>Pass Through</td>
<td>(126)</td>
<td>1,637</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>Support Tool Residual</td>
<td>N/A</td>
<td>Direct</td>
<td></td>
<td>53,267</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>DES-Exposed Cohorts-Option 3</td>
<td>HHSN261201000120C-Dartmouth</td>
<td>Direct</td>
<td></td>
<td>48,857</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>DES-Exposed Cohorts-Option 4</td>
<td>HHSN261201000120C-Dartmouth</td>
<td>Direct</td>
<td></td>
<td>182,678</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>PCRR SDM Project</td>
<td>N/A</td>
<td>Direct</td>
<td></td>
<td>23,179</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>Cif Mechanism</td>
<td>R01AI091699</td>
<td>Direct</td>
<td></td>
<td>273,280</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>Acriin Lung Screening</td>
<td>ACRIN 6654</td>
<td>Direct</td>
<td></td>
<td>25,260</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>A021202 Phase II</td>
<td>UNIV OF CHICAGO</td>
<td>Direct</td>
<td></td>
<td>56,724</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>CDC Colen</td>
<td>200-2013-M-57405</td>
<td>Direct</td>
<td></td>
<td>4,527</td>
</tr>
<tr>
<td>Vision Research</td>
<td>93.867</td>
<td>MUTION YR5</td>
<td>564bc</td>
<td>Pass Through</td>
<td>(91)</td>
<td>15,055</td>
</tr>
<tr>
<td>Vision Research</td>
<td>93.867</td>
<td>MUTION YR6</td>
<td>564bc</td>
<td>Pass Through</td>
<td>(91)</td>
<td>20,535</td>
</tr>
<tr>
<td>Vision Research</td>
<td>93.867</td>
<td>Role of HSV</td>
<td>R01EY010707</td>
<td>Direct</td>
<td></td>
<td>(1,464)</td>
</tr>
<tr>
<td>Federal Program</td>
<td>Cluster Title/CFDA Number</td>
<td>Project Name</td>
<td>Award Number/Pass-through Identification Number</td>
<td>Funding Source</td>
<td>Pass-Through Entity</td>
<td>Total Expenditures</td>
</tr>
<tr>
<td>-----------------</td>
<td>---------------------------</td>
<td>--------------</td>
<td>-----------------------------------------------</td>
<td>----------------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Vision Research</td>
<td>93.867</td>
<td>Effect of Spatial</td>
<td>R01EY018683</td>
<td>Direct</td>
<td>84,468</td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td>Vision Research</td>
<td>93.867</td>
<td>Bioinformatics Appro</td>
<td>R01EY022300</td>
<td>Direct</td>
<td>143,732</td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td>Vision Research</td>
<td>93.867</td>
<td>Equipment Supplement</td>
<td>2R01EY009083</td>
<td>Direct</td>
<td>375,242</td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td><strong>DEPARTMENT OF HOMELAND SECURITY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td>Emergency Preparedness Demonstration Program</td>
<td>97.001</td>
<td>III P Mgmt</td>
<td>2006CS001-000001</td>
<td>Direct</td>
<td>53,131</td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td><strong>DEPARTMENT OF THE INTERIOR</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td>Unknown</td>
<td>15.XXX</td>
<td>Deformation Damage on Sea Ice</td>
<td>E12PC003033</td>
<td>Direct</td>
<td>140,709</td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td>Unknown</td>
<td>15.XXX</td>
<td>Frictional Sliding of Sea Ice</td>
<td>E12PC00064</td>
<td>Direct</td>
<td>166,367</td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td><strong>RESEARCH &amp; DEVELOPMENT PROGRAMS FROM OTHER FEDERAL AGENCIES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td>Unknown</td>
<td>20.000</td>
<td>NAS-Wide Service Lev</td>
<td>5710003653</td>
<td>Pass Through (48)</td>
<td>73,581</td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td>Promotion of the Humanities_Research</td>
<td>45.161</td>
<td>Occom Circle</td>
<td>RQ-50470-10</td>
<td>Direct</td>
<td>43,457</td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td>Promotion of the Humanities_Office of Digital Humanities</td>
<td>45.169</td>
<td>NEH Workshop</td>
<td>HC-22977-15</td>
<td>Direct</td>
<td>38,922</td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td>National Leadership Grants</td>
<td>45.312</td>
<td>IMLS</td>
<td>LG-00-14-0185-14</td>
<td>Pass Through (38)</td>
<td>69,440</td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td>National Leadership Grants</td>
<td>45.312</td>
<td>BHL-IMLS</td>
<td>ML508673D</td>
<td>Pass Through (55)</td>
<td>99,583</td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td>Social Security_Research and Demonstration</td>
<td>96.007</td>
<td>SS Windfall Elim</td>
<td>300251870UM13-07</td>
<td>Direct</td>
<td>2,459</td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td>Social Security_Research and Demonstration</td>
<td>96.007</td>
<td>Means Testing</td>
<td>3002852924UM14-01</td>
<td>Pass Through (101)</td>
<td>108,904</td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Dense Granule Protein Factors</td>
<td>R21AI108489</td>
<td>Direct</td>
<td>170,290</td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td><strong>Total R&amp;D Programs from Other Federal Agencies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td><strong>Total Research and Development Cluster</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td><strong>Other Sponsored Programs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td>DEPARTMENT OF AGRICULTURE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td>Wildlife Habitat Incentive Program</td>
<td>10.914</td>
<td>good conservation wo</td>
<td>811428130GK</td>
<td>Direct</td>
<td>35,573</td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td>Unknown</td>
<td>10.9XX</td>
<td>Roadway and Bronto</td>
<td>EQIP 2008-741428130C4</td>
<td>Direct</td>
<td>7,919</td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td><strong>Total U.S. Department of Agriculture total</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td><strong>DEPARTMENT OF DEFENSE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td>Mathematical Sciences Grants Program</td>
<td>12.901</td>
<td>Conference Series</td>
<td>H98230-12-1-0293</td>
<td>Direct</td>
<td>3,721</td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td>Mathematical Sciences Grants Program</td>
<td>12.901</td>
<td>Conference Series - Orellana</td>
<td>H98230-14-1-0308</td>
<td>Direct</td>
<td>8,000</td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td><strong>Total U.S. Department of Defense total</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td><strong>NATIONAL AERONAUTICS AND SPACE ADMINISTRATION</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td>Unknown</td>
<td>43.000</td>
<td>Space Grant FY11</td>
<td>11-015</td>
<td>Pass Through (102)</td>
<td>343,586</td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>Low-Energy Ion</td>
<td>NNX12AK60H</td>
<td>Direct</td>
<td>3,854</td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td>Science</td>
<td>43.001</td>
<td>Cusp Alfvén Waves</td>
<td>NNX14AC03H</td>
<td>Direct</td>
<td>23,119</td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td><strong>Subtotal of 43.001</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Total Expenditures</strong></td>
</tr>
<tr>
<td><strong>U.S. National Aeronautics &amp; Space Administration total</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Total Expenditures</strong></td>
</tr>
</tbody>
</table>
### Dartmouth College

**Schedule of Expenditures of Federal Awards**

**Year Ended June 30, 2015**

<table>
<thead>
<tr>
<th>Federal Program</th>
<th>Cluster Title/CFDA Number</th>
<th>Project Name</th>
<th>Award Number/Pass-through Identification Number</th>
<th>Funding Source</th>
<th>Pass-Through Entity</th>
<th>Total Expenditures</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NATIONAL SCIENCE FOUNDATION</strong></td>
<td>Education and Human Resources</td>
<td>47.076</td>
<td>Cybersec &amp; Healthcare IT</td>
<td>NSF DUE-1104106</td>
<td>Pass Through (18)</td>
<td>29,997</td>
</tr>
<tr>
<td></td>
<td>Education and Human Resources</td>
<td>47.076</td>
<td>Polar Change</td>
<td>DGE-0801490</td>
<td>Direct</td>
<td>132,412</td>
</tr>
<tr>
<td></td>
<td>Education and Human Resources</td>
<td>47.076</td>
<td>GK Stipend 1 Year 5</td>
<td>DGE-0947790</td>
<td>Direct</td>
<td>576,358</td>
</tr>
<tr>
<td></td>
<td>Education and Human Resources</td>
<td>47.076</td>
<td>Pushing the Limits</td>
<td>DRL-1010577</td>
<td>Direct</td>
<td>159,704</td>
</tr>
<tr>
<td></td>
<td><strong>Subtotal of 47.076</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>898,471</strong></td>
</tr>
<tr>
<td></td>
<td><strong>National Science Foundation total</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>898,471</strong></td>
</tr>
<tr>
<td><strong>VETERAN’S ADMINISTRATION</strong></td>
<td>Intergovernmental Personnel Act (IPA) Mobility Program</td>
<td>27.011</td>
<td>VAQSP Residual</td>
<td>VA105-C00462</td>
<td>Direct</td>
<td>44,129</td>
</tr>
<tr>
<td></td>
<td>Intergovernmental Personnel Act (IPA) Mobility Program</td>
<td>27.011</td>
<td>VA Vet Care</td>
<td>VA241-12-C-0132</td>
<td>Direct</td>
<td>23,616</td>
</tr>
<tr>
<td></td>
<td>Intergovernmental Personnel Act (IPA) Mobility Program</td>
<td>27.011</td>
<td>VA Qual Scholars FY13</td>
<td>VA741-13-C-0011</td>
<td>Direct</td>
<td>288,254</td>
</tr>
<tr>
<td></td>
<td>Intergovernmental Personnel Act (IPA) Mobility Program</td>
<td>27.011</td>
<td>Zayfert IPA FY2014</td>
<td>405C47885</td>
<td>Direct</td>
<td>9,874</td>
</tr>
<tr>
<td></td>
<td>Intergovernmental Personnel Act (IPA) Mobility Program</td>
<td>27.011</td>
<td>Sherrieb IPA FY14</td>
<td>405C47319</td>
<td>Direct</td>
<td>20,201</td>
</tr>
<tr>
<td></td>
<td>Intergovernmental Personnel Act (IPA) Mobility Program</td>
<td>27.011</td>
<td>RCTP FY2014</td>
<td>405-C47217</td>
<td>Direct</td>
<td>1,785</td>
</tr>
<tr>
<td></td>
<td>Intergovernmental Personnel Act (IPA) Mobility Program</td>
<td>27.011</td>
<td>Friedman IPA</td>
<td>405-C47444</td>
<td>Direct</td>
<td>109,350</td>
</tr>
<tr>
<td></td>
<td>Intergovernmental Personnel Act (IPA) Mobility Program</td>
<td>27.011</td>
<td>IPA Mackenzie Yr 2</td>
<td>405-D47003</td>
<td>Direct</td>
<td>9,932</td>
</tr>
<tr>
<td></td>
<td>Intergovernmental Personnel Act (IPA) Mobility Program</td>
<td>27.011</td>
<td>IPA-Kingman Yr 2</td>
<td>405D47009</td>
<td>Direct</td>
<td>42,983</td>
</tr>
<tr>
<td></td>
<td>Intergovernmental Personnel Act (IPA) Mobility Program</td>
<td>27.011</td>
<td>VA Biosafety</td>
<td>VA241-14-Q-0159</td>
<td>Direct</td>
<td>5,000</td>
</tr>
<tr>
<td></td>
<td>Intergovernmental Personnel Act (IPA) Mobility Program</td>
<td>27.011</td>
<td>Sherrie IPA FY14</td>
<td>N/A</td>
<td>Direct</td>
<td>13,993</td>
</tr>
<tr>
<td></td>
<td>Intergovernmental Personnel Act (IPA) Mobility Program</td>
<td>27.011</td>
<td>Sherrieb IPA FY15</td>
<td>405-CS4140</td>
<td>Direct</td>
<td>60,603</td>
</tr>
<tr>
<td></td>
<td>Intergovernmental Personnel Act (IPA) Mobility Program</td>
<td>27.011</td>
<td>IPA Mackenzie FY15</td>
<td>405D54005</td>
<td>Direct</td>
<td>9,931</td>
</tr>
<tr>
<td></td>
<td>Intergovernmental Personnel Act (IPA) Mobility Program</td>
<td>27.011</td>
<td>IPA Mackenzie FY15</td>
<td>405D54005</td>
<td>Direct</td>
<td>9,931</td>
</tr>
<tr>
<td></td>
<td>Intergovernmental Personnel Act (IPA) Mobility Program</td>
<td>27.011</td>
<td>IPA Mackenzie FY16</td>
<td>405D54005</td>
<td>Direct</td>
<td>9,931</td>
</tr>
<tr>
<td></td>
<td>Intergovernmental Personnel Act (IPA) Mobility Program</td>
<td>27.011</td>
<td>Chesnut IPA</td>
<td>N/A</td>
<td>Direct</td>
<td>12,830</td>
</tr>
<tr>
<td></td>
<td>Intergovernmental Personnel Act (IPA) Mobility Program</td>
<td>27.011</td>
<td>VA Rural Clergy</td>
<td>N/A</td>
<td>Direct</td>
<td>4,407</td>
</tr>
<tr>
<td></td>
<td><strong>Subtotal of 27.011</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>656,888</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Unknown</strong></td>
<td>64.000</td>
<td>VA IPA</td>
<td>N/A</td>
<td>Direct</td>
<td>35,972</td>
</tr>
<tr>
<td></td>
<td><strong>Subtotal of 64.000</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>35,972</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Veteran’s Administration total</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>692,860</strong></td>
</tr>
<tr>
<td><strong>DEPARTMENT OF EDUCATION</strong></td>
<td>National Institute on Disability and Rehabilitation Program</td>
<td>84.133A</td>
<td>Dartmouth/Howard Collaboration</td>
<td>H133A080063</td>
<td>Direct</td>
<td>126,276</td>
</tr>
<tr>
<td></td>
<td>National Institute on Disability and Rehabilitation Program</td>
<td>84.133A</td>
<td>SE Tech Center</td>
<td>H133A120164</td>
<td>Direct</td>
<td>364,966</td>
</tr>
<tr>
<td></td>
<td><strong>Subtotal of 84.133A</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>491,241</strong></td>
</tr>
<tr>
<td></td>
<td>Graduate Assistance in Areas of National Need</td>
<td>84.200A</td>
<td>GAANN FY13</td>
<td>P200A120038</td>
<td>Direct</td>
<td>140,877</td>
</tr>
<tr>
<td></td>
<td>Graduate Assistance in Areas of National Need</td>
<td>84.200A</td>
<td>GAANN 2012</td>
<td>P200A120041</td>
<td>Direct</td>
<td>309,771</td>
</tr>
<tr>
<td></td>
<td>Graduate Assistance in Areas of National Need</td>
<td>84.200A</td>
<td>Increasing Graduate Educ. 2012</td>
<td>P200A120087</td>
<td>Direct</td>
<td>207,098</td>
</tr>
<tr>
<td></td>
<td>Graduate Assistance in Areas of National Need</td>
<td>84.200A</td>
<td>GAANN_Groszek 2012</td>
<td>P200A120042</td>
<td>Direct</td>
<td>196,910</td>
</tr>
<tr>
<td></td>
<td><strong>Subtotal of 84.200A</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>854,856</strong></td>
</tr>
<tr>
<td></td>
<td><strong>U.S. Department of Education total</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>1,345,898</strong></td>
</tr>
<tr>
<td><strong>DEPARTMENT OF HEALTH AND HUMAN SERVICES</strong></td>
<td>Global AIDS</td>
<td>93.067</td>
<td>GHESKIO PEPFAR YR3</td>
<td>PREAMWARD</td>
<td>Pass Through (45)</td>
<td>28,412</td>
</tr>
<tr>
<td></td>
<td>Global AIDS</td>
<td>93.067</td>
<td>SHARE IT</td>
<td>1U2G2821001075</td>
<td>Pass Through (56)</td>
<td>28,412</td>
</tr>
<tr>
<td></td>
<td><strong>Subtotal of 93.067</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>56,824</strong></td>
</tr>
<tr>
<td></td>
<td>Environmental Public Health and Emergency Response</td>
<td>93.070</td>
<td>NH Wells</td>
<td>03-44-4442010-2047-102.5</td>
<td>Direct</td>
<td>70,014</td>
</tr>
<tr>
<td></td>
<td><strong>Subtotal of 93.070</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>70,014</strong></td>
</tr>
<tr>
<td></td>
<td>Area Health Education Centers Point of Service</td>
<td>93.107</td>
<td>Model AHEC YR 10</td>
<td>U77HP03627-09-00</td>
<td>Direct</td>
<td>196,157</td>
</tr>
<tr>
<td></td>
<td><strong>Subtotal of 93.107</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>196,157</strong></td>
</tr>
</tbody>
</table>
# Dartmouth College

## Schedule of Expenditures of Federal Awards

**Year Ended June 30, 2015**

<table>
<thead>
<tr>
<th>Federal Program</th>
<th>Cluster Title/CFDA Number</th>
<th>Project Name</th>
<th>Award Number/Pass-through Identification Number</th>
<th>Funding Source</th>
<th>Pass-Through Entity</th>
<th>Total Expenditures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal and Child Health</td>
<td>93.110</td>
<td>Pedi Epilepsy</td>
<td>H98MC08578</td>
<td>Direct</td>
<td>(1,600)</td>
<td></td>
</tr>
<tr>
<td>Maternal and Child Health</td>
<td>93.110</td>
<td>MCH Lead Training YR20</td>
<td>2T73MC0024-17-00</td>
<td>Direct</td>
<td>790,588</td>
<td></td>
</tr>
<tr>
<td>Emergency Medical Services for Children</td>
<td>93.127</td>
<td>EMSC YR9</td>
<td>2H33MC06727-08</td>
<td>Direct</td>
<td>80,397</td>
<td></td>
</tr>
<tr>
<td>Emergency Medical Services for Children</td>
<td>93.127</td>
<td>Pedi EMS</td>
<td>H34MC26202</td>
<td>Direct</td>
<td>307,407</td>
<td></td>
</tr>
<tr>
<td>AIDS Education and Training Centers</td>
<td>93.145</td>
<td>NE AIDS Education Yr 14</td>
<td>WA00120885-ETC08</td>
<td>Pass Through</td>
<td>(97) 397</td>
<td></td>
</tr>
<tr>
<td>AIDS Education and Training Centers</td>
<td>93.145</td>
<td>NE AIDS Education Yr 3</td>
<td>WA00218321/RF52015022</td>
<td>Pass Through</td>
<td>(98) 60,903</td>
<td></td>
</tr>
<tr>
<td>Coordinated Services and Access to Research for Women, Infants, Children, and Youth</td>
<td>93.153</td>
<td>Family HIV Program Admin Supp</td>
<td>H12HA24881</td>
<td>Direct</td>
<td>481,393</td>
<td></td>
</tr>
<tr>
<td>Disabilities Prevention</td>
<td>93.184</td>
<td>Hemophilia Complications Yr 4</td>
<td>WA00269565RF5201513</td>
<td>Pass Through</td>
<td>(98) 17,164</td>
<td></td>
</tr>
<tr>
<td>Mental Health Research Grants</td>
<td>93.242</td>
<td>Cortico-hippocampal</td>
<td>F32MH105125</td>
<td>Direct</td>
<td>44,525</td>
<td></td>
</tr>
<tr>
<td>Mental Health Research Service Awards for Research Training</td>
<td>93.282</td>
<td>Ambiguous Facial Expressions</td>
<td>F31MH1090672</td>
<td>Direct</td>
<td>33,766</td>
<td></td>
</tr>
<tr>
<td>Centers for Disease Control and Prevention_Investigations and Technical Assistance</td>
<td>93.283</td>
<td>CA Screening Program FY12</td>
<td>N/A</td>
<td>Direct</td>
<td>(364)</td>
<td></td>
</tr>
<tr>
<td>Centers for Disease Control and Prevention_Investigations and Technical Assistance</td>
<td>93.283</td>
<td>CA Screening Program FY13</td>
<td>1017170</td>
<td>Direct</td>
<td>(138)</td>
<td></td>
</tr>
<tr>
<td>Cancer Research Manpower</td>
<td>93.398</td>
<td>OVCA Boost CD40 YR2</td>
<td>F31CA134188</td>
<td>Direct</td>
<td>145,807</td>
<td></td>
</tr>
<tr>
<td>Cancer Research Manpower</td>
<td>93.398</td>
<td>Neural predictors YR 2</td>
<td>F31CA1727203</td>
<td>Direct</td>
<td>44,113</td>
<td></td>
</tr>
<tr>
<td>Cancer Research Manpower</td>
<td>93.398</td>
<td>Michaelen YR2</td>
<td>5F30CA168079-02</td>
<td>Direct</td>
<td>44,399</td>
<td></td>
</tr>
<tr>
<td>Cancer Research Manpower</td>
<td>93.398</td>
<td>Refining Ovarian Cancer</td>
<td>F31CA186625</td>
<td>Direct</td>
<td>36,756</td>
<td></td>
</tr>
<tr>
<td>Health Care Innovation Awards (HCIA)</td>
<td>93.610</td>
<td>Weinstein_CMS_HVHC</td>
<td>1C1CMS30129-01-00</td>
<td>Direct</td>
<td>10,453,075</td>
<td></td>
</tr>
<tr>
<td>Adoptions Opportunities</td>
<td>93.652</td>
<td>Well-Being Outcomes thru DCVF</td>
<td>N/A</td>
<td>Direct</td>
<td>49,465</td>
<td></td>
</tr>
<tr>
<td>Adoptions Opportunities</td>
<td>93.652</td>
<td>Well-Being Outcomes FY15</td>
<td>42100300</td>
<td>Direct</td>
<td>410,647</td>
<td></td>
</tr>
<tr>
<td>Adoptions Opportunities</td>
<td>93.652</td>
<td>Partners for Change Yr 3</td>
<td>90CO1099</td>
<td>Direct</td>
<td>618,269</td>
<td></td>
</tr>
<tr>
<td>Social Services Block Grant</td>
<td>93.667</td>
<td>Support Contract SFY08</td>
<td>1S6075</td>
<td>Pass Through</td>
<td>(63) 3,000</td>
<td></td>
</tr>
<tr>
<td>Arthritis, Musculoskeletal and Skin Diseases Research</td>
<td>93.846</td>
<td>Ortho NIRSA YR 11</td>
<td>T32AR049710</td>
<td>Direct</td>
<td>145,807</td>
<td></td>
</tr>
</tbody>
</table>

Subtotal of 93.310: 788,988

Subtotal of 93.110: 788,988

Subtotal of 93.127: 387,776

Subtotal of 93.145: 61,210

Subtotal of 93.153: 481,393

Subtotal of 93.184: 44,525

Subtotal of 93.242: 381,393

Subtotal of 93.249: 17,164

Subtotal of 93.282: 33,766

Subtotal of 93.283: 186,092

Subtotal of 93.398: 145,807

Subtotal of 93.610: 10,453,075

Subtotal of 93.652: 1,078,381

Subtotal of 93.667: 3,000

Subtotal of 93.846: 145,807
<table>
<thead>
<tr>
<th>Federal Program</th>
<th>Cluster Title/CFDA Number</th>
<th>Project Name</th>
<th>Award Number/Pass-through Identification Number</th>
<th>Funding Source</th>
<th>Pass-Through Entity</th>
<th>Total Expenditures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes, Digestive, and Kidney Diseases Extramural Research</td>
<td>93.847</td>
<td>F30 Hahn Year 2</td>
<td>F30DK094540</td>
<td>Direct</td>
<td></td>
<td>1,311</td>
</tr>
<tr>
<td>Diabetes, Digestive, and Kidney Diseases Extramural Research</td>
<td>93.847</td>
<td>Hahn F30 YR3</td>
<td>F30DK094540</td>
<td>Direct</td>
<td></td>
<td>46,484</td>
</tr>
<tr>
<td>Extramural Research Programs in the Neurosciences and Neurological Disorders</td>
<td>93.853</td>
<td>Myoclonic Epilepsy Yr 3</td>
<td>F31NS077537</td>
<td>Direct</td>
<td></td>
<td>51</td>
</tr>
<tr>
<td>Subtotal of 93.847</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>47,795</td>
</tr>
<tr>
<td>Allergy and Infectious Diseases Research</td>
<td>93.855</td>
<td>Myeloid And Lymphoid YR13</td>
<td>T32AI007363</td>
<td>Direct</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subtotal of 93.855</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>51</td>
</tr>
<tr>
<td>Vision Research</td>
<td>93.867</td>
<td>Laminar V1 Yr 2</td>
<td>F32EY023165</td>
<td>Direct</td>
<td></td>
<td>55,645</td>
</tr>
<tr>
<td>Subtotal of 93.867</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>55,645</td>
</tr>
<tr>
<td>Medical Library Assistance</td>
<td>93.879</td>
<td>Biomed Library CONNECT</td>
<td>WA00190134/RFS2014125</td>
<td>Pass Through</td>
<td>(98)</td>
<td>23,056</td>
</tr>
<tr>
<td>Subtotal of 93.879</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>23,056</td>
</tr>
<tr>
<td>National Bioterrorism Hospital Preparedness Program</td>
<td>93.889</td>
<td>Injury Prevention FY14</td>
<td>STNHFY14</td>
<td>Direct</td>
<td></td>
<td>3,935</td>
</tr>
<tr>
<td>National Bioterrorism Hospital Preparedness Program</td>
<td>93.889</td>
<td>Emergency Preparedness Yr 2</td>
<td>90077021</td>
<td>Direct</td>
<td></td>
<td>219,274</td>
</tr>
<tr>
<td>Subtotal of 93.889</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>223,209</td>
</tr>
<tr>
<td>Special Projects of National Significance</td>
<td>93.928</td>
<td>HIT Capacity</td>
<td>H97HA25006</td>
<td>Direct</td>
<td></td>
<td>1,390</td>
</tr>
<tr>
<td>Subtotal of 93.928</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1,390</td>
</tr>
<tr>
<td>Block Grants for Community Mental Health Services</td>
<td>93.958</td>
<td>Montana IPS Training</td>
<td>14-331-74078-0</td>
<td>Direct</td>
<td></td>
<td>33,772</td>
</tr>
<tr>
<td>Subtotal of 93.958</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>33,772</td>
</tr>
<tr>
<td>PPHF Geriatric Education Centers</td>
<td>93.969</td>
<td>NNE-GEC YR7</td>
<td>UB4H19206</td>
<td>Direct</td>
<td></td>
<td>468,737</td>
</tr>
<tr>
<td>Subtotal of 93.969</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>468,737</td>
</tr>
<tr>
<td>International Research and Research Training</td>
<td>93.989</td>
<td>Dart/Pos AITRP YR 10</td>
<td>D43TW006807</td>
<td>Direct</td>
<td></td>
<td>110,701</td>
</tr>
<tr>
<td>International Research and Research Training</td>
<td>93.989</td>
<td>Dart/Penn Res Ethics Train YR 4</td>
<td>R2STW007693</td>
<td>Direct</td>
<td></td>
<td>195,166</td>
</tr>
<tr>
<td>International Research and Research Training</td>
<td>93.989</td>
<td>TRIM-TB Supplement Yr 3</td>
<td>D43TW009573</td>
<td>Direct</td>
<td></td>
<td>400,962</td>
</tr>
<tr>
<td>Subtotal of 93.989</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>706,829</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>Fisher_HITECH_EHR</td>
<td>1013115823</td>
<td>Pass Through</td>
<td>(8)</td>
<td>43,489</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>NH-WIP</td>
<td>1021329</td>
<td>Pass Through</td>
<td>(62)</td>
<td>1,075,046</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>PCSA Enhanc &amp; Studies YR 2</td>
<td>HHSH2502012002022C</td>
<td>Direct</td>
<td></td>
<td>106,844</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>PCSA Enhanc &amp; Studies YR 3</td>
<td>HHSH2502012002022C</td>
<td>Direct</td>
<td></td>
<td>364,542</td>
</tr>
<tr>
<td>Unknown</td>
<td>93.XXX</td>
<td>H3N2 LA Flu Vaccine</td>
<td>5-25462</td>
<td>Pass Through</td>
<td>(106)</td>
<td>1,604,308</td>
</tr>
<tr>
<td>Subtotal of 93.XXX</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1,604,308</td>
</tr>
<tr>
<td>U.S. Department of Health and Human Services total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>17,868,458</td>
</tr>
</tbody>
</table>

OTHER FEDERAL PROGRAMS

| Academic Exchange Programs - Undergraduate Programs                             | 19.009                    | YALI                   | FY14-YALI-Dartmouth-01                             | Pass Through  | (40)                | 40,820            |
| Academic Exchange Programs - Undergraduate Programs                             | 19.009                    | YALI 2015              | FY15-YALI-Dartmouth-02                             | Pass Through  | (40)                | 63,676            |
| Subtotal of 19.009                                                             |                            |                        |                                                  |               |                     | 104,496           |
# Dartmouth College
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2015

<table>
<thead>
<tr>
<th>Federal Program</th>
<th>Cluster Title/CFDA Number</th>
<th>Project Name</th>
<th>Award Number/Pass-through Identification Number</th>
<th>Funding Source</th>
<th>Pass-Through Entity</th>
<th>Total Expenditures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Promotion of the Arts_Grants to Organizations and Individuals</td>
<td>45.024</td>
<td>NEA 2013-2014</td>
<td>13-5400-7069</td>
<td>Direct</td>
<td></td>
<td>10,475</td>
</tr>
<tr>
<td>Promotion of the Arts_Grants to Organizations and Individuals</td>
<td>45.024</td>
<td>NEA Artsworks Presenting</td>
<td>14-5400-7038</td>
<td>Direct</td>
<td></td>
<td>18,934</td>
</tr>
<tr>
<td>Promotion of the Arts_Grants to Organizations and Individuals</td>
<td>45.024</td>
<td>Art Works 15-16</td>
<td>15-5400-7017</td>
<td>Direct</td>
<td></td>
<td>33,000</td>
</tr>
<tr>
<td>Promotion of the Arts_Grants to Organizations and Individuals</td>
<td>45.024</td>
<td>Southern Exposure</td>
<td>26289</td>
<td>Pass Through</td>
<td>(53)</td>
<td>22,500</td>
</tr>
<tr>
<td>Subtotal of 45.024</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>84,909</td>
</tr>
<tr>
<td>Promotion of the Arts_Partnership Agreements</td>
<td>45.025</td>
<td>NEFA The Nile Project</td>
<td>14-28074</td>
<td>Direct</td>
<td></td>
<td>10,000</td>
</tr>
<tr>
<td>Promotion of the Arts_Partnership Agreements</td>
<td>45.025</td>
<td>NEFA Homer's Coat</td>
<td>14-28165</td>
<td>Pass Through</td>
<td>(60)</td>
<td>5,000</td>
</tr>
<tr>
<td>Promotion of the Arts_Partnership Agreements</td>
<td>45.025</td>
<td>Shantala Shivalingappa</td>
<td>14-28663</td>
<td>Pass Through</td>
<td>(60)</td>
<td>10,000</td>
</tr>
<tr>
<td>Promotion of the Arts_Partnership Agreements</td>
<td>45.025</td>
<td>When the Wolves Came In</td>
<td>14-28577</td>
<td>Pass Through</td>
<td>(60)</td>
<td>5,000</td>
</tr>
<tr>
<td>Subtotal of 45.025</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30,000</td>
</tr>
<tr>
<td>Promotion of the Humanities_Office of Digital Humanities</td>
<td>45.169</td>
<td>NEH Metadata F2</td>
<td>HK-50021-12</td>
<td>Direct</td>
<td></td>
<td>48,470</td>
</tr>
<tr>
<td>Museums for America</td>
<td>45.301</td>
<td>IMLS NAAD Web Forum</td>
<td>MA-30-13-0480-13</td>
<td>Pass Through</td>
<td>(38)</td>
<td>66,893</td>
</tr>
<tr>
<td>Subtotal of 45.301</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>66,893</td>
</tr>
<tr>
<td>Subtotal of 98.000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>160,261</td>
</tr>
<tr>
<td>USAID Foreign Assistance for Programs Overseas</td>
<td>98.000</td>
<td>Kosovo exchange</td>
<td>S04-AID-167-A-14-00001</td>
<td>Pass Through</td>
<td>(125)</td>
<td>20,918</td>
</tr>
<tr>
<td>Subtotal of 98.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>20,918</td>
</tr>
<tr>
<td>Total Other Federal Programs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>315,947</td>
</tr>
<tr>
<td>Total Other Sponsored Programs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>21,747,404</td>
</tr>
<tr>
<td>Student Financial Assistance Cluster</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4,185,757</td>
</tr>
<tr>
<td>Federal Supplemental Educational Opportunity Grants</td>
<td>84.007</td>
<td>SEOG FY15</td>
<td>P007A142503</td>
<td>Direct</td>
<td>799,883</td>
<td></td>
</tr>
<tr>
<td>Federal Work-Study Program</td>
<td>84.033</td>
<td>FWS FY14</td>
<td>P033A132503</td>
<td>Direct</td>
<td>221</td>
<td></td>
</tr>
<tr>
<td>Federal Pell Grant Program</td>
<td>84.063</td>
<td>Pell FY14</td>
<td>P063P141791</td>
<td>Direct</td>
<td>987,578</td>
<td></td>
</tr>
<tr>
<td>Federal Pell Grant Program</td>
<td>84.063</td>
<td>PELL FY15</td>
<td>P063P141791</td>
<td>Direct</td>
<td>700</td>
<td></td>
</tr>
<tr>
<td>Total Student Financial Assistance Cluster</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2,398,775</td>
</tr>
<tr>
<td>Highway Safety Cluster</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4,185,757</td>
</tr>
<tr>
<td>State and Community Highway Safety</td>
<td>20.600</td>
<td>Pickup Truck FY14</td>
<td>304-145-004</td>
<td>Direct</td>
<td>16,144</td>
<td></td>
</tr>
<tr>
<td>State and Community Highway Safety</td>
<td>20.600</td>
<td>CPS for EMS FY14</td>
<td>304-145-003</td>
<td>Direct</td>
<td>4,050</td>
<td></td>
</tr>
<tr>
<td>State and Community Highway Safety</td>
<td>20.600</td>
<td>Statewide CPS FY14</td>
<td>304-145-002</td>
<td>Direct</td>
<td>38,168</td>
<td></td>
</tr>
<tr>
<td>State and Community Highway Safety</td>
<td>20.600</td>
<td>BUNH FY14</td>
<td>304-145-001</td>
<td>Direct</td>
<td>11,982</td>
<td></td>
</tr>
<tr>
<td>State and Community Highway Safety</td>
<td>20.600</td>
<td>virtual driver FY14</td>
<td>308-145-005</td>
<td>Direct</td>
<td>3,329</td>
<td></td>
</tr>
<tr>
<td>State and Community Highway Safety</td>
<td>20.600</td>
<td>Statewide CPSFY15</td>
<td>304-155-001</td>
<td>Direct</td>
<td>97,760</td>
<td></td>
</tr>
<tr>
<td>State and Community Highway Safety</td>
<td>20.600</td>
<td>Pickup Truck FY15</td>
<td>304-155-003</td>
<td>Direct</td>
<td>43,609</td>
<td></td>
</tr>
<tr>
<td>State and Community Highway Safety</td>
<td>20.600</td>
<td>CPS for EMS FY15</td>
<td>304-155-004</td>
<td>Direct</td>
<td>17,271</td>
<td></td>
</tr>
<tr>
<td>State and Community Highway Safety</td>
<td>20.600</td>
<td>Virtual Driver FY15</td>
<td>304-155-006</td>
<td>Direct</td>
<td>9,740</td>
<td></td>
</tr>
<tr>
<td>State and Community Highway Safety</td>
<td>20.600</td>
<td>BUNH FY15</td>
<td>304-155-005</td>
<td>Direct</td>
<td>53,545</td>
<td></td>
</tr>
<tr>
<td>Total Highway Safety Cluster</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>295,596</td>
</tr>
<tr>
<td>Total Federal Award Expenditures</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>158,630,773</td>
</tr>
</tbody>
</table>
Dartmouth College  
Schedule of Expenditures of Federal Awards  
Year Ended June 30, 2015

Pass-through entities referenced in this schedule are indicated below:

<table>
<thead>
<tr>
<th>Year</th>
<th>Schedule</th>
<th>Pass-through entity</th>
</tr>
</thead>
</table>
1. **Basis of Presentation**

   The accompanying schedule of expenditures of federal awards (the “Schedule”) summarizes the expenditures of Dartmouth College (“Dartmouth”) under federal government programs for the year ended June 30, 2015. The information in this schedule is presented in accordance with the requirements of U.S. Office of Management and Budget (OMB) Circular A-133, *Audits of States, Local Governments and Nonprofit Organizations*. Negative amounts on the Schedule represent adjustments to expenditures reported in the prior year. The Schedule includes Catalog of Federal Domestic Assistance (CFDA) and pass-through award numbers when available.

   For purposes of the Schedule, federal awards include all grants, contracts, and similar agreements entered into directly between the Dartmouth and agencies and departments of the federal government and all subawards to the Dartmouth by nonfederal organizations pursuant to federal grants, contracts, and similar agreements.

2. **Summary of Significant Accounting Policies for Federal Award Expenditures**

   Expenditures for direct and indirect costs are recognized as incurred using the accrual method of accounting and the cost accounting principles contained in the OMB Circular A-21, *Cost Principles for Educational Institutions*, and the regulations of the specific programs. Under those cost principles, certain types of expenditures are not allowable or are limited as to reimbursement.

3. **Facilities and Administrative Costs**

   Dartmouth recovers facilities and administrative (F&A) costs associated with research and development pursuant to arrangements negotiated with the Department of Health and Human Services (DHHS). Dartmouth submitted an F&A cost proposal in the fall of 2011 for negotiated F&A rates that became effective July 1, 2011. Dartmouth’s F&A cost rate for fiscal year 2015 is 62% for on-campus research.

4. **Federal Student Loan Programs**

   Loans made to eligible students and parents under federal student loan programs during the year ended June 30, 2015 are not included in the Schedule, and are summarized as follows:

<table>
<thead>
<tr>
<th>Program</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title IV Program Federal Perkins Loan Program (Perkins)</td>
<td>$4,259,914</td>
</tr>
<tr>
<td>Federal Direct Student Loans</td>
<td>26,953,957</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$31,213,871</strong></td>
</tr>
</tbody>
</table>

   Federal direct loans are issued by the U.S. Department of Education directly to students and their parents. The balances and transactions relating to these loans are not included in Dartmouth’s financial statements.

   The Perkins loans are administered and serviced directly by Dartmouth. In addition, Dartmouth continues to service Health Education Assistance Loans (HEAL) which were issued in previous years. Balances and transactions relating to these loans are included in Dartmouth’s financial statements.
Dartmouth College
Notes to Schedule of Expenditures of Federal Awards
Year Ended June 30, 2015

The balances outstanding on these loans at June 30, 2015 are as follows:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Perkins</td>
<td>$23,576,678</td>
</tr>
<tr>
<td>HEAL</td>
<td>128,531</td>
</tr>
<tr>
<td></td>
<td><strong>$23,239,207</strong></td>
</tr>
</tbody>
</table>

For the year ended June 30, 2015, Dartmouth claimed $279,400 in administrative cost allowances related to its student financial assistance programs, which are not included in the Schedule.

5. Pass-Through Awards

For the year ended June 30, 2015, Dartmouth received awards directly and from federal agencies, which were passed through to subrecipients. The amounts passed through are as follows:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Research and development</td>
<td>$21,639,793</td>
</tr>
<tr>
<td>Other</td>
<td>7,814,413</td>
</tr>
<tr>
<td></td>
<td><strong>$29,454,206</strong></td>
</tr>
</tbody>
</table>

These amounts are included in the total expenditures shown on the Schedule.
Independent Auditor’s Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards

To the Board of Trustees of Dartmouth College:

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in Government Auditing Standards issued by the Comptroller General of the United States, the consolidated financial statements of Dartmouth College (“Dartmouth”), which comprise the statement of financial position as of June 30, 2015, and the related consolidated statement of activities and changes in net assets, statement of operating expenses and cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated October 19, 2015.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered Dartmouth’s internal control over financial reporting (“internal control”) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of Dartmouth’s internal control. Accordingly, we do not express an opinion on the effectiveness of Dartmouth’s internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of Dartmouth’s financial statements will not be prevented, or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether Dartmouth’s financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under Government Auditing Standards.
Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Dartmouth’s internal control or on compliance. This report is an integral part of an audit performed in accordance with Government Auditing Standards in considering Dartmouth’s internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

PricewaterhouseCoopers LLP

October 19, 2015
Independent Auditor’s Report on Compliance with Requirements
That Could Have a Direct and Material Effect on Each Major Program and on Internal Control
Over Compliance in Accordance with OMB Circular A-133

To the Board of Trustees of Dartmouth College:

Report on Compliance for Each Major Federal Program

We have audited Dartmouth College’s (“Dartmouth”) compliance with the types of compliance requirements described in the OMB Circular A-133 Compliance Supplement that could have a direct and material effect on each of Dartmouth’s major federal programs for the year ended June 30, 2015. Dartmouth’s major federal programs are identified in the summary of auditor’s results section of the accompanying schedule of findings and questioned costs.

Management’s Responsibility

Management is responsible for compliance with the requirements of laws, regulations, contracts, and grants applicable to its federal programs.

Auditor’s Responsibility

Our responsibility is to express an opinion on compliance for each of Dartmouth’s major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States; and OMB Circular A-133, Audits of States, Local Governments, and Non-Profit Organizations. Those standards and OMB Circular A-133 require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about Dartmouth’s compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of Dartmouth’s compliance.

Opinion on Each Major Federal Program

In our opinion, Dartmouth complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2015.
Other Matters

The results of our auditing procedures disclosed an instance of noncompliance, which is required to be reported in accordance with OMB Circular A-133 and which is described in the accompanying schedule of findings and questioned costs as item 2015-001. Our opinion on each major federal program is not modified with respect to this matter.

Dartmouth’s response to the noncompliance finding identified in our audit is described in the accompanying management views and corrective action plan. Dartmouth’s response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

Management of Dartmouth is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered Dartmouth’s internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with OMB Circular A-133, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of Dartmouth’s internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of OMB Circular A-133. Accordingly, this report is not suitable for any other purpose.

PricewaterhouseCoopers LLP

January 5, 2016
1. **Summary of Auditor’s Results**

   **Financial Statements**
   Type of auditor’s report issued: Unmodified

   Internal control over financial reporting:
   - Material weakness(es) identified? _____yes  __x__ no
   - Significant deficiency(s) identified that are not considered to be material weakness(es)? _____yes  __x__ none reported

   Noncompliance material to financial statements noted? _____yes  __x__ no

   **Federal Awards**

   Internal control over major programs:
   - Material weakness(es) identified? _____yes  __x__ no
   - Significant deficiency(s) identified that are not considered to be material weaknesses? _____yes  __x__ none reported

   Type of auditor’s report issued on compliance for major programs: Unmodified

   Any audit findings disclosed that are required to be reported in accordance with section 510(a) of OMB Circular A-133? __x__yes  ____no

   **Identification of Major Programs:**

<table>
<thead>
<tr>
<th>CFDA Number(s)</th>
<th>Name of Federal Program or Cluster</th>
</tr>
</thead>
<tbody>
<tr>
<td>Various</td>
<td>Research and Development Cluster</td>
</tr>
<tr>
<td>27.011</td>
<td>VA Advanced Quality Program</td>
</tr>
<tr>
<td>Various</td>
<td>Student Financial Assistance Cluster</td>
</tr>
</tbody>
</table>

   Dollar threshold used to distinguish between type A and type B programs: $3,000,000

   Auditee qualified as low-risk auditee? __x__ yes  ____no
2. Findings Relating to the Financial Statements Reported in Accordance with Government Auditing Standards
   None Noted.

3. Federal Award Findings and Questioned Costs

   Finding 2015-001 – Equipment and Real Property Management

   Research and Development Cluster
   Grantor: National Center for Advancing Translational Sciences and Clinical Research Management, Inc. (Subcontract)
   Grant Name: Biomedical Informatics Year 2 and Development of Manufacturing, Warehousing, and Delivery of a Cryopreserved Platelets (CPP) Product to Support Efforts to Obtain U.S. Food and Drug Administration (FDA) Licensure – Base
   CFDA or Award Number: 93.350 and 12.XXX (Contract)
   Award Year: July 1, 2014 - June 30, 2015

   Criteria
   Institutions of higher education, hospitals, and other non-profit organizations shall follow the provisions of OMB Circular A-110. OMB Circular A-110 requires that equipment be used in the program for which it was acquired or, when appropriate, other Federal programs. Equipment records shall be maintained, a physical inventory of equipment shall be taken at least once every two years and reconciled to the equipment records, an appropriate control system shall be used to safeguard equipment, and equipment shall be adequately maintained.

   Condition
   Of two selected grants that had capitalizable equipment purchases during fiscal year 2015, three out of six of the equipment items were not listed on the report of federally funded equipment.

   Questioned Cost
   None noted.

   Cause
   The cause of this noncompliance is due to the implementation of a new fixed assets system during fiscal year 2014. The new system requires manual entry of equipment purchased from the Computer Store, which is a service center at Dartmouth. Additionally, the system does not properly flag federally funded equipment that is purchased through a subaward with a non-federal entity. These purchases of federally funded equipment were appropriately recorded in the schedule of expenditures of federal awards but were excluded from the report of federally funded equipment.

   Effect
   Federally funded equipment could be purchased, sold, transferred or disposed of without knowledge to Dartmouth College. Also, federally funded equipment may not be properly inventoried within the two year requirement.

   Recommendation
   We recommend that Dartmouth implements a manual review to ensure that all federally funded equipment purchases are properly identified and accurately recorded within the fixed asset system.

   Management’s Views and Corrective Action Plan
   Management’s views and corrective action plan is included at the end of this report after the summary schedule of prior audit findings.
Finding 2014-001 – Equipment and Real Property Management

Research and Development Cluster
Grantor: National Cancer Institute, Tufts University and Office of the Director
Grant Name: Effectors Myc Function, Leaders YR31 S4, NCCC Core, Invasive Behavior, Mechanistic Analysis and Orbitrap
CFDA Number: 93.393, 93.859 and 93.351
Award Year: July 1, 2013 - June 30, 2014

Condition
Throughout testing of equipment inventory, PwC noted three departments had not completed their physical inventory counts within the two year requirement as of June 30, 2014.

Recommendation
PwC recommended that Dartmouth implement the necessary policies and procedures to ensure that all departments that have federally funded equipment perform a physical inventory within the two year requirement.

Status
Dartmouth has implemented a radio frequency identification system (RFID) and revised policies and procedures to ensure effective and timely physical inventories. Equipment inventories are now recorded on an individual asset basis and all federally funded assets were re-inventoried using the new RFID system.
Finding 2014-002 – Allowable Costs

Other Sponsored Programs
Grantor: Department of Health and Human Services
Grant Name: The high value healthcare collaborative: engaging patients to meet the triple aim
CFDA Number: 93.610
Award Year: July 1, 2013 – June 30, 2014

Condition
During fiscal year 2014, there were 52 wage related cost transfers and 25 non-wage related cost transfers for a total of 77 transfers for this award. Of the 25 non-wage related cost transfers performed during fiscal year 2014, PwC selected four for testing from this award and did not note any exceptions. Of the 52 wage transfers for this award, none were selected for review. However, management brought to PwC’s attention that during fiscal year 2014, six employees’ labor allocations were adjusted incorrectly and outside the time period required for compliance with Dartmouth’s wage transfer policy. This policy states that wage transfers should be completed within 90 days of the original charge. Although the adjustments were not in compliance with Dartmouth’s policy, the costs were determined to be allowable. The impact to fiscal year 2014 was removal of $49,000 of salary and fringe benefit costs (from a total of $1.2 million for the award).

Recommendation
PwC recommended that Dartmouth reiterate the importance of its policies and procedures around cost transfers to grant managers and principal investigators in order to ensure there is an understanding of the impact when such policies and procedures are not followed.

Status
All labor charges that were not processed on a timely basis in compliance with Dartmouth College’s wage transfer policy were removed from the grant. The Office of Sponsored Projects provided training to the department related to labor charges and Dartmouth’s wage transfer policy. In addition, a training session was provided for all departments on how to allocate costs on sponsored awards.
December 22, 2015

To Whom It May Concern:

Re: Fiscal Year 2015 Audit Findings on Equipment (2015-001)

Dartmouth’s Management Response: Dartmouth acknowledges that the manual process to record equipment purchased from our internal Computer Store, which included email notification to an individual’s email account, resulted in equipment not being recorded properly. Dartmouth has changed the notification process to include centrally monitored email accounts to ensure appropriate notification and recording of assets. Dartmouth has implemented reporting to identify equipment purchased on subawards from non-federal entities for inclusion in the fixed asset system. We will also investigate options for automating this process.

Tammy Moffatt
Director of Procurement, Payables, and Inventory